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Abstract 
 
Motor neuron disease (MND) is rapidly progressive and invariably fatal, and 
with no significantly impactful therapies available to date there is desperate and 
unmet clinical need. Recent discoveries in the underlying pathology and 
genetics of MND suggest that altered proteostasis, RNA regulation and glial 
contribution play key roles in molecular pathogenesis. I have used a 
combination of human induced pluripotent stem cell (hiPSC) models and 
functional genomic technologies to characterize early pathogenic events in 
VCP-related MND. I hypothesize that the early pathogenic events in MND differ 
during the differentiation of motor neurons and astrocytes; therefore I first 
generated enriched populations of both motor neurons (MNs) and astrocytes 
(ACs) from control and VCP mutant patient iPSCs. Next to understand if 
changes in RNA regulation contribute to pathogenic events in VCP-related 
MND, I carried out a temporal analysis using RNA sequencing (RNAseq) of 
control and VCP mutant iPSCs neural derivatives. Additionally, I examined the 
results of this transcriptional study in light of collaborative live cell imaging 
experiments, performed across a matched time-course, that have uncovered 
cell-type specific organellar dysfunction in VCP mutant MNs. This paradigm 
importantly enabled us to discriminate primary from secondary pathogenic 
events in VCP-related MND. Further, after the onset of pathogenesis I also 
used individual nucleotide resolution UV cross linking with immunoprecipitation 
(iCLIP) to study RNA interactions of the candidate RNA-binding protein TDP43, 
which forms the pathological hallmark of MND. Together, this provides new 
insights into the earliest molecular pathogenic events in MND and has 
highlighted the contribution of both motor neurons and astrocytes. By 
identifying key disease mechanisms this study aims to guide future therapeutic 
strategy. 
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Preface 
 
This thesis describes my doctoral research performed at the Institute of 
Neurology, UCL between October 2013 and July 2016.  
 
Some of the work presented here has been achieved collaboratively. The VCP-
mutant hiPSC lines used throughout my thesis were generated by Dr Selina 
Wray. In chapter 3, Electrophysiology was carried out by Sarah Crisp and 
axonal transport by Alexander Fellows, supervised by Professor Dimitri 
Kullmann and Professor Gipi Schiavo respectively. The public RNAseq data 
used in chapter 3 was downloaded from the NCBI GEO database (GEO: 
GSE73721) (Ye Zhang et al. 2016). Analysis of iCLIP data in Chapter 4 and 6 
was partially done through the iCOUNT web server, which was established by 
Dr. Tomaž Curk and is helped maintained by Igor Ruiz. In addition the 
calculation of binding by RBPs to repeat elements (Alu’s elements presented) 
was carried out by Nejc Haberman and analysis of RNAseq strandedness and 
distribution of reads binding to exonic, intronic or intergenic reads was carried 
out by Raphaelle Luiser from Nicholas Luscombe’s lab. All Live cell imaging 
work in Chapter 5 (Cell death assays, Mitochondria dynamics, ER-mitochondria 
colocalisation, Glutathione levels, ROS production and ER stress), plus the 
analysis of ATP/KCl/Glutamate response and the mitochondrial membrane 
dependence upon complex I presenting in Chapter 3 was done in collaboration 
with Dr. Sonia Gandhi, Dr. Minee Choi and Dr. Zhi Yao. Confocal synaptic 
analysis presented in chapter 5 was carried out by Dr. Andras Lakatos. Finally 
in chapter 6, motif analysis of selected sites was performed by Nejc Haberman.  
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Chapter 1; Introduction 
Neurodegenerative diseases are characterized by the progressive deterioration 
of region- and/or subtype-specific neurons. They vary in terms of severity, age 
of onset, prognosis and a number of pathogenic mechanisms have been 
implicated including oxidative stress, axonal transport deficits, mitochondrial 
dysfunction, excitotoxicity, calcium dysregulation, neuroinflammation, DNA 
damage and aberrant RNA processing (Ferraiuolo et al. 2011; R. Johnson et 
al. 2012). However one common pathological hallmark observed across the 
spectrum of neurodegenerative diseases is the accumulation and aggregation 
of misfolded protein (Soto 2013; Yerbury et al. 2016).  
Motor Neuron Disease 
Motor Neuron Disease (MND) encompasses many different neurodegenerative 
conditions, including progressive bulbar palsy (PSP), progressive muscular 
atrophy (PMA), primary lateral sclerosis (PLS) and Kennedy’s disease. The 
most common form of MND is often referred to as amyotrophic lateral sclerosis 
(ALS) or sometimes as Lou Gehrig’s disease and this is what I refer to 
throughout this thesis as MND.   
 
MND is a rapidly progressive and invariably fatal neurodegenerative disease. 
The average age of onset is 55 years (S. Chen et al. 2013) and prevalence is 
1/400 in those with European ancestry (Hardiman, van den Berg, and Kiernan 
2011), with the incidence being 20% higher in males. It affects both the upper 
and lower motor neurons (MNs) (Hardiman, van den Berg, and Kiernan 2011); 
Upper MNs are those originating from the motor cortex or brainstem that 
convey impulses to the lower MNs, which originate in the anterior horn of the 
spinal cord and synapse at muscles. Patients suffer from premature loss of 
MNs resulting in progressive paralysis, loss of speech, inability to swallow and 
usually die within 3-5 years of symptom onset due to respiratory complications. 
Despite extensive research there are no effective treatments to date; the only 
available disease modifying therapy is Riluzole, a glutamate antagonist 
approved over 20years ago, which only prolongs life by 3 months (Hardiman, 
van den Berg, and Kiernan 2011). Other treatments are currently just 
symptomatic. 
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Genetics underlying MND 
The cause of MND is largely unknown but several risk factors have been 
identified; older age, male sex and genetic (Ingre et al. 2015). The majority of 
MND cases are sporadic with only ~10% being familial (S. Chen et al. 2013), 
where the disease has been passed down through generations through genetic 
mutation. Over 20 causative genes have been identified in familial MND 
(fMND) (listed in Table! 1.1.A) and these are usually inherited in an autosomal 
dominant pattern. Further, several of these genes associated with fMND have 
also been reported in a small number of sporadic MND cases, including FUS, 
C9ORF72, SOD1 and TDP43 (Turner et al. 2013). On top of this many other 
genes have been identified that increase susceptibility in sporadic MND (Listed 
also in Table 1.1.B)(S. Chen et al. 2013).  
 
 Chromosome 
locus  
Gene  Protein  Other 
Diseases 
caused by 
the gene 
Key molecular 
pathways 
implicated in 
      
A) 2q33-2q35  Alsin  Alsin  PLS, 
IAHSP 
Oxidative stress 
 14q11.2  ANG Angiogenin - Aberrant RNA 
Processing 
 9p21  C9ORF72  Chromosome 9 
open reading 
frame 72 
FTD Aberrant RNA 
Processing 
 2p13  DCTN1  Dynactin  - Axonal transport 
 6q21  FIG4 Phosphoinositid
e- 
5phosphatease  
CMT 4 J Apoptosis 
 16p11.2 FUS Fused in 
Sarcoma 
- Aberrant RNA 
Processing 
 10p13  OPTN  Optineurin  Primary 
open 
angle 
Glaucoma 
Protein 
aggregation 
 9q34  SETX  Senataxin  SCAR1 Aberrant RNA 
! 16!
and AOA2 Processing 
 9p13.2-21.3 SIGMAR1 Sigma Non 
Opiod 
Intracellular 
Receptor 
FTD Metabolic 
disturbance 
 21q22.1 SOD1 Cu/Zn SOD-1  - Apoptosis, 
Oxidative stress, 
Mitochondrial 
disruption, 
microglia 
activation, 
protein 
aggregation, 
metabolic 
disturbance, 
axonal transport 
 15q15-21 SPG 11  Spatacsin HSP Axonal transport 
 1p36.2  TARDBP  DNA-binding 
protein  
FTD Aberrant RNA 
Processing, 
protein 
aggregation 
 Xp11  UBQLN2  Ubiquilin 2  ND Protein 
aggregation, 
protein 
degradation 
 9q21-22 Unknown Unknown FTD - 
 18q21  Unknown  Unknown  - - 
 20q13.3 VAPB Vesicle 
associated 
membrane 
protein 
associated 
protein B  
SMA Apoptosis, 
metabolic 
distrubance 
 9p13.3  VCP  Valosin 
Containing 
Protein 
IBMPFD Protein 
aggregation, 
protein 
! 17!
degradation, 
apoptosis 
      
B) 14q11.2 APEX1  Apurinic 
Endonuclease 
DNA repair 
enzyme 1  
- DNA repair, 
oxidative stress 
 12q24.12 ATXN2  Ataxin-2 SCA2   
 3p11.2 CHMP2B  Chromatin 
Modifying 
Protein 2B 
FTD Protein 
degradation 
 6p22.2 HFE  Haemochromat
osis 
HHC Oxidative stress, 
metabolic 
disturbance 
 22q12.2 NEFH  Neuro filament 
Heavy 
- Axonal transport 
 4q32.1-q34.3 NEK1 NIMA Related 
Kinase 1 
- DNA repair, 
microtubule 
stability, 
neuronal 
morphology 
 17q21.31  PGRN  Progranulin FTD Inflammation, 
microglia 
activation 
 7q21.3 PON 
1,2,3  
Paraoxonase - Oxidative stress 
 12q13.12 PRPH  Peripherin - Axonal transport 
 5q12.2-q13.3 SMN1  Survival Motor 
Neuron 1 
SMA Aberrant RNA 
Processing, 
protein 
aggregation 
 5q12.2-q13.3 SMN2  Survival Motor 
Neuron 2  
SMA Aberrant RNA 
Processing, 
protein 
aggregation 
 6p21 VEGF  Vascular - Hypoxia-
! 18!
Endothelial 
Growth Factor   
response 
 
Table 1.1; Genes identified in MND (adapted/updated from (S. Chen et al. 2013))  
A) Lists genes identified to cause fMND. B) Lists additional susceptibility genes 
identified in sporadic MND. Abreviations for table 1.1; PLS Primary Lateral Sclerosis, 
IAHSP Infantile onset ascending hereditary spastic paralysis, SCAR 1 Autosomal 
Recessive Spino-cerebellar ataxia, AOA2 Ataxia Ocular Apraxia 2, HSP Hereditary 
spastic paraplegia, SMA Spinal Muscular Atrophy, CMT 4 J Charcot-Marie Tooth 
disease type 4 J, SCA2 spinocerebellar ataxia type 2, HHC hereditary 
hemochromatosis, IBMPFD Inclusion body myopathy with Pagets disease and fronto 
temporal dementia. 
 
From the genetic mutations identified, a number of biological pathways have 
been highlighted to potentially play a role in disease pathogenesis (Table 1.1, 
column 5); for example oxidative stress (SOD1 mutations) and intracellular 
trafficking (Dynactin mutations)(Pasinelli and Brown 2006). However, for 
reasons discussed below, the two most common hypotheses are that abnormal 
RNA metabolism and/or altered proteostasis play a key role in the 
pathogenesis of MND (Ferraiuolo et al. 2011).  
The role of abnormal ribostasis and proteostasis in MND 
All neurodegenerative disorders, including MND, exhibit the aggregation of 
misfolded protein, but the role of these aggregates in disease pathogenesis 
remains unresolved. It is vital for all cells to maintain a fine balance of protein 
production, concentration, conformation, location and degradation for normal 
cell metabolism and to be able to respond to changes in their environment. 
There are numerous stages involved in the production of a functional protein; 
including transcriptional regulation where RNA undergoes elaborate processing 
and translational control. Transcriptional regulation is necessary to generate 
the diversity and specificity of proteins required within different cell types and 
compartments, and is predominately regulated by a complex network of RNA 
binding proteins (RBPs). Translational control is particularly important to 
spatially regulate protein production and is markedly evident under stress 
(Spriggs, Bushell, and Willis 2010). Additionally, there are hundreds of 
chaperones, enzymes, and specialized proteins involved in folding, clearance 
and translocation networks within the cell that work together to ensure proteins 
are managed appropriately (summarized in Figure 1). However during stress, 
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in aging and disease these networks become overloaded and dysfunctional 
leading to the accumulation and aggregation of RNA, misfolded and 
aggregation-prone proteins. These aggregated proteins in MND are 
predominately ubiquitinated and are seen in the spinal cord and multiple brain 
regions (Baloh 2011). 
 
 
Figure 1; Schematic representation of key pathways controlling protein 
homeostasis, taken from (Yerbury et al. 2016). The!balance!and!management!of!effective!protein!production!and!degradation!in!the!cell!is!crucial.! Protein! synthesis! begins!with! transcription! in! the! nucleus! and! continues! in! the!cytoplasm!where! it! is! translated!and! folded.!Protein! folding! takes!place!with! the!help!of!many! molecular! chaperones! and! the! ubiquitinFproteasome! system! (UPS).! MisFfolded!proteins! are! dealt! with! either! by! being! bound! to! by! Heat! shock! protein! (HSPs)! in! the!cytoplasm!or!can!be!sorted!by!the!endoplasmic!reticulum’s!degradation!pathways!(ERAD),!however!both!result!in!the!recruitment!to!the!UPS.!Alternatively!if!a!misFfolded!protein!is!not! dealt! with! it! will! aggregate! and! be! removed! by! autophagy.! Extracellular! protein!homeostasis! pathways! are! also!monitored! by!molecular! chaperones,! called! extracellular!chaperones! (EC),!which!will! direct!misFfolded! proteins! to! specific! cell! surface! receptors!where!they!are!engulfed!and!degraded!in!the!lysosome.!
 
In 2006 a landmark finding was published when the primary component of the 
cytoplasmic and ubiquitin-positive neuronal inclusions seen in MND was 
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discovered to be a predominately nuclear RNA binding protein (RBP), TDP43 
(Manuela Neumann et al. 2006). Here, both the full length and C-terminal 
fragment of TDP43 is phosphorylated, cleaved, mislocalised to the cytoplasm 
and aggregated. This is now recognized as the pathological hallmark of MND 
and is present in over 97% of all cases.  
 
This was followed by a discovery in 2008 showing that mutations in the gene 
TARDBP, that encodes TDP43, are causative of MND and account for 4% of 
fMND (Sreedharan et al. 2008). The majority of mutations within TARDBP are 
found within the C-terminal Glycine rich domain, which is a highly unstructured 
region commonly found in RBPs but the function of this region is largely 
unknown. A feature of intrinsically unstructured proteins is that its cellular levels 
are strictly regulated. TDP43 binds to its own 3’UTR causing a negative 
feedback loop to auto regulate its own expression(Ayala et al. 2011); when 
bound an intron in 3’UTR is alternatively spliced leading to nonsense-mediated 
decay (NMD)(Bembich et al. 2014). This prevents the deleterious accumulation 
of TDP43 (Ayala et al. 2011) however in MND it has been shown that there is a 
loss of this autoregulation pathway leading to increased protein production 
(Budini and Buratti 2011). Increased levels of TDP43 have been shown to be 
toxic in multiple species; yeast, chicken and drosophila (B. S. Johnson et al. 
2008; Voigt et al. 2010). In addition, mutant TDP43 has been shown to have 
increased stability that contributes to the formation of pathological inclusions 
(Ling, Polymenidou, and Cleveland 2013).  
 
Further, the studies around TDP43 have also raised the hypothesis that 
dysregulated RNA metabolism plays a key role in the pathogenesis of MND. 
This notion was further reinforced when additional mutations in another RBP, 
FUS, were found to cause MND (Vance et al. 2009). Patients with the FUS 
mutation are among the minority that does not present typical TDP43 
mislocalisation, but they do present aggregation of the mutated protein FUS 
(Kwiatkowski et al. 2009; Vance et al. 2009). FUS has similar structural 
domains to TDP43; a glycine rich domain, nuclear localization sequence plus 2 
RRMs, however unlike TDP43, mutations in FUS are found throughout the 
gene (Lagier-tourenne, Polymenidou, and Cleveland 2010). Both TDP43 and 
FUS also have striking functional similarities. They are involved in pre-mRNA 
splicing, microRNA biogenesis, transcriptional regulation, mRNA stabilization, 
transport and translation (Lagier-tourenne, Polymenidou, and Cleveland 2010). 
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However it is not clear whether these mutations cause disease through a loss 
of function (loss of RBP from nucleus), a gain of toxic function by the formation 
of cytoplasmic granules and/or nuclear inclusions, or both.  
 
To further strengthen the relevance of RNA metabolism in MND, an intronic 
hexanucleotide expansion in C9ORF72 was discovered in 2011 that accounts 
for 40% of fMND making it the most common known cause of MND (Dejesus-
hernandez et al. 2011; Renton et al. 2011). Three different pathogenic 
mechanisms have been pursued for the expansion; haploinsufficiency (loss of 
function of the protein that contains the repeat), toxic gain of function of the 
mutant/expansion containing protein, and RNA toxicity due to the RNA 
produced containing the repeat. Both products from the transcription (RNA 
repeats) and translation (RAN translation) of expanded gene lead to toxic 
species found to be aggregated in MND.   
 
Additional causative mutations have been identified that also implicate 
abnormalities in proteostasis, ribostasis or both, including mutations within 
genes encoding VCP, VAPB, UBQLN2 and CHMP2B have been discovered to 
cause adult onset MND (S. Chen et al. 2013). Moreover several of these 
mutated proteins have been found to be constituent of the aggregated granules 
in both mutation carrying and sporadic patients, for example OPTN and 
UBQLN2 (Blokhuis et al. 2013). Together this indicates aggregation and de-
regulated proteostasis plays a widespread role in degeneration in MND.   
 
Given the strong evidence to date, it is expected that dysfunction in both RNA 
and protein metabolism contribute to MND pathology. However an important 
and unresolved question against this background is: what is the precise 
sequence of molecular events that initiates pathogenesis in MND?  
 
Cell autonomous and non cell autonomous mechanisms of disease 
Classically it has been thought that neurodegenerative diseases cause the 
selective degeneration and death of a subset of neurons, it is becoming 
increasingly recognized that glia also play key roles in neurodegeneration. 
Astrocytes (ACs) are the most abundant cell in the nervous system and provide 
critical support for many neuronal functions. For example they assist by 
buffering the extracellular environment, particularly ion homeostasis, rapid 
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removal of neurotransmitter molecules/glutamate from synapse terminal to 
prevent continuous firing, and to provide metabolic support/supply of nutrients 
(lactate, antioxidants etc). Given the complexity and importance of AC 
homeostatic control in the brain it is unsurprising that their involvement has 
been implicated in several neurodegenerative disorders. In MND the 
contribution of glia has been shown to act via both cell autonomous and/or non 
cell autonomous mechanism of injury (Bilican et al. 2012; Di Giorgio et al. 
2007; Maragakis and Rothstein 2006; Nagai et al. 2007).   
 
Firstly there have been several lines of evidence to support a non-cell 
autonomous role for glia in MND. For MND caused by mutations in the gene 
encoding superoxide dismutase 1 (SOD1), it has been shown that the selective 
expression of mutant SOD1 protein within ACs is deleterious to healthy MNs 
(Di Giorgio et al. 2007; Nagai et al. 2007), but that the presence of MNs are 
important for initiating pathogenesis. It was further showed that damage came 
from the release of soluble toxic factors. Further for SOD1 related MND early 
astroglial atrophy has been reported directly surrounding spinal MNs and is 
observed prior to their degeneration (Rossi et al. 2008), suggesting that the 
presence of sick ACs has an impact upon surrounding MNs. Glia proliferation 
and activation has also been associated with disease progression in MND. 
Since, non cell-autonomous injury by ACs has also been implicated in sporadic 
MND (Haidet-Phillips et al. 2011; K. Meyer et al. 2014), suggesting the 
possibility of common pathogenic mechanisms.  
 
Additional evidence for non-cell autonomous role of ACs comes the 
observation that loss of the astrocytic glutamate transporter GLT-1 leads to MN 
death by excitotoxicity (J D Rothstein et al. 1995; Jeffrey D. Rothstein et al. 
1996). Further evidence to suggest a loss of function mechanism in ACs comes 
from transgenic and KO animal models which have shown that many AC-
specific genes play a role in neuroprotection and degeneration, for example a 
deficiency in the glutamate transporter EAAT2 (the human equivalent of GLT-1) 
has been seen in ACs surrounding synapses in human sporadic MND tissue. 
These converging lines of evidence suggests that a role of ACs in 
neurodegeneration is due to a loss of their regular supportive functions, but 
importantly it does not exclude any toxic gain of function mechanism(s). 
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Next some studies have explored non-cell autonomous pathogenic 
mechanisms using hiPSC-derived ACs from patients with familial and sporadic 
MND. ACs differentiated from hiPSCs from either familial (SOD1 and 
C9ORF72) or sporadic cases, were found to be deleterious to both MN survival 
and neurite outgrowth in co-culture paradigms. Using this co-culture paradigm, 
the study was able to determine whether this non-cell autonomous effect was 
dependent on MND-AC toxicity or lack of support. The addition of wild type AC-
conditioned media failed to rescue motor-neuron cell death, suggesting a toxic 
gain of astrocytic function (K. Meyer et al. 2014).   
 
Separately, there is reason to hypothesize a cell autonomous effect in ACs in 
neurodegeneration/MND, one being due to many of the known causative genes 
being ubiquitously expressed. Therefore since the mutation is present in ACs 
too, it can be reasoned that the mutant protein could also be having aberrant 
effects in ACs too. Evidence to suggest a cell autonomous role for ACs in MND 
initially comes from studies of the TARBP (the gene encoding TDP43) mutant 
M337V. The expression of TARDBP mutant M337V in AC resulted in 
mislocalisation of TDP43 protein, the key pathological feature of MND (Bilican 
et al. 2012). Additionally, TDP43 pathology has since been seen in ACs of both 
familial & sporadic MND cases, advocating a possible role for ACs in all TDP43 
proteinopathies (Serio et al. 2013). However, when TARDBP mutant ACs are 
co-cultured with either control or TARDBP mutant MNs, mutant ACs were not 
toxic (Serio et al. 2013).  
 
Overall the role and underlying mechanism of both astrocytic cell autonomous 
and/or non-cell autonomous mechanisms of injury in MND currently remains 
inconclusive. TDP43 mutations have been shown to affect both MNs (Bilican et 
al. 2012) and ACs (Serio et al. 2013) in human iPSC cellular models, but there 
remains some controversy as to whether TDP43 mutations result in non-cell 
autonomous mechanisms injury. Two studies in 2013 give seemingly 
contrasting results from cellular and animal models (Serio et al. 2013; Tong et 
al. 2013). This is also in apparent contrast with the non-cell autonomous 
toxicity previously reported in the context of sporadic, C9ORF72 and SOD1 
mutations (Di Giorgio et al. 2007; K. Meyer et al. 2014; Nagai et al. 2007). 
However, these results could point towards mutation-specific AC pathology and 
at least partially divergent underlying mechanisms of disease in ACs in familial 
MND. The lack of concrete conclusions so far could be due to the lack of 
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systematic approaches used so far to investigate AC-neuron interactions; a 
variety of model systems have been used eg. different species, different 
causative mutations. Hence, in order to precisely elucidate key aspects of 
cellular autonomy, further systematic strategies are required and could be 
achieved using hiPSC platform systems. 
 
These data provide a clear rationale for studying both ACs and MNs to 
investigate disease mechanisms. I hypothesise that the early pathogenic 
events in MND differ during the differentiation of MNs and ACs. 
 
Vasolin containing protein (VCP) and its physiological 
functions 
VCP is a highly abundant, ubiquitously expressed protein and is classified as 
an AAA+ ATPase (ATPases associated with a variety of cellular activities). It 
has a substrate and cofactor binding N terminal domain and 2 ATPase 
domains (with un-equivalent enzymatic activity), that come together to form a 
hexameric ring structure (H. Meyer and Weihl 2014). It functions as a 
chaperone for a diverse range of cellular functions, including cell cycle 
progression/regulation, membrane turnover and plays a primary role in protein 
homeostasis (Yamanaka, Sasagawa, and Ogura 2012). These various 
activities of VCP are largely determined by cofactor/substrate availability. One 
interactor of VCP was discovered to be neurofibromin-1, implicating VCP 
functions in the regulation of synaptogenesis (Weihl 2011).   
 
VCP is involved several stages of protein control and its plays a major role in 
protein degradation (Yamanaka, Sasagawa, and Ogura 2012). Intracellular 
protein degradation is particularly important for non-dividing cells, such as 
neurons, and functions to remove and prevent the accumulation of damaged or 
abnormal protein, and it also serves to regulate cellular processes by removing 
enzymes and regulatory proteins that are no longer needed. It can be 
accomplished by two pathways; ubiquitin-dependent targeting to the 
proteasome or via autophagy targeting to the lysosome. VCP plays a role in 
both systems.  
 
VCP facilitates proteolysis firstly by its interaction with ubiquitin, usually through 
adapter proteins (often ligases) and secondly via its segregase functions. VCP 
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can extract proteins for degradation by utilizing energy from the hydrolysis of 
ATP to aid conformational changes as a segregase or unfoldase (Yamanaka, 
Sasagawa, and Ogura 2012). It extracts aberrant proteins from organellar 
membranes (notably both the ER and mitochondrial membranes), chromatin, 
complex assemblies and also from stalled defective translation products from 
the ribosome, and assists in their translocation to the cytosol. For example at 
the mitochondria, VCP’s ubiquitin-proteosome functions play an important role 
in quality control. This is primarily through its interaction with vsm1, which 
locates to the mitochondria under stress and is required for protection against 
oxidative stress (Yamanaka, Sasagawa, and Ogura 2012). Additionally at the 
ER VCP works in a complex with Ufd1 and Npl4 to retrotranslocate ER-
associated degradation (ERAD) substrates (Ye et al., 2001). ERAD is the cells 
mechanism for removing proteins that fail to fold properly in the ER. It occurs 
by transporting the misfolded proteins out of the ER to the cytosol where they 
get ubiquitinated and degraded by the proteasome. In addition to ERAD VCP 
has been associated with other roles at the ER; within neurons, it works in a 
complex with p47 and ATL1 to regulate tubular ER formation and ER 
distribution, extension into dendrites and protein synthesis efficiency which in 
turn influences dendritic spine formation (Shih and Hsueh 2016).  
 
Another core function of VCP is within the cell cycle. Its precise role is not yet 
fully characterised but many functions have been revealed for VCP throughout 
several stages in the cell cycle (Vaz, Halder, and Ramadan 2013; Yamanaka, 
Sasagawa, and Ogura 2012). The transition between phases of the cell cycle is 
tightly regulated, primarily by CDKs that are co-ordinated by transcription and 
ubiquitin dependent degradation. VCP is a critical regulator of G1 through 
degradation of Far1p, an arrest factor (CDK inhibitor) and substrate of VCP-
mediated proteolysis (Fu et al. 2003). Additionally VCP regulates DNA 
replication and S phase progression by interaction with adapter proteins Ufd-1 
or Npl-4. Further during mitosis there are profound changes in cellular 
physiology, eg. spindle disassembly, extensive remodeling of golgi network, 
ER-golgi morphogenesis, nuclear envelope disassembly and reformation. 
These events are partially controlled by VCP dependent degradation, for 
example through its association with aurora-B (spindle and chromatin 
disassembly), XMAP215/TPX2/Plx1 (spindle assembly) and p47/p37 
(regulation of membrane fusion of intracellular organelles, including the ER and 
Golgi).  
! 26!
 
More recently there has been an emerging role for VCP in RNA regulation and 
the translational stress response. VCP has been shown to act in post-
transcriptional regulation at the ribosome (Lykke-Andersen and Bennett 2014) 
and in guiding dendritic pruning through regulating RNA metabolism (Rumpf et 
al. 2014). Also functions for VCP have been described in the disassembly of 
mRNA–protein complexes (mRNPs), via binding and extraction of HuR 
(component of mRNP complexes) leading to proteosomal degradation. mRNPs 
control transport and stability of mRNAs, but under global inhibition of 
translational, mRNPs aggregate in stress granules or p-bodies. These are also 
cleared by a VCP-dependent mechanism, but instead of proteosomal 
degradation VCP directs aggregates to the lysosome for degradation by 
autophagy (Buchan et al. 2013). 
The role of VCP in MND 
1-2% of familial cases of MND are caused by mutations in the gene encoding 
valosin-containing protein (VCP) (J. O. Johnson et al. 2010; Koppers et al. 
2012). Mutations in the VCP gene lead to a broad range of phenotypes 
including the multisystem degenerative disorder Inclusion body myopathy with 
Pagets disease of the bone and frontal temporal dementia (IBMPFD) as well as 
MND (J. O. Johnson et al. 2010; Koppers et al. 2012).   
 
There have been several studies to date exploring the underlying pathogenesis 
of VCP’opathies (Bartolome et al. 2013; Ju et al. 2009; Ritson et al. 2010; H. F. 
Wang et al. 2011; Yi et al. 2012; Yin et al. 2012). Interestingly, it has been 
shown that VCP’opathies are also characterised by the accumulation and 
mislocalisation of TDP43, the pathological hallmark of MND. Post mortem 
material from patient cases with either MND or IBMPFD, caused by VCP 
mutations, have been described to present striking cytoplasmic mislocalization 
and aggregation of TDP43 in the frontal and temporal lobes (M Neumann et al. 
2007). This is replicated in disease models of VCP causing MND; 
overexpression of disease causing VCP mutations leads to TDP43 
mislocalization from the nucleus to the cytoplasm of transfected cells, 
transgenic mice (Ju et al. 2009) and human post-mortem tissue (J. O. Johnson 
et al. 2010). This suggests there could be common mechanisms underlying 
VCP, sporadic MND and TDP proteinopathies.  
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VCP has been idenitified as a recognition factor; it recognises abnormal 
proteins and polyglutamine-containing proteins, and its co-localisation has 
been seen with aggregates in multiple neurodegenerative diseases; nuclear 
inclusions in Huntington’s disease, lewy bodies in lewy body diseases and 
ubiquitin positive intranuclear inclusions in MND (M. Hirabayashi et al. 2001; 
Mizuno et al. 2003). On top of this VCP has also been explored as “an effector 
of neurodegeneration”. In the absence of VCP, disrupted aggresome formation 
and degradation of expanded polyglutamine-containing proteins is observed 
(Kobayashi et al., 2007). Similarly a number of studies have shown a role for 
VCP in the disassembly of stress granules (Buchan et al. 2013). Stress 
granules are aggregates of protein and RNA (stored translational initiation 
complexes) that appear in the cytoplasm when a cell is under stress. They are 
usually highly dynamic, continually dissociating and reforming and are present 
in most neurodegenerative diseases, including MND. In cells carrying a 
mutation in VCP it has been shown that there is constitutive presence of stress 
granules (Buchan et al. 2013). A similar phenotype is observed when 
autophagy was inhibited (Buchan et al. 2013).  
 
Given VCPs functions in protein degradation, it is not surprising that defective 
protein clearance has been highlighted in VCP LOF models. Firstly loss of VCP 
activity has been shown to lead to the accumulation of ubiquitinated proteins 
and impaired ERAD (Dalal et al., 2004; Wójcik et al., 2004). It has also been 
shown that the loss of VCP causes the accumulation of autophagosomes, 
implicating that VCP is involved in the maturation and targeting of 
autophagosomes to the lysosome for degradation (Ju et al. 2009). Defects in 
protein clearance also seen with other MND causing mutations (TDP43, SOD1) 
and in sporadic MND suggesting there could be a common theme across MND 
pathogenesis (Kiskinis et al. 2014; Ling, Polymenidou, and Cleveland 2013; 
Manuela Neumann et al. 2006). On top of protein clearance further defects in 
protein homeostasis have been shown in VCP mutant cells; rER morphology is 
impaired in VCP mutant mice neurons resulting in reduced protein synthesis, 
which in turn leads to lower expression of synaptic proteins and a reduced 
synaptic density, a characterised feature in MND (Shih and Hsueh 2016).  
 
Other factors that have been explored in VCP’opathies include mitochondrial 
dysfunction (Bartolome et al. 2013) and synaptogenesis (H. F. Wang et al. 
2011), which could both cause cellular death. A loss of VCP or presence of a 
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clinically relevant mutation in VCP was shown to lead to reduced mitochondrial 
membrane potential, increased oxidative phosphorylation and reduced ATP 
levels (Bartolome et al. 2013). Mitochondrial deficiency has also been more 
broadly implicated in MND (reviewed in. Cozzolino and Carri 2012) however to 
date it is not clear whether it is a primary event in disease pathogenesis. In 
addition VCP mutants have been shown to lose interaction with neurofibromin-
1 leading to dendritic spine loss in hippocampal neurons (H. F. Wang et al. 
2011).  Since synaptic deficiency is observed in MND (Devlin et al. 2015; Pun 
et al. 2006; Shoichi Sasaki and Iwata 1995; Shoichi Sasaki and Maruyama 
1994) this function of VCP in synaptogenesis may be of importance in disease 
pathogenesis.  
 
For my PhD I have selected to study VCP-related MND. This is because it is 
pathologically representative of the majority of MND cases (i.e. displays 
nuclear to cytoplasmic mislocalisation of TPD-43); which excludes mutations in 
FUS and SOD1. Secondly VCP mutations are rare and we are one of few labs 
with the unique opportunity to study MND using hiPSCs carrying a VCP 
mutation. Here I aim explore RNA regulation and to define the earliest 
molecular events in VCP-related MND. 
 
Models of disease 
There are many model systems which can be used to study MND and until 
recently a lot of research into MND has been conducted using mouse models. 
These approaches have generally had a poor transitional yield, which could be 
due to a number of reasons. Potential therapies have often showed promise in 
pre-clinical animal models but did not translate successfully in clinical trials. It is 
possible that fundamental interspecies differences and poor timing in pre-
clinical study design may explain the failure in clinical translation. For example 
ceftriaxone, a modulator of the glutamate receptor EAAT2, failed in phase III 
human clinical trails showing no efficacy but in the SOD1-D93A mice is was 
shown to reduce excitotoxicty and increasing lifespan when administered 
before symptom onset (Fonslow et al. 2012; Jeffrey D Rothstein et al. 2005).  
 
Furthermore, many models used have not been truly representative of human 
MND. This can be highlighted as a further potential weakness in previous trial 
designs, where many pre-clinical animal models have overexpressed mutant 
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SOD1. In human MND, SOD1 mutations accounts for only a minority of the 
total cases and these patients do not present with the pathological hallmark 
that >97% of sporadic and familial MND cases do (a nuclear to cytoplasmic 
mislocalisation of TDP43). These facts suggest that SOD1 mutants may not be 
pathomechanistically representative of MND. Another model generated to 
study MND has been in mice carrying mutations in TARDBP gene, although 
some events in MND are recapitulated (eg. detection of ubiqutinated proteins 
and MN specific degeneration is seen) there are striking differences in the 
symptoms observed compared to human MND. Only 25% of MNs are seen to 
degenerate compared to 90% in SOD1 and human forms of MND, and they 
develop a severe gastrointestinal pathology, which is the cause of their 
premature death (Esmaeili et al. 2013). On the other hand animal models are 
an invaluable tool as they enable us to study the early stages and progression 
of disease within an vivo environment.  
 
In addition, post-mortem tissue from MND patients has been used to study 
disease pathology, although it is only representative of the end stages of 
disease. Therefore the use of human induced pluripotent stem cells offers an 
unparalleled approach to study early molecular pathogenesis in MND.  
Human induced Pluripotent Stem cells 
Human induced pluripotent stem cells (hiPSCs) are stem cells derived from 
reprogramming adult somatic cells, usually fibroblasts, to an embryonic-like 
state.  
They hold several major advantages as a new approach to modelling human 
development and disease; 
i) They have theoretically a limitless self renewal capacity  
ii) capable of differentiating into any cell type in the body across the three 
germ layers, which is a particular advantage for deriving neuronal cell 
types as they are difficult to obtain from human tissue. 
iii) fully humanized model system and  
iv) mutations are expressed at representative pathophysiological doses 
removing the need for artificial overexpression, knock down or knockout 
studies.  
Additionally as this is essentially a developmental system, iPSCs allow us to 
recapitulate the earliest pathogenic events occurring during disease 
manifestation in a clinically relevant model system.  
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As with all models there are limitations too. One of the biggest criticisms of 
using hiPSCs to model neurodegenerative diseases, where aging is a major 
risk factor, is that the relative age of the hiPSC-derivatives has been shown to 
be comparable to a fetal maturational stage (Defects et al. 2015; Miller et al. 
2013; Rickie Patani, Lewis, et al. 2012). Another major limitation using current 
hiPSCs models is that they lack the dynamic and complex in-vivo environment, 
found within an organism. However, this could be advantageous when trying to 
model complex diseases such as MND since we can focus on understanding 
the contribution of the different cell types separately to begin with. 
 
The use of hiPSCs as a model system for MND has previously been 
demonstrated, for example cells carrying TDP43 mutations have been shown 
to recapitulate key aspects of MND, such as selective vulnerability, premature 
death and elevated levels of TDP43 (Bilican et al. 2012).  By revealing specific 
disease-associated phenotypes this thereby validates the use of this model 
system for investigating the underlying mechanisms of MND and developing 
new screening platforms for therapeutic intervention. Although many disease-
relevant phenotypes have been shown, the precise time-course of pathogenic 
events has not yet been studied therefore for my PhD I aimed to temporally 
analyse neural derivatives from control and VCP mutant hiPSCs, in order 
to study the earliest events in pathogenesis of MND. I will differentiate both 
MNs and ACs in order to analyse cell specific events.  
 
Neuronal development in humans 
In order to take full advantage of iPSC technology as a disease model system, 
as well as for drug discovery and regenerative medicine, it is critical to 
establish accurate in vitro methods for directed differentiation. It has been a 
major challenge in neuroscience to understand the developmental ‘logic’ of 
human neuronal and glial specification, which in turn is used to guide optimal 
differentiation strategies of pluripotent stem cells (PSCs). 
 
The development of the human nervous system can be divided into 3 main 
stages. Beginning from fertilization, cells undergo asymmetric division to 
produce the early blastocyst which is divided into the inner cell mass (ICM) and 
trophectoderm. The ICM gives rise to the epiblast, which in turn gives rise to 
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three germ layers (ectoderm, mesoderm and endoderm) during gastrulation. 
The nervous system is derived from the ectoderm lineage. Therefore firstly, like 
other mammals, the development of the human nervous system begins with 
the induction of neuroectoderm; an area of the ectoderm is specified to form 
the neural plate, then this folds to form the neural tube. Secondly the neural 
precursor cells (NPC) within the neural tube are patterned, which refers to the 
spatial separation of NPCs into distinct progenitor domains. And finally these 
‘patterned precursors’ go on to give rise to defined neuronal cell types; first 
neurons followed by glia. All these processes progressively restrict cell fate and 
are tightly regulated by a variety of coordinated mechanisms including gene 
expression programmes, cell-cell contact and positional relationships, cell 
signaling and epigenetic modifications.  
i) Neural induction  
Neural induction is a complex process where ectodermal cells are specified to 
the neural lineage. In 1924 Spemann and Mangold discovered ‘the organiser’, 
which was an area of specialised cells (located in the dorsal blastopore lip) 
capable of inducing the neural plate in the ectoderm. Since it has been shown 
that the organiser can induce neural fate when transplanted ectopically within 
and across species (Stern 2005) by the release of signals to inhibit BMP4 
(noggin, chordin, follistatin). The concept of inductive signals orchestrating 
neural induction was widely accepted until the proposition of the Default model, 
which hypothesises that ectodermal cells become neurally specified by default 
whereas the epidermis is induced by BMP4 signals (Grunz and Tacke 1989; 
Hemmati-brivanlou and Melton 1994). Since it has been accepted that neural 
induction occurs through inhibitory signalling that suppress epidermal cell fate. 
A gradient is established between BMP ligands and antagonists controls 
epidermal versus neural fate. However there are many challenges to this model 
(Stern 2005), for example BMP4 inhibition isn’t sufficient for neural induction 
(allows expression of sox2 but not sufficient for sox3 an early marker), 
suggesting the involvement of additional mechanisms.  
 
In addition to BMP antagonism other members of the TGF-b signaling family 
have been identified to play a role in neural induction. Nodal inhibition in neural 
induction is well established and has been tested across a variety of species 
(Camus et al. 2006; Chambers et al. 2009). Further factors have also been 
discovered to contribute to neural induction and include FGF and WNT 
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signaling, however their exact role remains controversial and is likely to depend 
heavily upon the timing (Zirra, Wiethoff, and Patani 2016). 
ii) Patterning (Motor neuron precursor specification) 
There are many different types of neurons, located at defined positions in the 
nervous system with specific functions in functional circuits. Patterning is the 
process that specifies neural precursor positioning in the developing embryo, 
which in turn influences their differentiation fate. The default positional identity 
in the developing embryo after neural induction is anterior (i.e. in the forebrain), 
so upon terminal differentiation, the resulting neural precursors will give rise to 
cortical neurons. Developmentally, MNs in the spinal cord arise from the pMN 
domain in the ventral horn, where transcription factors NKX6.1, Pax6 and Olig2 
are expressed (Wichterle et al. 2002). 
 
In vivo neural patterning is chiefly controlled by secreted extracellular signaling 
molecules called morphogens. Morphogens are molecules that spread over 
variable distances, here across the neural tissue, establishing different 
signaling gradients, which often function in combination and in opposing 
directions (eg. BMP4 and SHH across the neural tube). The activity of these 
molecules is spatiotemporally integrated to determine the specific combination 
of transcription factors that are activated in distinct compartments of the CNS. 
The same signals are used reiteratively, at different times and positions during 
development. 
 
Neural patterning occurs across both the anterior to posterior (AP) and dorsal 
to ventral (DV) directions in the neuroaxis, giving rise to the diversity of cells 
forming the nervous system. AP patterning occurs prior to DV patterning. 
Anterior to posterior fates are progressive re-specified by a number of signaling 
molecules; including fibroblast growth factors, retinoic acid, transforming 
growth factor 10 and WNTs (Zirra, Wiethoff, and Patani 2016). An approximate 
AP axis is set up during neural induction, and then secondary organizers are 
established. Elongation of the AP axis is regulated by retinoic acid (RA) and 
FGF, which also coordinate the timing of differentiation; RA (among many other 
functions) caudalises progenitors and promotes cell to become neuronal/cell 
cycle exit and FGF inhibits cell differentiation to prevent it occurring too early 
while neural tube still being formed etc. 
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The distinct domains along the AP axis are defined by expression of the 
homeotic (HOX) genes. This is established by graded signaling throughout the 
hindbrain and spinal cord to establish positional boundaries of HOX gene 
expression. Most anterior progenitors express HOXa1 and HOXb1 only, then 
the more posterior regions express higher numbered HOX paralog genes; at 1-
5 in hindbrain and Cervical region, 4-8 in brachial region, 8-9 in the thoracic, 
and 10-13 in lumbar region of the neural tube (Philippidou and Dasen 2013).   
 
AP patterning is followed by DV patterning and again it requires the interplay of 
graded concentrations of selected cues in a specific window of time to direct 
lineage restriction. Signals for DV patterning are mostly the same at all levels of 
AP axis. Opposing gradients of BMP and sonic hedgehog (SHH) establish cell 
patterning across the neural tube; BMP signals from roofplate/dorsal and SHH 
in notochord and floor plate/ventral. These morphogenic signals work together 
to create distinct progenitor domains where a unique combination of 
transcription factors are expressed leading to differentiation of a select subtype 
of neurons. Opposing signaling gradients result in the expression of unique 
combinations of homeodomain and basic helix-loop-helix transcription factors, 
which results in the establishment of discrete progenitor domains. SHH 
signaling promotes ventralisation and the expression of class II transcription 
factors OLIG2, NKX2.2 and NKX6.1, which typically arise in the pMN domain of 
spinal cord and give rise to motor neuron precursors.  
 
Within the spinal cord MNs can be further subdivided. They reside in distinct 
motor columns: at cervical and lumbar levels they are split into the lateral 
(LMC) and medial motor columns (MMC), and at thoracic levels into the 
preganglionic (PGC), MMC, and hypaxial motor column (HMC) (Philippidou 
and Dasen 2013). Each motor column is distinguished by the different 
combinatorial expression of a few genes; LHX3, HB9, ISL1 and FOXP1. 
iii) Terminal differentiation of neurons and glia  
Although NPCs cell fate has been restricted in their developmental potential 
they are still a type of multi-potent cell that can self-renew and are capable of 
differentiating into both neurons and glia. To begin with NPCs rapid proliferate 
and expand through symmetric divisions but in later stages of development 
NPCs undergo asymmetric division that gives rise to two distinct daughter cells; 
one NPC and one differentiated cell. NPCs potency is temporally regulated, 
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first giving rise to neuronal cell types but later their phenotypic potential 
becomes restricted and they give rise to glial cells (ACs and oligodendrocytes). 
However the mechanisms underlying this regulation are not completely 
characterised yet. 
 
The developmental program in NPCs that controls their terminal fate into either 
neurons or glia is known as the gliogenic switch. There is limited progress in 
understanding the regulation and timing of this switch but both cell intrinsic 
programs (epigenetic programs and transcription factors) and by external cues, 
including growth factors and cytokines released from neighbouring tissues, 
have been shown to contribute (Kasai, Satoh, and Akiyama 2005; Majumder et 
al. 2013; Morrison et al. 2000). Consistent with the sequence of developmental 
events, pro-neural genes first act whilst gliogenic genes remain supressed, 
then later pro-neural genes will be inhibited while a gliogenic fate is promoted.  
 
The balance of neuronal and astrocytic signals need to be precisely to 
controlled, firstly to ensure that a dividing undifferentiated population of NPCs 
remains available (to later differentiate into glia) and secondly at later stages 
pro-neural signals must be inhibited to efficiently promote a gliogenic potential 
but the timing is crucial to ensure all neurons that are required in the adult brain 
are generated before neurogenesis is terminated. Notch signalling is critical for 
several stages of control; it promotes self-renewal of NPCs, inhibits 
neurogenesis and promotes gliogenesis (Zhou et al. 2010). Signals to maintain 
the self-renewable fate of NPCs come from neighbouring terminally 
differentiated neuronal cells, through a process known as lateral inhibition. 
Once a cell is committed to neuronal differentiation it signals to the surrounding 
NPCs to prevent all progenitors differentiating into neurons. Notch signals via 
specific bHLH transcription factors, including HES1, HES3, HES5, which signal 
to maintain the NPC pool and in addition to promote gliogenesis, partially 
through stat3 signalling (Zhou et al. 2010). 
 
In contrast to Notch signalling, BMP and WNT signals have been shown to 
promote neuronal differentiation but also act to promote astrocytic 
differentiation (Wen, Li, and Liu 2009). It is a common theme that the same 
pathways often operate at different times during development to produce 
contrasting cellular effects. Here the differing effects of BMP/WNT signalling 
could be due to the contribution of epigenetic factors. Over time in NPCs the 
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demethylation of AC-specific sites, eg. the GFAP promotor where stat3 binds to 
promote gene expression, enables NPCs to become more responsive to 
signals promoting gliogenesis (Hatada et al. 2008). Among the most prominent 
signals promoting astroglioenesis is the JAK-STAT pathway, which becomes 
robustly activated during the transition from neuronal to glial differentiation, 
triggered by cytokines and/or growth factors such as CNTF, LIF and IL6. DNA 
methylation tightly regulates JAK-STAT signaling during neurogenesis (Fan et 
al. 2005).  
 
After the gliogenic switch, precursors migrate to populate all areas of the CNS, 
expand and terminally differentiate into ACs. AC specification initially generates 
immature ACs, which are essential for coordinating with neurons the formation 
of functional synapses. During early post natal stages ACs undergo drastic 
morphology changes and maturation (Freeman 2010). Mature adult ACs are 
involved in a variety of functions including insulating synapses and removing 
excess transmitters preventing excitotoxicity.  
 
RNA regulation in neuronal cells  
Gene expression is controlled at many stages before the production of a 
functional protein; these stages include transcription (initiation and elongation), 
RNA processing, translation, post-translational regulation & modifications to 
control degradation/abundance, stability and localization. Such regulation is 
essential for maintaining cellular homeostasis, and coordinating rapid cellular 
responses to stimuli. It is also particularly important in highly polarized, 
complex cells such as neurons as it enables diverse cell type specific functions 
(Rickie Patani, Sibley, et al. 2012).  
 
Neurons heavily rely on gene regulation at the RNA level, expressing more 
microRNA, alternatively spliced mRNA and small RNA than any other cell type. 
Due to improved methods, our knowledge of how RNA is processed and 
regulated differently within neurons has greatly increased (Kiebler, Scheiffele, 
and Ule 2013). Post-transcriptional mechanisms play a key role in neuronal 
RNA regulation, heavily influencing mRNA transport and local translation 
(Kapeli and Yeo 2012). For example the localization of mRNA to dendrites is 
critical for the integration of multiple stimuli from thousands of cells in a timely 
manner and the stimulation by synaptic input can trigger local mRNA 
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translation at the synapse terminal (Bramham and Wells 2007). Additionally 
many neuron-specific proteins have been identified, including neuron-specific 
RBPs such as NOVA, ELAV and NeuN (Darnell 2013). Their specialized RNA 
regulatory networks allow for increased cellular complexity in neurons, 
localization of messenger RNA (mRNA) to distinct subcellular environments 
(eg. axons, dendrites) and regulation of their gene expression profile in 
response to synaptic stimuli.  
 
The importance of RNA regulation and selected RBPs in neurons is further 
highlighted through the association with several neurological diseases. A key 
example being MND, where causative mutations have been discovered within 
RBPs and intronic regions, abnormal splicing and other post transcriptional 
defects have also been shown to contribute to the underlying pathology 
(Almeida et al. 2013; Kwiatkowski et al. 2009; Manuela Neumann et al. 2006; 
Rogelj et al. 2012; Tollervey et al. 2011; Vance et al. 2009). Thus emphasizing 
the importance of studying RNA regulation within neuronal cells, which could 
possibly uncover new cell-specific and/or disease specific regulatory 
mechanisms.  
Regulation by RBPs 
All stages of RNA regulation are tightly controlled by RNA binding proteins 
(RBPs). These RBPs interact extensively with different RNAs in a 
spatiotemporally regulated manner to carefully orchestrate gene expression. 
They regulate gene expression at many different stages to influence cellular 
functions and their roles generally differ within nuclear and cytoplasmic 
compartments of the cells (Glisovic et al. 2008). In the nucleus, RBPs regulate 
RNA helicase activity, RNA polymerase elongation, mRNA splicing, maturation, 
and nuclear export. In the cytoplasm, they control RNA transport, silencing, 
translation, and degradation.  
 
RBPs interact with many mRNAs and proteins via conserved domains, glycine 
rich regions and RNA recognition motifs (RRMs). In the cytoplasm they form 
dynamic complexes called RNA granules, which help regulate RNA activity and 
distribution. Depending on their composition they are subdivided into 
ribonucleoprotein complexes (RNPs), stress granules (SG) and P-bodies 
(Vanderweyde et al. 2013). Neuronal function depends on RNPs for storage of 
mRNAs (for rapid response to metabolic or environmental changes) and for the 
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transport of mRNAs, RBPs recognize localization elements in UTRs of mRNA 
enabling them to direct the localization while also suppressing translation until 
required. This has been well studied in relation to dendritic transport of RNAs 
and synaptic plasticity as mentioned above (Doyle and Kiebler 2011). P-bodies 
are involved in control of mRNA degradation and often interact with miRNA 
machinery. SG control the stability and translational activity of selective 
mRNAs. They play a critical role in fine-tuning protein expression under 
conditions of stress and more recently have been implicated in neurological 
disease conditions too, again emphasizing selective neuronal functions 
(Vanderweyde et al. 2013). A number of disease associated RBPs have been 
demonstrated to colocalise with and/or influence dynamics of SG (eg. Ataxin2, 
TDP43) (Colombrita et al. 2009; Dewey et al. 2010; Nonhoff et al. 2007; 
Vanderweyde et al. 2013). Additionally unfolded protein aggregates are a 
common feature in the pathology of MND, over 95% of patients present with 
cytoplasmic aggregates of the RBP TDP43 (Manuela Neumann et al. 2006). 
Protein aggregates share many similarities with SG; interactions within 
complexes are mediated by low complexity regions such as glycine-rich 
domains, they contain ubiquitinated proteins and are dissociated by molecular 
chaperones. Nevertheless there are some fundamental differences too, under 
healthy conditions SG serve a characterized biological function and their 
formation is reversible, whereas in disease the function of the aggregates seen 
in MND/neurodegeneration is not yet fully understood but insights have shown 
that their dynamics are altered and formation becomes irreversible (Baron et al. 
2013; Molliex et al. 2015).  
Methods to study RNA regulation 
There are many different techniques available to study RNA regulation, 
including RNA sequencing (RNAseq), ribosome profiling and RT-PCR. 
Methods to study RNA regulation have advanced significantly in the past 
decade or so, from traditional biochemical approaches where a single 
RNA/RBP is studied at once to techniques that allow us to view entire cellular 
events on a global scale. Using high-throughout methodologies enables us to 
better grasp the complexity of RNA regulation in a given biological sample. 
These genomic techniques produce large amounts of data that require 
considerable computational analysis, which must be handled appropriately to 
ensure correct interpretation of biological relevance. Here I have chosen to use 
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RNA sequencing and iCLIP methodologies to begin to study RNA regulation in 
MND.  
i) RNAseq 
Initially microarrays opened up the opportunity to get a general view of the 
overall RNA activity, however there were many challenges associated with the 
method including a high signal-to-noise ratio and varying probe specificity and 
sensitivity. Subsequently the development of RNA sequencing has 
revolutionized genomics technologies by allowing us to capture a ‘snap-shot’ of 
the entire transcriptome in a high throughput, unbiased way. This in turn 
permits analysis of cellular dynamics by looking at gene expression and 
splicing changes in a highly quantitative and accurate manner. Advantages of 
using RNAseq over other techniques, such as microarrays, include: F The ability to detect transcripts that are not known (therefore there is no bias 
into what you select for as it doesn’t rely on any known genomic sequences), 
novel splice variants etc. F Allows some analysis of post transcriptional changes F Can detect Mutations/SNPs 
 
ii) Individual crosslinking and immunoprecipitation (CLIP) 
Given the key role of RBPs in the regulation of gene expression it is important 
to understand their precise functions, which we can begin to characterize by 
identifying a selected RBPs RNA targets and binding sites to nucleotide 
resolution. Single RBPs bind many RNAs and most RBPs bind to several sites 
on an individual RNA, so it is important to understand the complete landscape 
of protein-RNA interactions. Individual crosslinking and immunoprecipitation 
(CLIP) allows this. Further we can integrate this positional information with a 
functional read out such as RNAseq data to determine its effect on the 
transcriptome.  
 
There have been many techniques developed to study RNA-protein 
interactions in vivo beginning with RNA immunoprecipitation protocol (RIP). 
RIP detects RNA molecules bound to a protein of interests by 
immunoprecipitation followed by rt-PCR, microarray (RIP-chip) or high-
throughput sequencing (RIP-seq). However there are several major drawbacks 
to this methodology; firstly is the reliance on the specificity of protein-RNA 
interaction being maintained throughout cell lysis which can lead to the 
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detection of non-specific, false-positive interactions, and secondly RIP is 
unable to pinpoint the site of RNA interaction which is an important 
consideration in the mechanistic implications of RBP-RNA interactions.  
 
In 2003 Cross-linked immuno-precipitation (CLIP) was developed, which 
involves in vivo UV-cross-linking of RNA-binding proteins (RBPs) to interacting 
RNA targets (within 1A distance of each other). UV crosslinking only crosslinks 
directly bound nucleic acid-protein interactions - a major advantage compared 
to the use of formaldehyde, which had previously been used but was found to 
induce protein-protein crosslinking too and other artifacts leading to poor 
distinction between direct and indirect interactions (Ule et al. 2005). UV 
crosslinking allowed for more stringent purification conditions throughout and 
massively improved signal-to-noise ratio and the detection rate of non-specific 
interactions. Since, cross-linking of RNA-protein complexes has emerged as 
the standard for identifying functional interactions. Following crosslinking in the 
CLIP method is cell lysis, RNase digestion to generate optimal size fragments 
for sequencing, immuno-purification of the RBP-of-interest, treatment with 
proteinase K to digest the bound protein and linker ligation to allow RT-PCR 
amplification of the bound RNA to generate a library for sequencing (sanger 
was originally used) (Ule et al. 2003). An important quality control step included 
is the SDS-page purification of RBP-RNA complexes, after linker ligation. This 
visualization allows for selection of RBP of interest and removed free RNA.  
 
Subsequently there have been several variations of the CLIP methodology. 
Firstly high-throughput sequencing of RNA isolated by CLIP (HITS-CLIP) 
combined CLIP with high-throughput sequencing giving a greater sequencing 
depth which enabled a more comprehensive map of RBP-RNA interactions in 
vivo (Licatalosi et al. 2008). Still a major drawback of the approach is the 
resolution of binding which is correlated to the length of fragmented RNA 
(typically 30-60nts). New strategies were developed shortly afterwards to 
overcome this, in 2010 Hafner et al present photoactivatable-ribonucleoside-
enhanced CLIP (PAR-CLIP) (Hafner et al. 2010) Briefly, PAR-CLIP uses 
photoactivatable nucleotide analogues such as 4-thiouridine (4-SU) or 6-
thioguanosine (6-SG), which are cross-linked efficiently with UVA at 365nm 
(oppose to the standard with UVC at 254nm) and cause a base transition at the 
crosslink site during reverse transcription. This enables us to detect the 
crosslink site by analyzing the site of mutation in the resulting cDNA 
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sequences. The approach is of course limited to cell cultures that can 
effectively incorporate photoactivable nucleotide analogues.  
 
In addition, in 2011 Konig et al demonstrate individual nucleotide-resolution 
CLIP  (iCLIP) (König et al. 2011).  Until 2011 it was established that reverse 
transcriptase read through sites of residual peptide-RNA cross-links. However 
Zhang and Darnell discovered that the reverse transcriptase used in CLIP 
skipped a nucleotide at the crosslink site due to a couple of peptides remaining 
attached to the RNA after proteinase K digestion (Chaolin Zhang and Robert B. 
Darnell 2011). Thus errors at these sites can be leveraged to map protein-RNA 
interactions with single nucleotide resolution. Moreover iCLIP was developed 
where they reasoned that reverse transcription would be truncated at the site of 
binding due to a couple of peptides remaining attached to the RNA after 
proteinase K digestion. Therefore, they were able to show reverse transcription 
arrest at the binding site could be used to define cross-link sites to nucleotide 
resolution; the mapped truncation site is located one nucleotide downstream of 
the cross-link site. In iCLIP the adapter ligation is altered to accommodate the 
transcriptional arrest. A unique adapter containing P3 and P5 sequences is 
used, and after reverse transcription the RNA and adapter are circularized, 
then cut between P3/P5 sequences before PCR and sequencing. All 
approaches discussed are multi-step and multi-day protocols, which require 
tightly controlled conditions to ensure accurate profiling of the RBP-of-interest 
(Huppertz et al. 2014), but more comprehensive review and comparison of the 
approaches is discussed elsewhere (König et al. 2012; Modic, Ule, and Sibley 
2013). 
 
To date CLIP has been successfully used to study multiple RBPs revealing 
their diverse role in post transcriptional regulation, for example regulation of 
alternative splicing by Nova (Licatalosi et al. 2008) or competitive binding 
between RBPs to control cryptic  element  exonization such as hnRNPC  and  
U2AF65 (Zarnack et al. 2013). It has also revealed important insight into 
disease linked RBPs such as TDP43 and FUS (Lagier-Tourenne et al. 2012; 
Rogelj et al. 2012; Tollervey et al. 2011). Lastly, CLIP has recently been 
adapted for the simultaneous capture and monitoring of all RBPs following 
oligo-dT capture of mRNA (Baltz et al. 2012). Fittingly, CLIP is now considered 
the method of choice to study the control of post-transcriptional networks by 
RBPs.  
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Aims of this thesis 
The overarching aim of this thesis is to capture the earliest pathogenic events that 
occur in MND using control and VCP-mutant carrying patient derived hiPSCs. I use a 
combination of patient specific hiPSC-derived neural derivatives and functional 
genomic technologies, including RNA sequencing (RNAseq) and individual nucleotide 
resolution UV cross linking with immunoprecipitation (iCLIP), to understand the role of 
dysfunction RNA regulation in VCP-related MND.  Further, I address collaboratively the 
presence and onset of other phenotypes, that have been previously associated with 
MND in our VCP hiPSC derived neural cells.  
 
More specifically my aims for the PhD are; 
 
1) To develop and refine directed differentiation strategies for hiPSC to 
spinal cord MNs and ACs. 
 
2) Optimise the functional genomic techniques, RNAseq and iCLIP, to 
explore molecular events in hiPSCs.  
 
3) To conduct a temporal and unbiased transcriptome-wide analysis of 
early molecular events in MND caused by VCP mutations using RNA 
sequencing. 
 
4) In Parallel to 2), conduct a temporal analysis through the 
differentiation and maturation of MNs and ACs to examine a range of 
other phenotypes (rationalized by pathways previously implicated in 
MND) that could contribute to VCP-related MND.  
 
5) Characterise the role of TDP43 in VCP-related MND 
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Chapter 2; Methods 
iPSC culture 
Derivation of Human Fibroblasts and iPSC Generation 
Dr. Selina Wray and team acquired dermal fibroblasts and cultured them in 
OptiMEM +10% FCS medium. They transfected the following episomal 
plasmids into the fibroblast samples for iPSC generation: pCXLE hOct4 shp53, 
pCXLE hSK and pCXLE hUL (Addgene), as previously reported (Okita et al. 
2011). Informed consent was obtained from all patients prior to skin biopsy. 
iPSC maintenance  
hiPSC were propagated using an adherent monolayer system on plates pre-
coated with Gel-trex basement membrane matrix (150µg/ml) with Essential 8 
medium (containing DMEM/F-12, L-ascorbic acid, selenium, transferrin, 
NaHCO3, insulin, fibroblast growth factor-2 and transforming growth factor β1) 
(A1517001, Thermo Scientific). 
 
Passaging: hiPSC were passaged when cells reached approximately 70% 
confluency using 0.5mM Ethylenediaminetetraacetic Acid (EDTA) in DPBS.  
 
Freezing procedure: EDTA is used to dissociate the cells, taken up in 90% 
medium and 10% dimethylsulfoxide (DMSO), a cyroprotectant and placed in a 
freezing vial. Vials were placed at -80°C overnight in a cyropreservant 
container, that controls the rate of cooling, then transferred the following day for 
long term storage in liquid nitrogen.  
 
Thawing procedure: The cryovial of cells was held in a 37°C water bath until 
only an ice crystal remains, 1ml of media was then added dropwise onto the 
cells, which were next added to a larger tube containing approx. 10mls of 
medium, centrifuged at 180x G for 5 minutes, resuspended in 1ml of medium 
and plated onto pre-coated plates. 
Motor Neuron differentiation 
The differentiation of hiPSCs to motor neurons was divided into 3 stages; 
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1) Neural conversion  
For neural conversion cells were plated to 100% confluency and fed for 10days 
with neural maintenance media (consisting of DMEM/F12 Glutamax, 
Neurobasal media, Pen Strep, L-Glutamine, N2 supplement, Non essential 
amino acids, B27 supplement, B-mercaptoethanol and Insulin) supplemented 
with 10µM SB431542 and 1µM Dorsomophin – (dual SMAD inhibition). Media 
was changed daily during these 10days. After 10days the neural epithelial 
sheet is lifted, washed 3x in neural maintenance media and spun for 1minute at 
1000g, before plating down onto laminin coated plates (laminin used at 10-
40µg/ml in DPBS). The neural epithelial sheet was lifted by spiking dispase 
(1:5) into the media and incubating at 37°C for approximately 15minutes, once 
the edges started to lift detachment of the sheet was aided by gently tapping 
the culture dish and/or gently pipetting up and down around the edges using a 
p1000.  
2) Patterning 
The next phase in differentiation is patterning. For generation of spinal cord 
motor neurons we fed the neurally converted cells daily with neural 
maintenance media supplemented with 1µM Pur (ventralise) and 0.5µM RA 
(caudalise) for 8days. During these 8days cells are cultured in clumps and are 
were fed with extra care in order to not disrupt cellular clumps/cell-to-cell 
signaling, sometimes this involved only partially removing the media and 
replacing with fresh.  
3) Terminal differentiation 
After patterning, NPCs were split using accustase to promote a single cell 
suspension (media was removed and NPCs were incubated with accutase at 
37°C for 2-3minutes). Cells were then terminally differentiated on laminin 
coated plates (laminin used at 20-40µg/ml in DPBS) fed with neural 
maintenance media for a minimum of 35 days.  
 
Accelerated motorneurogenesis protocol (A more detailed version of 
the protocol can be found in appendix 8.1) 
hiPSCs were first differentiated to neuroepithelia by plating hiPSC to 100% 
confluency and feeding with neural maintenance media supplemented with 3 
compounds; 2µM SB431542, 1µM dorsomorphin and CHIR99021 (3 µM) for 7 
days. At day 8, the neuroepithelial layer was lifted using dispase, plated onto 
! 44!
laminin coated plates and patterned for 7days with 0.5µM RA and 1µM 
Purmorphamine, to respectively caudalise and ventralise precursors to the 
pMN domain. At day 14 progenitors were expanded in neural maintenance 
media supplemented with 0.1µM Purmorphamine for an additional 4 days 
patterning before being plated on fresh laminin for terminal differentiation. To 
generate synchronized postmitotic neurons, the cultures were treated from day 
18 with 0.1µM compound E to promote cell cycle exit. During terminal 
differentiation media was changed 2-3 times weekly.  
Neural Propagation 
After Neural Patterning (Day14), neural precursors can be 
expanded/propagated before terminal differentiation to increase the 
yield/material generated. For this purpose neural precursors are plated on gel-
trex and fed with neural maintenance media supplemented with 10ng/µl FGF 
for a maximum of 30days. Precursors are then terminally differentiated as 
above in neural maintenance media plus 0.1µM compound E on laminin‐coated 
plates. 
Astrocyte differentiation 
For astrocyte differentiation, hiPSC under went neuronal conversion and 
patterning as described above. Afterwards, they were propagated in gel-trex 
coated flasks in neural maintenance media supplemented with 20ng/µl FGF for 
50-90days. They were passaged approximately every 7days using EDTA and 
as they aged, progressively harsher trituration with a p1000 was used. Media 
was changed 2-3 times per week. For terminal differentiation propagated 
precursors were plated onto freshly coated gel-trex plates and fed 2-3 times 
weekly with neural maintenance media supplemented with 10ng/µl BMP4 and 
10ng/µl LIF for a minimum of 2weeks.  
Astrogliogenesis after an accelerated conversion to spinal neural 
precursors 
For astrocyte differentiation, hiPSCs also undergo an accelerated neural 
conversion and patterning using the method described above. As before an 
additional propagation phase is required before terminal differentiation to allow 
NPCs to undergo the gliogenic switch, this was again done by plating 
precursors on gel-trex coated plates and feeding 2-3 times weekly with neural 
maintenance media supplemented with 10ng/µl FGF. Terminal differentiation is 
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as before (treated with 10ng/µl BMP4 and 10ng/µl LIF for a minimum of 
2weeks).  
Electrophysiology 
MNs were plated at approximately 50,000 cells/cm2 on glass coverslips and 
allowed to mature for 2-3 weeks. Whole-cell patch-clamp recordings and 
analysis were carried out by Sarah Crisp, in Dimitri Kullmann’s lab. Coverslips 
were continuously perfused in a recording chamber with extracellular solution 
containing 125 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 2.5 mM KCl, 10 mM 
HEPES, 30 mM glucose, pH 7.3 with NaOH, 290 mOsm, at room temperature. 
Neurons were visualised using an Evolve Delta EMCCD camera 
(Photometrics) and MultiManager software, connected to an Olympus IX73 
microscope with difference interference contrast optics. Recordings were made 
using 5-6 MΩ pipettes filled with K-gluconate intracellular solution (126 mM K-
gluconate, 4 mM NaCl, 1 mM MgSO4, 0.02 mM CaCl2, 0.1 mM BAPTA, 15 
mM glucose, 5 mM HEPES, 3 mM MgATP, 0.1 mM NaGTP, pH 7.3 with KOH, 
280 mOsm with sucrose), to achieve an access resistance of less than 20 MΩ. 
Cells showing >20% change in series resistance during the course of recording 
were rejected. Current clamp recordings were obtained using a MultiClamp 
700B amplifier (Molecular Devices), acquired at 50 kHz and filtered at 10 kHz. 
Data acquisition and offline analysis were performed using LabView 2014 
(National Instruments). The calculated liquid junction potential was 15.1 mV. All 
values shown are corrected for liquid junction potential. After setting the bridge 
balance and adjusting the holding current to keep the cell at −70 mV, 1-
second-long current injections, in 1-10 pA incremental steps, were delivered. A 
hyperpolarising step was used to determine passive properties. Depolarising 
steps were used to elicit action potentials. Parameters of action potentials were 
measured for the first action potential (defined as peak > 0 mV) elicited with 
each current injection. Values are reported as mean ± s.e.m. 
Imaging techniques 
Immunocytochemistry (ICC) 
Cells were plated onto pre-coated Ibidi 8 well chamber slides and left to 
attach/grow for a minimum of 4hours. Medium was removed and cells were 
washed twice in phosphate buffered saline (PBS) before being fixed in 4% 
paraformaldehyde in PBS for 30 minutes. Cells were washed twice each for ten 
minutes in PBS supplemented with 0.3% Triton-X (PBST). Non-specific 
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antibody binding was blocked with 5% normal goat serum in PBST for 60 
minutes and then incubated overnight at 4°C with primary antibody in 5% 
normal goat serum in PBST. Cells were washed three times for ten minutes 
each in PBST then incubated with complementary Alexa Fluor secondary 
antibody at 1:200 dilution in 5% normal goat serum in PBST for one hour at 
room temperature in the dark. Cells were washed once in PBST containing 
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) nuclear stain (two drops 
in 1 ml PBST) for ten minutes then washed a further two times for ten minutes 
in PBST and after removal of PBST one drop of ProLong Gold AntiFade was 
applied to each well and chamber slides were allowed to dry out in the dark 
overnight. Slides were inverted and cells were visualized under 
immunofluorescence. 
 
Table 2.1; Antibody table 
Target Company 
antibody 
bought from 
Catalog 
number 
Species Dilution 
Islet1 DSHB 40.2D6 Mouse IgG1 1:50 
HoxB4 DSHB I12 Mouse 
IgG2a 
1:50 
Olig2 Millipore AB9610 Rabbit 1:200 
FOXP1 Abcam AB16645 Rabbit 1:200 
SMI32 Cambridge 
Bioscience 
SMI-32R-500 Mouse IgG1 1:1000 
CHAT EMD Millipore AB144P Goat 1:100 
BIII tubulin Sigma T8578  Mouse 1:500 
3CB2 (VIM) DSHB 3CB2  Mouse IgM 1:5 
NFIA Abcam ab41851 Rabbit 1:1000 
GFAP Dako M 0761  Mouse IgG1 1:200 
GLAST Antibodies-
online 
ABIN350309 Rabbit 1:500 
TDP43 Proteintech 10782-2-AP Rabbit 1:500 
ATP5B Abcam ab14730 Mouse 1:500 
PDI New England 
Biolabs 
2446 Rabbit 1:50 
Syt1 Synaptic clone 41.1 Mouse 1:250 
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Systems 
 
MAP2 Abcam ab5392 Chicken 1:500 
 
Microscopy 
 Fluorescence 
All ICC was analyzed using fluorescence microscopy unless stated otherwise. 
Coverslips were imaged using the Hamamatsu camera controller C10600 and 
Leica DM5500B microscope. For each coverslip a minimum of 3 images were 
acquired at a magnification of 64x. Images were counted manually and 
statistics performed using Prism Graphpad version 6.  
 Confocal analysis of TDP43 
Coverslips were imaged using a Zeiss 710 Confocal, at 63x magnification, 1.4 
N.A. oil objective. A minimum of 3 Z-stack images were acquired per coverslip. 
Settings for acquisition and thresholding were kept standard for each 
experimental set. Image analysis was performed in Fiji software version 2.0.0-
rc-41/1.50d. Area of TDP43 staining was calculated for both nucleus (outlined 
by DAPI) and cytoplasmic compartments using analyze particle function, and 
the relative percentages of total were calculated. 
 Analysis of ER-mitochondria colocalization. 
ER-mitochondria colocalisation was analysed by Zhi Yao, under the 
supervision of Sonia Ghandi. Cultures (n=3) were immunolabelled for ATP5B 
and PDI. Cells were imaged using a Zeiss 710 confocal system with a 63x, 1.4 
N.A. oil objective. Z series of images were acquired using a pinhole diameter of 
1 Airy units (AU). Settings for acquisition and thresholding were kept standard 
for each experimental set. Colocalization of red and green signals was 
quantified with Zen software.  
 Analysis of synaptotagmin-1 staining 
Assessment of SYT1 positive puncta was performed by Dr. Andras Lakatos 
following published methods (Tyzack et al. 2014). Briefly, I immunolabelled 
cultures (3-4 technical repeats) for pre-synaptic (synaptotagmin-1), MN (Chat) 
and dendritic (MAP-2) markers. Following, Andras used confocal laser 
microscopy in 5mm depth to scan cultures and images were collected by 1mm 
apart. Scanning parameters were defined for the control groups and the same 
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settings were used for the mutant hiPSCs. SYT1 positive puncta were analysed 
using ImageJ (v1.0, NIH, plugin written by B. Wark and was provided to Dr A. 
Lakatos by Dr C. Eroglu). Threshold values were kept the same across the 
optical sections. The number of SYT-1 positive puncta colocalising with either 
the MAP-2/Chat immunoreactive soma or main dendrites was counted (N=26-
32 cell). SYT1 densities were defined by the number of puncta per cell 
area/dendrite length for each line. 
 
Live Cell imaging assays 
All live cell imaging experiments were done in collaboration with Minee Choi, 
Zhi Yao and Sonia Gandhi, except the axonal transport which was carried out 
by Alexander Fellows under the supervision of Gipi Schiavo.  
 Cell Survival Assays 
Cells were plated on Geltrex substrate and differentiated in 96 well plate. To 
determine the percentage of cell death, cells were loaded with 5ug/ml Hoechst 
33342 (cell permeable nuclear dye) and 1ug/ml membrane impermeant 
propidium iodide (PI) for 15 mins at room temperature in normal culture media. 
Image acquisition was performed using the ImageXpress system (Molecular 
Divices). Hoechst-stained nuclei were imaged using the 377nm excitation/530 
emission filter set and images were used to determine objects for total cell 
counting. PI staining were imaged using the 531nm excitation/590nm emission 
filter set. The number of PI positive cells were determined using the 
multiwavelength cell scoring module of the MetaXpress software. The threshold 
for counting PI+ cells was kept standard for each experimental set.  
 Measurement of mitochondrial membrane potential 
Mitochondrial membrane potential was measured by loading the cells with 
25nM tetramethylrhodamine methyl ester (TMRM, Life Technologies) for 40 
min in physiological buffer (138 mM NaCl, 5.6 mM KCl, 4.2 mM NaHCO3, 1.2 
mM NaH2PO4, 1.2 mM MgCl2, 2.6 mM CaCl2, 10 mM D-glucose and 10 mM 
HEPES). TMRM fluorescence signal was acquired using a Zeiss 710 confocal 
system with a 63x, 1.4 N.A. oil objective. Z series of images were acquired 
using a pinhole diameter of 1 Airy units (AU). TMRM fluorescence intensity was 
quantified by measuring the average TMRM fluorescence above threshold area 
on the maximal projection of the Z series using Metamorph software. Settings 
for acquisition and thresholding were kept standard for each experimental set.  
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 Imaging of intracellular ROS production 
ROS generation was measured with dihydroethidine (DHE, 10-40µM, 
Invitrogen). All imaging was performed in physiological buffer (138 mM NaCl, 
5.6 mM KCl, 4.2 mM NaHCO3, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.6 mM 
CaCl2, 10 mM D-glucose and 10 mM HEPES). To avoid accumulation of 
oxidized products, DHE was added immediately before measuring and was 
present in solution throughout the experiments. Imaging was performed either 
with a CCD camera on an epifluorescence inverted microscope or with the 
FLIPR system (Molecular devices).  
 Determination of GSH level 
Reduced glutathione (GSH) level was measured by incubation live cells with 
40µM monochlorobimane (mCB) for 1 hour in physiological buffer (138 mM 
NaCl, 5.6 mM KCl, 4.2 mM NaHCO3, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.6 mM 
CaCl2, 10 mM D-glucose and 10 mM HEPES). The fluorescence signal of GS-
mCB adduct was imaged using a Zeiss 710 confocal system with a 63x, 1.4 
N.A. oil objective and excitation 405nm / emission at 490 nm. GS-mCB 
fluorescence intensity was quantified by measuring the average fluorescence 
intensity above threshold area on the maximal projection of the Z series using 
Metamorph software. Settings for acquisition and thresholding were kept 
standard for each experimental set. 
 Axonal transport 
Motor neurons derived from human iPSCs were incubated with 30 nM HcT 
labeled with AlexaFluor 555 for 30 min at either day 6 or 19 days post terminal 
differentiation. Cultures were washed and fresh media was applied. Cells were 
then imaged using a Zeiss LSM 780 microscope equipped with a Zeiss X63, 
1.40 NA DIC Plan-Apochromat oil-immersion objective whilst kept at 37 °C. 
Retrograde transport was assessed using Motion Analysis software (Kinetic 
Imaging). 
Mouse primary motor neurons were cultured and kept until days 6-7 in vitro 
when method above was applied.  
Statistics using prism 
All experiments have a minimum of technical n=3 and biological n=2, unless 
otherwise stated. GraphPad Prism 6 was used to perform all statistical 
analysis.  Error bars represent mean ± SEM. Two-way analysis of variance was 
used to analyse independent variables in different groups. For SYT1 staining 
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analysis, Kruskal-Wallis (Dunn) post hoc tests was applied to analyse data 
pairs. Statistical significance was accepted at P-values of <0.05. *, **, *** 
indicate significance of P<0.05, P<0.01 and P<0.001 respectively. 
Biochemistry 
Western blot analysis 
Protein levels of a number of markers were quantified by Dr. Zhi Yao. Briefly, 
protein samples were extracted using 2x laemmli buffer (4% (w/v) SDS, 20% 
Glycerol, 120 mM Tris-Cl (pH 6.8)). Total protein concentration was quantified 
using BCA assay (Pierce). Equal amount of protein samples were then loaded 
and separated by SDS PAGE and transferred onto a nitrocellulose membrane. 
Samples were then incubated with primary antibodies overnight at 4°C followed 
by horseradish peroxidase conjugated secondary antibodies (Dako). The blots 
were imaged and the density was analysed using Bio-red imaging software. 
 
Functional Genomics/preparation of libraries for high 
throughput sequencing 
RNA isolation  
 1. Column-based RNA isolation 
Cell pellets were resuspended in 1ml qiazol (for up to 1x10^6cells) and left at 
room temp for 5minutes. (If extracting from brain tissue use Qiagen 
TissueRupter (9001273) to homogenize). An equal volume of 100% EtOH was 
added and mixed well by vortexing. The sample was applied directly to a 
Direct-zol RNA column (R2052, Cambridge Bioscience), placed in 2ml 
collection tube and spun through for 1min at 10,000g at 4°C. (A maximum of 
700µl can be applied to the column at one time so if necessary spin through 
part of sample, remove waste and repeat with remaining sample.) Waste and 
collection tube were discarded and the sample was in column DNAse treated. 
The column was then washed twice with 400µl RNA pre-wash buffer, once with 
700µl RNA wash buffer and spun through for 1min at 10,000g and 4°C to dry 
column. The column was placed inside a new 1.5ml collection tube and the 
RNA sample was eluted in 50µl of nuclease free H20. 
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 2. An automated RNA isolation approach 
RNA was extracted using an automated approach, using the promega Maxwell 
RSC instrument and Maxwell® RSC simplyRNA Cells Kit (AS1390, Promega). 
Before the automated process, cell pellets were homogenized with a chilled 1-
Thioglycerol/homogenisation solution, triturated and vortexed to break up the 
pellet then immediately before loading cells were lysed and vortexed again. A 
DNase step is included in the automated process. Up to 16 samples were 
processed at once. 
 Post RNA extraction QC 
Samples are measured with nanodrop to check RNA concentration, pure RNA 
samples will have a 260/280 ratio of 2.0-2.1 and on the agilent bioanalyser to 
assess quality, RNA integrity (RIN) scores are >8 for downstream applications 
(few exceptions were processed with RIN scores >7.5).  
RNA sequencing (including steps for ribosomal RNA depletion) 
 Approach 1; NEXTflex Directional RNAseq  
Firstly ribosomal RNA (rRNA) was depleted using the Qiagen generead rRNA 
depletion kit. After rRNA depletion (or PolyA selection of mRNA), 100ng of 
each sample was taken forward for library preparation using the NEXTflex 
Directional RNA-Seq Kit (dUTP-Based) v2. Briefly, samples were fragmented 
(enzymatically) to obtain optimal size for sequencing, first strand synthesis was 
followed by second strand synthesis with dUTP to retain directionality, ends of 
fragments were adenylated before the ligation of adapters (which include 
barcodes).  Finally samples underwent UDG digestion and 15cycles PCR 
reaction. Quality of each library was checked individually using a DNA1000 
bioanalyser prior to multiplexing and sequencing on a Hiseq.  
 Approach 2; Truseq stranded mRNA library preparation 
Firstly, using the Truseq stranded mRNA RNAseq kit (RS-301-2001/2, 
Illumina), the poly-A containing mRNA molecules were purified from 0.1-4ug 
total RNA input using poly-T oligo attached to magnetic beads. Following 
purification, the mRNA was fragmented into small pieces using divalent cations 
under elevated temperature. The cleaved RNA fragments were copied into first 
strand cDNA using reverse transcriptase and random primers. Strand 
specificity was achieved by replacing dTTP with dUTP in the Second Strand 
Marking Mix (SMM), followed by second strand cDNA synthesis using DNA 
Polymerase I and RNase H. The incorporation of dUTP in second strand 
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synthesis quenched the second strand during amplification, because the 
polymerase used is not incorporated past this nucleotide. The addition of 
Actinomycin D to First Stand Synthesis Act D mix (FSA) prevented spurious 
DNA-dependent synthesis, while allowing RNA-dependent synthesis, improving 
strand specificity. These cDNA fragments next underwent ‘end repair’ 
(adenylation) where a single 'A' base was added to each strand, followed by 
ligation of an adapter (containing 6nucleotide barcode – allows multiplexing for 
sequencing). The products were then purified and enriched with PCR 
amplification to create the final cDNA library.  
 Approach 3; Truseq Access RNAseq  
The Truseq Access kit (RS-122-2101/2, Illumina) uses total RNA sequencing to 
create a template library, from which the coding regions are captured and 
sequenced. So firstly the total RNA (100ng input) was fragmented into small 
pieces, cDNA was generated using random priming during first and second 
strand synthesis and sequencing adapters were ligated to the resulting double-
stranded cDNA fragments. The coding regions of the transcriptome were then 
captured from this library using sequence-specific probes, then a final round of 
PCR amplification and second strand digestion occurred to create the final 
library. 
iCLIP 
Reagents: 
RT primers used: 
Rt22clip NNAGAGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt23clip NNAGTCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt24clip NNATACNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt25clip NNATCANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt26clip NNCAAGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt27clip NNCAGANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt28clip NNCCACNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt29clip NNCCCTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt35clip NNGAGTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt36clip NNGATGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
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Rt37clip NNGCAGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt38clip NNGCTCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt39clip NNGGACNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC  
Rt40clip NNGGCGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt41clip NNGTATNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt42clip NNGTTANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt43clip NNTAACNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt44clip NNTACANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt46clip NNTCTANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
 
Pre-adenylated 3’ adaptor DNA (ordered from IDT): 
L3-App: rAppAGATCGGAAGAGCGGTTCAG/ddC/  
 
Cut_oligo:  
GTTCAGGATCCACGACGCTCTTCaaaa 
 
PCR primers:  
P3 Solexa:  
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCG
CTCTTCCGATCT 
 
P5 Solexa:   
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT
TCCGATCT 
Buffers:
Lysis Buffer 
 
 
 
50 mM Tris-HCl, pH 7.4  
100 mM NaCl  
1% Igepal CA-630 (Sigma I8896)  
0.1% SDS  
0.5% sodium deoxycholate 
 
 
High salt wash 
 
 
 
50 mM Tris-HCl, pH 7.4  
1M NaCl  
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1M EDTA 
1% Igepal CA-630 (Sigma I8896)  
0.1% SDS  
0.5% sodium deoxycholate
  
PNK Buffer 
 
 
 
 
 
50 mM Tris-HCl, pH 7.4  
100 mM NaCl2  
20 mM Tris-HCl, pH 7.4  
10 mM MgCl2 
0.2% Tween-20 
 
5x PNK pH 6.5 Buffer:  
(freeze aliquots of the 
buffer, do not thaw and 
freeze again)  
 
 
350 mM Tris-HCl, pH 6.5  
50 mM MgCl2 
5 mM dithiothreitol  
 
4x Ligation Buffer 
(freeze aliquots of the 
buffer, do not thaw and 
freeze again)  
 
200 mM Tris-HCl, pH 7.8  
40 mM MgCl2 
4 mM dithiothreitol  
 
PK Buffer  
 
 
100 mM Tris-HCl, pH 7.4  
50 mM NaCl  
10 mM EDTA 
  
PK Buffer + 7 M Urea  
 
 
 
100 mM Tris-HCl, pH 7.4  
50 mM NaCl  
10 mM EDTA  
7 M urea 
 
Method (as displayed in Figure 2.1): 
Cell samples were UV crosslinked with 0.15mJ/cm2 254nm UV light, to 
preserve RNA-RBP interactions by covalently binding protein-RNA in vivo. 
Cells were lysed in lysis buffer plus 1/100 protease inhibitors and 1/1000 anti-
RNase, then sonicated (30second bursts followed by 30secounds rest, x 
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10cycles) and partially fragmented by incubation with RNase I at 37°C for 
3minutes, to produce optimal size fragments for sequencing (RNase 
dilution/conditions adjusted per experiment, I used 1/1000 dilution low RNase 
and 1/10 dilution for high RNase). Protein-RNA complexes were 
immunoprecipitated under stringent conditions using antibodies specific to 
target protein. Next the RNA in the protein-RNA complexes is 
dephosphorylyated, an adapter is ligated to the 3’ end of each RNA molecule 
and the 5’end is labeled with p32. Gel electrophoresis and nitrocellulose 
transfer, under denaturing conditions, were carried out to remove RNA not 
bound by the protein of interest and to visualize the protein-RNA complexes. 
The p32 signal guided the excision of protein-RNA complexes off the 
membrane. Proteins were digested away using proteinase K (This usually 
leaves a single peptide/amino acid at the crosslink site) and remaining RNA 
underwent reverse transcription, which truncated at the crosslink site 
preserving the position of binding. The oligonucleotides for reverse 
transcription contain two inversely oriented adaptor regions (P3/5) separated 
by a BamHI restriction site as well as a barcode region at their 5′ end 
containing a 2-nt barcode to mark the experiment and a 3-nt random barcode 
to mark individual cDNA molecules enabling multiplexing and removal of PCR 
duplicates. Gel purification was used to remove primers and size-select cDNA 
samples. Single stranded cDNA is then circularized, and an oligo 
complementary to the BamHI site was annealed to allow BamHI to cut at the 
restriction site, linearizing the cDNA. Finally libraries were PCR amplified and 
multiplexed (usually mixing the medium and high fragments of each library in a 
ratio of 1:2 respectively). 
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Figure 2.1; Schematic representation of the iCLIP protocol identifying RNA–
protein interactions in vivo.  
Library quantification and sequencing 
It is important to accurately quantify libraries before sequencing to ensure 
optimal sequencing capacity. Overestimation of library concentration results in 
lower cluster density after bridge PCR, however underestimation of library 
concentration results in too many clusters on the flow cell, which can lead to 
poor cluster resolution. I have used several methods to check quality of 
libraries before sequencing.  
 Bioanalyser 
Agilent bioanalyser 2100 was run with the agilent RNA nano 6000 kit (5067-
1511) to check total RNA quality before samples are used for downstream 
experiments. The standard protocol from agilent was followed. Two peaks 
representing ribosomal RNA usually dominate the trace and these are used to 
calculate RIN score. The agilent High sensitivity DNA 1000 kit (5067-4627) was 
then used check library quality, which is usually normally distributed with an 
average fragment size of 275-300nt (again the standard protocol from agilent 
was followed).  
Taken&from&Huppertz&et&al.&2014&
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 Qubit 
The Qubit dsDNA HS (High Sensitivity) Assay Kit (Q32854, Thermo Scientific) 
was used with the Qubit® Fluorometer to measure library concentration. The 
assay is highly selective for double-stranded DNA (dsDNA) over RNA and is 
designed to be accurate for initial sample concentrations from 10 pg/µL to 100 
ng/µL.  
 qPCR Kapa 
qPCR is widely regarded as the gold standard for accurate quantification of 
DNA libraries as it is the only technique capable of measuring the number of 
amplifiable molecules. KAPA SYBR FAST qPCR kit (KK4824, Insight Biotech) 
was used for final library quantification before sequencing.  
 High-throughput Sequencing 
Libraries were sent for high throughput sequencing at the Institute of 
Neurology’s NGS core facility using the Hiseq2500. They were typically 
sequenced on a single-end read rapid flow cell for 50 cycles plus separate 
indexing cycles to enable de-multiplexing (an additional cycle was ran after the 
final cycle and the final index cycle to ensure accurate basecalling for the final 
cycles).  
Computational methods 
Mapping and annotation of RNAseq data 
For the processing and analysis of RNAseq samples I have set up a 
bioinformatics pipeline, with the guidance of Dr. Chris Sibley (the same 
workflow is used to analyze all three RNAseq approaches) (Figure 2.2). 
 
Primary analysis was carried out during sequencing on the Illumina Hiseq2500; 
RTA realtime analysis software converts TIFF images to intensity scores and 
then to basecalls. Alan Pittman next generated FastQ files from the basecalls, 
using casava version 1.8.2. FastQ files  are de-multiplexed raw data files that 
contain information on the bases and their quality. Samples were taken forward 
if 90% of the data had a quality score >Q30 and had passed filter (an 
automated Illumina QC step which analyses each cluster quality individually 
and removes poor quality data).  
 
Next I removed the 3’ Solexa adapter sequence and sequences shorter than 
24 nucleotides using fastx_clipper (part of the Fastx toolkit, version 0.0.13), 
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generating ‘clipped’ data. Afterwards the quality of the sequencing data was 
checked using FastQC, version 0.11.2. (Fastq raw data files were used as 
input). FastQC displayed multiple summary graphs to easily visualize the data 
quality; information includes sequence quality per base & per tile & across 
sequences, sequence content per base, GC % per sequence, distribution of 
sequence lengths across all sequences, sequence duplication levels, adapter 
content and kmer content.  
 
Secondary analysis included aligning, annotating, and counting the data. I 
aligned the clipped data using tophat2 a splice aware aligner; this extracted 
transcript sequences and used bowtie indexes to align reads to a reference 
genome (bowtie2-2.2.3 was used to compile hg19 or mm10). I allowed 1 
mismatch and have used annotation taken from ensembl (version 60). At this 
stage the % of each library that maps to the genome and number of duplicated 
reads was assessed (all samples I have used map >80-90% to hg19/mm10). 
Samtools flagstat was used to detect any duplicated reads. Additionally the % 
of ribosomal reads, strandedness, % mapping to exons/introns/intergenic 
regions in each library was evaluated before continuing with any downstream 
analysis. I used Seqmonk to get an overview of quality across all experimental 
samples but a more accurate calculation was performed by Dr. Raphealle 
Luisier in Prof. Nicholas Luscombe’s lab. Raphaelle used Bowtie to map 
ribosomal reads and then tophat2 to map those reads that did not correspond 
to rRNA, strandedness was calculated by counting the reads which align on (+) 
versus (-) strand of each transcript and then counting the fraction which map to 
the colinear strand (antisense strand given RNAseq approached used) and the 
percentage of reads mapping to intronic, exonic and intergenic regions was 
counted using HTSeq count. A threshold of >70% mapping to exonic regions, 
<1% rRNA and >90% strandedness is used throughout this thesis. 
 
Following this, I counted the aligned reads and genomic features (eg. genes) 
using htseq-count (version HTseq-0.6.1 & python version 2.7.9). I used S 
resolution mode, which allows one count per feature, but if the read contains 
more than one feature it is counted as ambiguous (and not counted for any 
features) and if the read doesn’t overlap any feature, it is counted as 
no_feature. The output BAM/SAM files were also used to visualize the data in 
the IGV browser (indexing BAI files were generated using samtools). 
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Finally the data is normalized and interpreted using a variety of downstream 
analysis tools. Initially I normalized the data by calculating rpkm values (reads 
per kilobase per million mapped reads) using the edgeR package in R, which 
takes into account the gene length. These RPKM values were firstly used to 
carry out a final quality check of the data; I confirmed the expression of cell-
specific markers in each sample before continuing with any further analysis, for 
example CHAT, Islet1, BetaIII and Olig2 expression in the MN samples. RPKM 
values were also used to analyze the expression of selected genes of interest 
across samples after they have undergone log transformation to account for 
differences in library size.  
Differential expression analysis 
After carrying out essential sample and experimental quality checks, principal 
component analysis and hierarchical clustering was performed to assess 
sample clustering using DEseq2 package on R (version 3.2.3). Next Differential 
expression was carried out using DESeq2 (version 1.10.1). DEseq assumes a 
negative binomial distribution model and uses a scaling factor normalisation to 
account for different sequencing depth between samples and Benjamini-
Hochberg method to control the FDR. The thresholds used to detect 
differentially expressed genes in this thesis were ≥1.5 log (fold change), FDR < 
0.1 and p < 0.05, unless otherwise stated.  
 
Further gene ontology (GO-term) analysis was performed using the DAVID 
software online (https://david.ncifcrf.gov/). All genes with base mean >10 were 
used as the background.  
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Figure 2.2; RNAseq analysis pipeline 
iCLIP 
iCLIP libraries have been analysed on the icount server (http://icount.biolab.si), 
which is set up and maintained by Tomaz Curk  (König et al. 2011; Tollervey et 
al. 2011; Ule et al. 2010). Firstly sequencing data passes several QC/filtering 
stages and then was mapped (to hg19) and annotated (using ensemble version 
60). Crosslink sites were identified and the level of binding at each site 
quantified. The % binding within different genomic regions eg. Intronic, ncRNA 
was counted (downloaded from sumtype files). Mapped data was downloaded 
from cross-link maps tab for individual samples and grouped tab for pooled 
data (sum of multiple repeats). For this thesis G files were used for all analysis 
with the exception of repeat element analysis (chapter 4) where B files were 
used. G files contain single hits in the genome (random barcodes were taken 
into account). B files include both single and multiple hits in the genome (up to 
Fastq files generated (demultiplexed raw data) 
Align and annotate ‘Clipped’ RNAseq reads to reference genome 
(hg19/mm10)  (Tophat2 and Bowtie) 
Visualize 
reads in a 
genome 
broswer 
(IGV) 
Count RNAseq reads and genomic features  (Htseqcount) 
Assess the % rRNA reads, 
strandedness, and genomic 
distribution (Seqmonk) 
Sequence quality (FastQC) 
Calculate 
RPKM values 
Removal of sequences <24 nt and adapter sequences 
Differential expression 
analysis (DEseq2) 
RNAseq libraries are sequenced on Hiseq2500 
(Quality assessments) 
GO analysis 
Principle component 
analysis 
Confirm the expression of 
cell-type specific markers 
Normalization 
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20 multiple hits are allowed) and the results are weighted (the weight of the 
sequence is divided by the number of its multiple hits). 
 
Crosslink clusters were identified using peaks analysis, parameters were set to 
create clusters that are 15nt apart and sites with FDR <0.05 were considered 
significant.  
 
To calculate the base frequencies of iCLIP sequence reads, the genomic 
sequence corresponding to the first 10 nucleotides of all reads plus 11 
nucleotides of preceding sequence was extracted. 1000 sequences were 
randomly selected per sample and were presented graphically using Weblogo 
(version 2.8.2). Further sequence analysis of iCLIP crosslink sites was 
performed using kmer analysis. Standard kmer analysis was performed by 
extending the position of the crosslinking site 10 nt in both directions then 
enriched pentamer z-scores were calculated by taking the true score (total 
number of times the kmer is counted in defined 20nt region surrounding x-link 
site) divided by the mean random score (number of times the kmer is counted 
in the same sequences after random shuffling).  
  
% of binding to repeat elements and motif enrichment analysis was processed 
by Nejc Haberman. Motif enrichment was performed using dreme (version 
4.11.2) using tetramers and pentamers and the two sets of site to compare 
were used as the background for each other. Finally Crosslink sites between 
grouped were compared using compare analysis on icount.  
Graphics in R 
Graphics (heatmaps/correlation plots/bar plots/box plots) were generated in R 
version 3.2.3, using Bioconductor version 3.1 (BiocInstaller 1.18.5). Ggplot2 
(2.1.0) package was used for bar, box and scatterplots.  
 
Materials list 
!
Reagent Catalogue number Supplier 
4-12%BisTris gel 
1.0mmx12wells 
NP0322BOX Life Technologies 
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4-12%BisTris gel 
1.0mmx15wells 
NP0316BOX Life Technologies 
4-thiouridine T4509-100MG Sigma 
4′,6-Diamidino-2-
phenylindole 
dihydrochloride (DAPI) 
D9542 Sigma 
6%TBE gel 1mmx12wells EC62652BOX Life Technologies 
6%TBE gel 1mmx15wells EC62655BOX Life Technologies 
6%TBE UREA gel 
1mmx10wells 
EC6865BOX Life Technologies 
Accutase A11105-01 Invitrogen 
Agilent RNA 6000 Nano 
Kit 
5067-1511 Agilent 
Agilent High Sensitivity 
DNA Reagents 
5067-4627 Agilent 
Alexa Fluor® 568 Goat 
Anti-Mouse IgG1 (γ1) 
A-21124 Thermo fisher scientific 
Anti-3CB2 antibody (VIM) 3CB2 DSHB 
Anti-ATP5B Antibody ab14730 Abcam 
Anti-Choline 
Acetyltransferase Antibody 
(CHAT) 
AB144P EMD Millipore 
Anti-FOXP1 antibody AB16645 Abcam 
Anti-Human SLC1A3 
rabbit antibody (GLAST) 
ABIN350309 Antibodies-online 
Anti-MAP2 antibody ab5392 Abcam 
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Anti-neurofilament H 
(SMI32) 
SMI-32R-500 Cambridge Bioscience 
Anti-NFIA antibody ab41851 Abcam 
Anti-Olig2 antibody AB9610 Millipore 
Atto633 adapter 
Non-catalog 
synthesis request 
(/5rApp/AGATCGGA
AGAGCGGT 
TCAG/3Mod/) 
Intergrated DNA 
Technologies 
B27 supplement 17504-044 Thermo-scientific 
Compound E ALX-270-415-M001 Enzo Life sciences 
Costar-X filter spin 
columns 
CLS8161-100EA Sigma 
Coverslips (round 
13/22mm thick) 
631-0158 VWR 
Cryovials 2ml (2) 430488 Sigma-Aldrich 
Dimethyl sulfoxide D2650 Sigma 
Direct-zol™ RNA 
MiniPrep, 200 preps, w/ 
Zymo-Spin™ IIC Columns 
R2052 Cambridge Bioscience 
Dispase 17105-041 Invitrogen 
Dithiothreitol D9779-10G Sigma 
DMEM-GLUTAMAX 31966-047 
GIBCO (Life 
Technologies) 
DMEM/F12 10565018 Thermo-scientific 
dNTPs R0191 Life Technologies 
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Donkey anti-Goat IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
568 conjugate 
A-11057 Thermo fisher scientific 
Dorspomorphin 3093/10 R and D systems 
Dulbecco's Phosphate-
Buffered Saline (DPBS) 
14190-250 Life Technologies 
Dynabeads® Protein A 10002D Life Technologies 
Dynabeads® Protein G 10004D Invitrogen 
Essential 8 Medium A1517001 Thermo-scientific 
Ethylenediaminetetraaceti
c acid (EDTA) 
15575-020 Life Technologies 
Fluorescence Mounting 
Medium 
S302380-2 Dako 
FOXP1 AB16645 Abcam 
Geltrex A1413302 Invitrogen 
GeneRead rRNA 
Depletion Kit (6) 
180211 Qiagen 
GlycoBlue™ Coprecipitant 
(15 mg/mL) 
AM9516 Life Technology 
Goat anti-Chicken IgY 
(H+L) Secondary 
Antibody, Alexa Fluor® 
488 conjugate 
A-11039 Thermo fisher scientific 
Goat anti-Mouse IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
A-11004 Thermo fisher scientific 
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568 conjugate 
Goat anti-Mouse IgG2b 
Secondary Antibody, 
Alexa Fluor® 488 
conjugate 
A-21141 Thermo fisher scientific 
Goat anti-Rabbit IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
488 conjugate 
A-11008 Thermo fisher scientific 
HoxB4 antibody I12 DSHB 
IBIDI chamber slides IB-80826 Thistle Scientific 
Igepal (NP-40) I8896 Sigma 
Islet1 antibody 40.2D6 DSHB 
L-Glutamine 25030-024 Invitrogen 
Laminin L2020 Sigma 
Leukemia Inhibitory Factor 
human 
L5283 Sigma 
Library Quantification Kit - 
Illumina/Universal 
KK4824 Insight Biotechnology 
LookOut Mycoplasma 
PCR Detection Kit 
MP0035-1KT Sigma 
Low Molecular weight 
DNA Ladder 
N3233L New England Biolabs 
Magnesium chloride 63020-1L Sigma 
Maxwell(R) RSC 
simplyRNA Cells 
AS1390 Promega 
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Maxwell(R) RSC System AS4500 Promega 
Monoclonal Anti-β-Tubulin 
III 
T8578 Sigma 
Monoclonal Mouse Anti-
Human Glial Fibrillary 
Acidic Protein (GFAP) 
M 0761 Dako 
MycoAlert mycoplasma 
detection kit 
LT07-318 Lonza 
N2 supplement 17502-048 Thermo-scientific 
Neurobasal 12348-017 Thermo-scientific 
Non-essential amino acids 11140-050 Life Technologies 
PageRuler Prestained NIR 
Protein Ladder 
26635 Thermo-scientific 
Pageruler Prestained 
Protein Ladder 
26616 Thermo Scientific 
Paraformaldehype (PFA) 2199983 MP Biomedicals 
PDI antibody 2446 New England Biolabs 
Penicillin Streptomycin 15070063 Invitrogen 
phospho-TDP43 anitbody, 
Ser409/410-1 (pTDP43) 
CAC-TIP-PTD-P01 Cosmo Bio Ltd 
Pipetting reservoir sterile 
polystyrene 50mL 
11543412 Fisher 
ProLong® Gold Antifade 
Reagent 
P36934 Life Technologies 
Protease inhibitors 539134-1SET Calbiochem/Merck 
PROTRAN BA85 30cm x 10401196 GE Healthcare Life 
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3m 1/pk BA membrane Sciences 
Purmorphamine 540220-5MG 
Calbiochem (EMD 
Millipore) 
Qubit dsDNA HS Assay 
Kit 
Q32854 Thermo Scientific 
Recombinant Human 
BMP-4 
314-BP-050 R & D systems 
Recombinant Human 
FGF-basic 
100-18B Peprotech 
Retinoic acid R2625 Sigma 
RNase I AM2295 Invitrogen 
RNase inhibitor AM2692 Invitrogen 
Salubrinal (5mg) 324895 Merck Chemicals ltd 
SB431452 1614/10 R and D systems 
Sodium arsenite solution 35000-1L-R Sigma Aldrich 
Sodium chloride S5150-1L Sigma 
Sodium-deoxycholate D6750-100G Sigma 
Sodiumdodecylsulfate BP166-500 Fisher Scientific 
StemMACS CHIR99021 130-104-172 Macs Miltenyl Biotec 
Sucrose S0389-500G Sigma 
SuperScript® II Reverse 
Transcriptase 
18064014 Thermo-scientific 
SuperScript® III Reverse 
Transcriptase 
18080-085 Thermo-scientific 
Synaptotagmin 1 antibody clone 41.1 Synaptic Systems 
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(Syt1) 
T4 DNA Ligase M0202S New England Biolabs 
T4 Polynucleotide Kinase M0201L New England Biolabs 
TBE 5X J885-1L Amresco (VWR) 
TDP43 antibody 10782-2-AP Proteintech 
Tris HCL T2194-1L Sigma 
Triton X-100 T8532 Sigma 
Trizol LS 10296028 Life Technologies 
TruSeq RNA Access 
Library Prep Kit, Set A/B 
RS-301-2001/2 Illumina 
TruSeq Stranded mRNA 
Sample Prep Kit - 
TruSeq® Stranded mRNA 
LT - Set A/B 
RS-122-2101/2 Illumina 
Turbo DNase Kit AM1907 Life Technology 
Tween-20 P1379-1L Sigma 
Whatman™ 1823-010 
Grade GF/D Glass Fiber 
Filter Paper without 
Binder, Diameter: 1cm, 
Pore Size: 2.7µm (Pack of 
100) 
1823-010 Sigma 
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Chapter 3; Developing the model system 
Introduction 
There are many different model systems used to study MND. However to date, 
the translation of MND research has not been fruitful, therefore it would benefit 
from models that more accurately capture clinical pathophysiology. I have 
chosen to utilise hiPSC technology, which holds several major advantages to 
modelling human disease; it’s a fully human model system, mutations are 
expressed at representative pathophysiological doses and, as this is essentially 
a developmental system, it allows us to recapitulate the earliest pathogenic 
events occurring during disease manifestation.  
 
To effectively utilize hiPSCs to model MND I had to first develop and refine our 
culture and differentiation strategies, to make sure they are robust, efficient and 
validated. As previously discussed the cells most vulnerable in MND are motor 
neurons (MN) but there is a strong rational to also study the role of glia in the 
disease pathogenesis. In this chapter I describe the differentiation protocols I 
have developed for both spinal cord MN and astrocytes (AC).  
 
Prior to the discovery of hiPSCs in 2006, there has been much work carried out 
on the development of the nervous system, and more specifically on motor 
neurogenesis, in both mouse and human ESCs (X.-J. Li et al. 2005; Wichterle 
et al. 2002). The studies, particularly in rodent systems, have provided key 
insights into some of the processes underlying differentiation and fate 
restriction. Although there are fundamental differences between species and 
questions to whether artificially generated stem cells are equivalent to 
embryonic stem cells, the knowledge gained from these past studies has been 
since exploited in ES and iPSC.  
An overview of motoneurogenesis strategies to date (prior to 2013) 
Generally protocols for the differentiation of neuronal cells from pluripotent 
stem cells are divided into 4 main stages;  
1/ neural conversion,  
2/ patterning, 
3/ propagation  
4/ and finally terminal differentiation. 
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During 2000’s the generation of MN from both mouse (Wichterle et al. 2002) 
and human ESCs (Lee et al. 2007; Li et al. 2005) was described. All followed 
an embryoid body culture approach for neural induction; briefly this is where 
neural differentiation is initiated by the withdrawal of feeders and utilizes 
differential adhesion of NPCs (Zhang et al. 2001). This approach was shown to 
recapitulate early stages of neural development in vitro, such as the formation 
of neural tube–like structures (Zhang et al. 2001). Additionally, these early MN 
approaches all utilized RA and SHH agonist signals in a time-dependent 
manner to generate region specific motor neuron precursors. After terminal 
differentiation cells were functionally characterized by looking at synaptic 
function using electrophysiology techniques and myotube co-culture to assess 
neuromuscular transmission (Li et al. 2005).  
 
From these earlier studies using RA and SHH signaling to promote motor 
neurogenesis, the yield of MN generated from mouse ESCs was greater than 
with human ESC (hESC). In 2008 the efficiency of motor neurogenesis was 
improved in hESC to generate a nearly homogenous population of ventral 
spinal progenitor cells and 50% final MN population (li et al. 2008). This was 
achieved by altering the timing of exposure to SHH signals, which was shown 
to promote division of olig2 progenitors and subsequently increase post-mitotic 
MNs. They also speculated that suspension culture was better for 
differentiation as got rid of ‘flat cells’ and produced a more homogenous 
population. 
 
Since, there have been many more studies that have improved our 
understanding of, and protocols for, motor neurogenesis. Namely, in 2011 
Patani et al demonstrated for the first time the generation of MNs in the 
absence of retinoic acid (Patani et al. 2011). RA signaling plays many roles in 
MN differentiation and is used reiteratively in development at distinct positions 
and in time. For example RA promotes the up-regulation of HOX gene 
expression and of Class I HD genes involved in D-V neural patterning. This 
diversifies MN subtypes from MN precursor pools.  
Progress in motor neurogenesis approaches 2013-present  
In the last few years significant develop has been made to overcome some of 
the major limitations in MN differentiation to date; including reducing the long 
culture time and improving poor efficiency and heterogeneity.  
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Firstly in 2013 Mackenzie Amoroso et al presented an approach to generate 
predominantly limb innervating MNs in 3weeks (Amoroso et al. 2013). They 
used a suspension culture system and a cocktail of rationalized signals; Rho-
associated kinase inhibitor Y27632 to enhance single cell survival, FGF2 to 
enhance propagation, SB435142 and LDN193189 (= dual anaplastic 
lymphoma kinase (ALK) inhibition) for neutralization, RA and SHH for 
patterning, ascorbic acid to enhance neuronal yield, and growth factors (BDNF, 
IGF-1, GDNF, CTNF).  This overall resulted in a 50% MN yield.  
 
In 2014 two studies presented the use of Wnt signaling to increase efficiency of 
motor neurogenesis. Hong Chen et al describe a novel protocol achieving 90% 
motor neurogenesis in 21days, which uses CHIR99021 (a GSK3b antagonist) 
in addition to the commonly used motor-neuron/neutralization factors; smad 
inhibition, RA and Pur. Additionally they block cellular proliferation to enhance 
the generation of post-mitotic neurons (Chen et al. 2014). Then Yves Maury et 
al presented a large scale differentiation of both spinal cord and cortical MNs in 
14days using an embryoid body system (Maury et al. 2014). They analyzed 
multiple combinations of developmental cues (target pathway, timing and 
concentration of cues) to reveal the importance of wnt signaling (by 
CHIR99021). Wnt signaling from an early stage in differentiation (day0) was 
shown to increased the yield of Olig2 positive precursors (>80%) and reduced 
the time to generate them.  
 
Finally in 2015 Elizabeth Calder et al also demonstrated an approach to 
increase MN yield, by early exposure to RA. RA was shown to direct MN 
specification by suppression of GLI3 and worked independent of SHH signaling 
(Calder et al. 2015).  
Astrogliogenesis differentiation strategies 
Compared to Neurogenesis, astrogliogenesis has been relatively poorly studied 
but their development shares many similarities to that of neurons. 
Differentiation methods for glia are divided into 4 general phases; neural 
conversion, patterning, propagation and terminal differentiation. This is similar 
to neurons and many of the same principles apply.  
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To date, less attention has been paid to patterning of region-specific AC 
subtypes, comparatively to their neuronal counterparts. However this is 
essential given the functional, genetic and structural differences between 
region specific ACs. In relation to MN biology and disease, there is much 
interest in generation of spinal cord ACs so several groups have previously 
published methods to generate spinal cord ACs (Krencik et al. 2011; Roybon et 
al. 2013). In 2011, Krenick et al showed in hESCs that the regional identity of 
NPCs, specified by a single morphogen, is maintained through 
astrogliogenesis. Therefore, the same principles that are previously outlined for 
neural conversion and patterning can be followed for generating region-specific 
ACs.  
 
Next NPCs undergo a propagation phase to promote generation of gliogenic 
precursors (GPCs). Often, to promote gliogenesis, NPCs are propagated in 
presence of growth factors, namely EGF and FGF, and is further assisted by 
frequent passaging to reduce cell-cell contact as this promotes neuronal fate 
(Caldwell et al. 2001; Krencik et al. 2011).  ACs can terminally differentiate 
spontaneously from GPCs after the removal of mitogens, following temporally 
regulated intrinsic mechanisms (≈180days). But as this can be time consuming 
developmental insights have been used to target and accelerate 
astroglioenesis pathways by capitalizing on extrinsic signaling cues. Signals 
that induce expression of STAT, NF1A transcription factors or Smad signaling 
have been shown to promote expression of astrocytic genes GFAP, S100B and 
GLAST. Several in vitro approaches have targeted the JAK-STAT pathways 
and/or utilized BMP signaling. The JAK-STAT pathway has been activated with 
neuroregulin or using members of the interleukin IL6 family such as CNTF and 
LIF (Krencik et al. 2011), resulting in phosphorylation and nuclear localization 
of STAT3. Using a combination of LIF-mediated JAK-STAT signaling and BMP-
mediated Smad signaling (by BMP4) was shown to be more effective in 
inducing the expression of astrocytic genes and down-regulating the 
expression of genes typically found in precursor cells, than targeting either 
pathway individually (Gupta et al. 2012). In addition, using insights from the 
gliogeneic switch, targeting epigenetic modifications using Aza-Cytidine a DNA 
methyltransferase inhibitor and Trichostatin-A a histone deacetylase inhibitor, 
has also been used to accelerate AC differentiation (Majumder et al. 2013).  
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To summarise the approaches used to generate spinal cord ACs; both utilized 
RA and SHH signaling to specify a spinal cord identify, expanded NPC 
populations in suspension culture and in media supplemented with EGF and 
FGF2 (Krencik et al. 2011; Roybon et al. 2013) and terminal differentiation was 
promoted by FBS, CNTF or LIF.  
Characterization of Neural populations 
A crucial step in developing methods to generate specific cell types in vitro is 
the characterization of cell-type-specific populations. This can be done by 
assessment of cellular morphology, expression of cell type-specific markers 
and functional characteristics. I discuss these methods used for cell-specific 
validation within the results but here I first outline some of the key genetic 
markers for both MNs and ACs.  
Motor neuron markers 
Extensive research spanning decades has carefully dissected MN 
differentiation pathways therefore a set of core cell-type-specific markers have 
been identified and are commonly used. Neural specification is first identified 
by the loss of pluripotency markers (Oct4, Nanog) and gain in neural markers 
such as Pax6, Sox1 and nestin. For MNs the standard markers that are 
consistently used are HB9 (an early MN marker), CHAT (a mature MN maker), 
SMI32 and Islet1. In addition there are more general neuronal markers often 
used in parallel, such as Beta III tubulin (neuronal marker), MAP2 (dendritic 
marker) and PDS95 (post-mitotic synaptic marker).  Further, studies of subtype 
specification mean that we are able to narrowly pin point the positional identify 
of MNs through expression of the HOX gene ‘postcode’. There are 39 Hox 
genes, arranged in 4 clusters; HOXA, HOXB, HOXC and HOXD and into 13 
paralogue groups HOX1-13 (Philippidou and Dasen 2013). In the hindbrain, 
Hox genes from paralog groups 1–5 are expressed, while in the spinal cord 
expression of Hox4-Hox13 is detected. Hox genes 4-11 align with MN pool 
subtypes, 4 being the most cervical and 11 in the lumbar region. 
Astrocytes 
The knowledge of reliable markers for the characterisation of AC is much less 
defined than for motoneurogenesis. AC display huge genetic and 
morphological diversity making their identification challenging. GPCs are 
commonly identified by expression of NF1A and/or CD44 and for ACs GFAP 
expression has generally been considered the gold standard marker, however 
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there are limitations to its use. It’s expression is seen to vary considerably 
depending on AC subtype diversity, morphology, activation state and during 
age(Sofroniew and Vinters 2010). This highlights the need to use a range of 
markers in parallel, such as APQ4, GLAST, ALDH1L1 and GLT1 (a 
mature/postnatal marker).  
Current limitations in hiPSC strategies 
Aside from the progress made in neural developmental understanding and 
refining our differentiation methods in vivo there are several key limitations to 
our current methods.  
 
The majority of stem cell culture and differentiation strategies have been poorly 
controlled, extremely labour-intensive and costly. Former stem cell culture 
strategies routinely used MEFs (and other alternative) feeder layers to support 
stem cell cultures in their proliferative undifferentiated state. These feeder 
layers are highly variable, impractical for large-scale culture, allowed some 
differentiation to occur and would not compatible for clinical application in the 
future. Therefore there has been a considerable effort to move to feeder-free 
and xeno-free culture systems. In 2001 Xu et al demonstrated for the first time 
that hESCs could be cultured without a feeder layer on extracellular matrices 
(C. Xu et al. 2001), then a further study in 2005 explored what secreted factors 
from MEFs aided pluripotency (R.-H. Xu et al. 2005).  
 
Further, there is also heterogeneity and inefficiency within the differentiation of 
stem cells, making methods not suitable for large-scale expansion. As outlined 
above, a lot of previous work has been carried out on MN differentiation. The 
above differentiation approaches all differ in terms of which developmental 
cues were employed for neural conversion and patterning (cues, their 
concentration and timing), the type of culture method used 
(suspension/monolayer), length of differentiation protocol and the purity of cells 
generated. A commonly employed methodology involved the formation of 
embryoid bodies (EBs). This type of suspension culture approach meant that 
extracellular signaling was poorly controlled leading to heterogeneous 
population of cells. A further hold back is due to the length of current 
differentiation protocols, for example the first protocol outlining the generation 
of ACs from hESC took 6months, which makes the technology extremely 
expensive and labour intensive. There are also less transparent reasons that 
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add to causing heterogeneity and variable maturity of cellular populations, for 
example cell density hugely influences cellular fate. Finally, another difficulty 
that I touched on above, is the characterization of differentiated iPSCs, 
particularly of ACs, due to the lack of reliable markers.    
 
To summarise, the majority of hiPSC approaches to date have involved poorly 
defined culture conditions, protracted differentiation and low yield. Here I 
address these issues; firstly by using a monolayer culture approach which 
enables uniform signaling resulting in a more homogenous population and 
increased yield of desired cell type. Secondly I use chemically defined culture 
conditions that can be easily replicated, which improves reliability and accuracy 
of the methods. Finally I analyze the transcriptional profile throughout 
astrogliogenesis to better characterize stages of AC development and maturity.  
Aims 
In this chapter my overarching aim was to establish efficient differentiation 
strategies for both spinal cord MNs and ACs from hiPSCs. 
 
Here I specifically ask: 
1) Can I differentiate spinal cord MNs using solely monolayer culture? 
2) Could the differentiation of MNs be accelerated? 
3) Could I enhance the enrichment of MNs generated by synchronizing cell 
cycle exit? 
4) Are the Derived MNs functional? 
5) Then, can I differentiate spinal cord ACs using solely monolayer culture? 
6) Are the derived ACs functional? 
7) How do the transcriptional profiles of neurogenic and gliogenic precursors 
differ?  
8) Can I define when the gliogenic switch occurs in our system?  
9) What are the underlying molecular pathways that instruct NPC to turn off 
neurogenesis and turn on gliogenesis? 
10) How does the transcriptional signature of our iPSC-derived AC compare to 
primary human ACs?  
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Differentiation of spinal cord motor neurons from hiPSCs 
using a monolayer culture system 
Prior to differentiation I cultured hiPSCs on gel-trex coated plates and treated 
them daily with chemically defined medium that contains extrinsic signals to 
maintain pluripotency: these signals include FGF2 (activates MAPK and Akt 
pathways), insulin and TGF-B (smad2/3/4 signaling). Next, following key 
developmental principles and using insights from previous studies, I have 
produced directed differentiation strategies for the generation of spinal MNs 
using, for the first time, a purely monolayer culture system (Figure 3.1.A). This 
follows 3 main stages (Figure 3.1.A);  
 
1/ Neural conversion 
Similar to previous strategies I first directed iPSCs towards the neuro-
ectodermal lineage. From the ectoderm germ layer, by default cells head 
towards a neural fate, however it has been shown that we can actively 
antagonise pathways that maintain pluripotency to accelerate neural 
conversion. As described by Chambers et al, simultaneously using two small 
molecule inhibitors of SMAD signaling, Noggin (BMP antagonist) and 
SB431542 (Activin/nodal anatagonist), neural conversion is achieved in 10-
12days, and it is more efficient (>80%) and homogeneous compared to 
previous embryoid body or feeder methods (Chambers et al. 2009). Therefore 
for neural induction I have followed a similar approach, published by Shi et 
al(Shi, Kirwan, and Livesey 2012), and applied dual smad inhibition, using 
10µM  SB431542  and 1µM  dorsomorphin for 10days, while cells are plated at 
100% confluency. This approach promotes the specification of anterior neural 
precursors.  
 
2/ Patterning (caudalisation and ventralisation of neural precursors)  
Following neural conversion I applied developmentally rationalised extrinsic 
signals to positionally re-specify them to the pMN domain of the spinal cord, 
which gives rise to motor neuron precursor cells. Following past studies I 
utilised RA and SHH signalling (X. J. Li et al. 2008; X.-J. Li et al. 2005; 
Wichterle et al. 2002) and applied gentle trituration to begin to dissociate the 
neural epithelial sheet, but I did not passage cells into a single cell-suspension 
at this stage. I used purmorphine, a SHH antagonist which has previously been 
show to activate/suppress an almost identical set of transcription factors that 
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are involved in specification of ventral spinal progenitors and MNs, as well as 
stimulating Gli1 the downstream target of SHH pathway (X. J. Li et al. 2008). 
Additionally the same study showed that purmorphamine treated cultures 
expressed Olig2, a marker of motor neuron precursors, several days before 
expression was detected following SHH treatment. Hence, neural precursors 
are treated for 8days with 0.5µM retinoic acid to caudalise and 1µM 
purmorphamine to ventralises the precursor cells, thus mimicking the 
developmental signaling environment for motor neurogenesis.  
 
3/ Terminal differentiation 
Finally motor neuron precursors were left to terminally differentiate on laminin-
coated plates for a minimum of 35days in neural maintenance media. During 
this time I passaged cultures twice to gently triturate clumps of NPCs and 
gradually break them up, this is important because if the cells are too confluent 
they will not efficiently differentiate but cell-cell contact is needed to some 
degree to promote neurogenesis therefore cells should not be plated to 
sparsely. As shown in the phase contrast images (Figure 3.1.B) derived 
neurons develop long axonal processes, typical of their distinct polarised 
morphology. However for precise characterisation of MNs and their 
subpopulations, assessing morphology is not very reliable and depending on 
cellular density it can be hard to visualise clearly the full cell.  
 
Notably I did not use any growth factors throughout this method, making the 
approach cost effective and distinguishable from other strategies.  
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Figure 3.1; Generating MN in monolayer culture 
A) Schematic to show the differentiation strategy employed for motor neurogenesis. 
Stages include; iPSC = induced pluripotent stem cells, NPCs = spinal neural 
precursors, MN = Motor neurons. B) Representative phase contrast images of 5 stages 
throughout differentiation. Representative immunocytochemistry images of MNs at Day 
35 in culture. C) BetaIII (green) displayed with DAPI D) and SMI32 (red) with FOXP1 
(green). E) quantitative immunocytochemistry of selected cellular markers BetaIII (N=3, 
500+ cells counted), FOXP1 (N=2, 100+ cells counted) and SMI32 (N=3, 500+ cells 
counted). Error bars represent mean ± SEM. F) Heatmap showing classic cell-type 
specific gene expression from iPSC and MN cellular populations (N=3+ technical 
repeats per time point). Points represent normalized FPKM values that are log2 
transformed and mean-centered.  
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To validate this MN differentiation protocol I carried out quantitative 
immunocytochemistry (qICC) using BetaIII tubulin (a general neuronal marker), 
SMI32 (a MN specific marker) and FOXP1 to gain insights into the MN subtype 
specified (Figure 3.1.C&D). This method produced cultures that are 58% 
neuronal, of which only 27% were MNs (Figure 3.1.E). Of the MNs (SMI32+ve 
cells), 59% were FOXP1 positive (Figure 3.1.E), which indicates they are from 
the lateral motor column (LMC), representing limb-innervating MNs.  
 
In addition to immunocytochemistry validation I performed RNA sequencing of 
terminal MN cultures and looked at candidate gene expression in MNs vs 
iPSCs (Figure 3.1.F). This shows that there is successful relative down 
regulation of pluripotency markers (Pou5F1/OCT4, Nanog, PODXL, Lin28A) 
and up-regulation of neuronal (MAP2, Pax6, Tubb3/BetaIII), MN specific (Oli2, 
Islet1, Chat) and mature/synaptic markers (PSD95, Syt1). 
 
Improving efficiency and accelerating motor neuron differentiation 
Since producing the above differentiation protocol, several studies have 
successfully reduced the differentiation time and increased the efficiency of 
motor neurogenesis (details above). Therefore, to maximize the potential of 
hiPSC technology and to improve accuracy of downstream analysis by having 
purer cultures, I asked if we can we accelerate our current 50+day 
differentiation method and also if we can increase the enrichment of MNs 
produced (which was previously 27%)? 
 
To adapt our existing protocol, I utilised key concepts from recent publications 
to produce a novel monolayer strategy for the differentiation of spinal MNs 
(Figure 3.2.A)(See appendix 8.1 for the detailed protocol). Namely the addition 
of CHIR99021 (a GSK3b antagonist / Wnt agonist) which if administered early 
in the differentiation protocol (during neural induction) increased efficiency of 
motor neurogenesis and the use of compound E which was shown to 
synchronize differentiation (H. Chen et al. 2014). This protocol uses a unique 
combination of signals to direct motor neuron specification and is broken into 4 
stages (Figure 3.2.A): 
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1/ Neural conversion  
Throughout neural induction CHIR99021 is used in addition to dual SMAD 
inhibition to aid neural specification. Maury et al have previously shown 
CHIR99021 increases the percentage of MN precursors specified (Maury, 
Côme, Piskorowski, Salah-mohellibi, et al. 2014).  
 
2/ Spinal MN Patterning  
Secondly, I patterned neural precursors with 0.5µM RA and 1µM 
purmorphamine for 7days (apposed to 8 as we previously did), and then I 
additionally treated NPCs for an additional 4 days with 0.1µM purmorphamine 
only. This was because it had previously been shown that longer SHH 
signaling is advantageous to generate NPCs specified to the pMN domain as 
longer exposure to SHH signals lead to sustained olig2 expression and 
increased the olig2 progenitor population (X. J. Li et al. 2008).  
 
3/ Propagation (optimal) 
I next included an optional stage for the propagation of NPCs that could be 
included when an increased yield of NPCs/MNs is required. To propagate 
NPCs I cultured NPCs for a maximum of 25days and 4 passages in the 
presence of 10ng/ul FGF (further details in the protocol found in Appendix.8.1). 
I show that propagating NPCs for up to 25days doesn’t alter the % MNs 
specified during terminal differentiation using SMI32 staining (Appendix 8.2). 
Further, I found that propagating NPCs not only increased the yield of MNs but 
also greatly facilitated cell plating at defined densities, which is of great 
importance for a variety of assays in including live cell imaging.  
 
4/ Terminal differentiation 
Finally I used Compound E (a Notch inhibitor) to accelerate terminal 
differentiation by synchronizing exit from the cell cycle exit. 
 
As previously, I did not utilize any growth factors throughout the protocol 
distinguishing our method from all other approaches. This significantly reduces 
the cost and thus makes the technology more widely accessible.  
 
To validate this new differentiation approach I have used immunocytochemistry 
to characterize both the percentage of motor neuron precursors and the 
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percentage of MNs specified. Motor neuron precursors were defined by the 
presence of Olig2, Hoxb4 and/or Islet1 expression (Figure 3.2.B). After 7days 
of neural conversion and 7days patterning cultures had 62% Olig2 +ve, 21% 
HOXB4 +ve and 16% Islet1 +ve cells (Figure 3.2.C). After 17days of terminal 
MN differentiation culture were stained with two MN specific markers; CHAT 
and SMI32, and showed cultures were >85% +ve for MNs (86% SMI32+ve and 
94% CHAT +ve) (Figure 3.2.D & E).  
 
Therefore, compared to the first protocol I developed for motor neurogenesis 
and presented above, this adapted protocol has resulted in the acceleration in 
differentiation of approximately 20 days and a 3-fold increase in enrichment for 
MNs (up to >86%). 
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Figure 3.2; Improving efficiency and accelerating motor neurogenesis 
A) Schematic to show our improved differentiation strategy for motor neurogenesis. B) 
Representative immunocytochemistry images of NPCs at D-4. Scale = 25µM, 
Displayed is i) Olig2 (green), DAPI (blue), ii) Islet1 (red), DAPI (blue) and iii) HOXB4 
(red), DAPI (blue) C) quantitative immunocytochemistry of selected cellular markers of 
spinal NPCs; Olig2, Islet1 and HOXB4. N=3 on independent inductions, Error bars 
represent mean ± SEM. D) Representative immunocytochemistry images of MNs at 
D17. Scale = 25µM. Displayed is i) SMI32 (green), DAPI (blue) and ii) CHAT (red), 
DAPI (blue). E) quantitative immunocytochemistry of selected cellular markers of spinal 
MNs; SMI32, CHAT. N=3 on independent inductions. Error bars represent mean ± 
SEM. 
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RNAseq validation of the accelerated Motor neuron differentiation 
protocol 
In addition to immunocytochemical validation, we conducted RNA sequencing 
to further confirm the specification of authentic MNs from the accelerated 
protocol. Libraries were prepared from pluripotent cultures, cultures after NI (D-
7), after patterning (NPCs), from derived MNs at D3 (D3MN) and at D17 
(D17MN)(Biological n=2 different control hiPSC lines, in technical replicate, 
overall n=4 per time point), using Truseq stranded mRNA RNAseq kit. All 
samples passed several stages of quality checks; including RIN scores >7.5, 
normal library distribution, 90% sequencing reads >Q30, rRNA reads <1%, 
exonic reads >70% (data not shown).  
 
We first compared the gene expression of pluripotent cells to terminally 
differentiated MNs (and to iPSC-derived ACs) (Figure 3.8.A). We analyzed the 
mRNA expression of established cell type specific markers for pluripotency 
(POU5F1, MYC, NR5A2, Nanog, PODXL and LIN28), of general neuronal 
lineage (BetaIII tubulin, MAP2, RBFOX3, DLG4, Syt1, STMN2, NCAM1, 
SLC18A3) and specifically for MNs (Chat, NEFH, Islet1). These cell-type 
specific markers were able to separately cluster distinct populations of iPSCs 
and terminally differentiated MNs (and later we show hiPSC-derived ACs too), 
both confirming the identity of predicted cell types and also demonstrating 
low/undetectable expression in alternative fates (Figure 3.8.A). Further, we 
looked at relative candidate gene expression across these cell types and show 
the RPKM values of 3 pluripotency markers (POU5F1, PODXL, Nanog) and 3 
MN markers (ISL1, SCL18A3 and CHAT) in both iPSCs and derived MNs 
(Figure 3.8.B).  
 
Next I gained insights into MN subtype identity by analyzing the gene 
expression of HOX genes during MN differentiation. In development, opposing 
gradients of FGF2/RA signaling results in differential expression of the HOX 
genes, and consequently different positional identity along the rosto-caudal 
axis. Based of previous studies, using 0.5µM RA for 7 days we expect to 
generate progenitors located in the cervical region of the spinal cord, which 
corresponds to HOX gene expression paralogues 3-5 (Maury et al. 2014; 
Philippidou and Dasen 2013). Using RPKM values generated from RNAseq 
data, I showed that at NPC stage most HOX genes are expressed but during 
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differentiation their expression is refined (Figure 3.3.A). In our culture we 
generally lose the expression of HOX1 and HOX6-13 but the expression of 
HOX4 is maintained. This supports our hypothesis that our protocol generates 
MN positioned approximately in the cervical section of the spinal cord.  
 
 
Figure 3.3; Expression of HOX genes throughout motorneurogenesis 
Multiple bar plots displaying the relative expression levels of HOX genes at 5 stages in 
motor neuron differentiation from hiPSCs; pluripotent, NI (Day7/after neural induction), 
NPC (Day14/after spinal cord patterning), D3MN (immature motor neurons) and 
D17MN (electrically active Motor neurons). N=3+ for each time point, from 2 biological 
lines. Error bars represent mean RPKM value ± SEM. 
Functional Characterization of hiPSC-derived Motor neurons 
The ability of a neuron to carry out its functions depends both upon its structure 
and its ability to generate and communicate electrical and chemical signals. 
MNs primary role is to integrate and propagate signals across long distances. 
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For this, the basic requirements are having 1/ the capacity (receptors) to 
receive external information, 2/ the required intracellular components to both 
process the information and communicate this within the subcellular 
compartments, and 3/ the ability to transmit an electrochemical signal to its 
target. Here I have collaboratively analyzed multiple parts of this 
communication network within our iPSC-derived MNs. 
Electrophysiology 
One of the gold standard methods for functional characterization of neurons is 
analyzing their electrical activity. After 17days of terminal MN differentiation, 
Sarah Crisp assessed functional maturation using electrophysiology profiling. 
Both the passive (n=12 neurons from a minimum of 3 separate inductions 
across 2 biological lines) and active (n=16 neurons from a minimum of 3 
separate inductions across 2 biological lines) properties were analyzed using 
whole cell patch clamping. Cells had a resting membrane potential of -57.7 ± 
1.9 mV (mean ± s.e.m.) and current steps of 4784 ± 726 MΩ were applied to 
depolarise the cells. In all cells, this input resistance evoked action potentials 
(rheobase 3.5 ± 0.5 pA); the take-off was -45.0 ± 0.7 mV, the peak was 9.1 ± 
2.3 mV and half-width was 4.1 ± 0.4 ms. For 1 of 16 cells only single action 
potentials were evoked, but the other 15 cells fired repetitively with increasing 
current injection (Figure 3.4.A). Tetrodotoxin (TTX) is a neurotoxin that binds to 
sodium channels blocking sodium permeablility and thus the ability to generate 
action potentials. In response to TTX (1mM) action potentials were reduced in 
frequency but not eliminated (n = 3) (Figure 3.4.B). Additionally spontaneous 
firing was recorded in some MNs. 
Calcium response 
In collaboration with Minee Choi, Zhi Yao and Sonia Gandhi, we used live cell 
imaging to assess the cytosolic calcium response to physiological calcium 
stimuli. After 17days of terminal MN differentiation, Minee Choi stimulated cells 
with glutamate/KCL to confirm the presence of glutamate receptors and voltage 
dependent calcium channels, which are characteristically present in neurons. 
She also stimulated cells with ATP, which is predicted to activate selected 
voltage-gated channels and initiate a calcium response in ACs. At day 17 of 
terminal differentiation, we confirmed that 98% of our MN cultures responded to 
KCL and glutamate stimulation, but not to ATP (Figure 3.4.C).  
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Axonal transport in Motor neurons 
The function of neurons, and in particular MNs, relies heavily on their unique 
morphology, polarization and subcellular compartmentalization into the soma, 
axonal and dendritic sections. Hence, cellular activities must be coordinated 
throughout these compartments and often, given the length of MNs, over long 
distances too. A network of axonal transport machineries and pathways helps 
achieve this.  
 
Transport occurs at differing speeds and directions (anterograde and 
retrograde). Anterograde transport make sure organelles, newly synthesized 
proteins and other messages from the soma reach their peripheral 
destinations. Then on the other hand retrograde transport ensures extracellular 
signals, ligands, aging proteins from the distal axon for recycling and 
degradation and selective organelles reach the cells soma. Slower speeds 
transport at 1mm/day (0.002-0.01µm/second) ranging up to faster speeds of a 
couple of hundred mm/day (0.5-4µm/second) (Tang et al. 2013). Although 
these faster speeds are still much slower than signals transmitted via action 
potentials.   
 
Some pathogens, for example tetanus toxin, exploit the fast retrograde 
transport process to invade the nervous system. They enter the distal tips on 
an axon and travel to the soma by retrograde transport. Here in collaboration 
with Giulia Tyzack, Alexander Fellows and Gipi Schiavo we have begun to 
characterize retrograde axonal transport in our iPSC-derived MN cultures.  
Alexander Fellows treated MN cultures with HcT (Hc binding domain of tetanus 
neurotoxin TeNT); a ligand that is specifically taken up by neurons and 
undergoes retrograde transport, and used fluorescent imaging techniques that 
enable the direct visualization of transport. This enables us to monitor the 
transport kinetics of axonal signaling endosomes, which are intracellular 
compartments essential for neuronal differentiation and homeostasis. 
 
We show that iPSC-derived MNs transport at speeds ranging up to ∼5µm/s, 
with an average speed of ∼2µm/s (Figure 3.4.E). Additionally we show no 
difference in the speed of retrograde transport in D3 and D17MN (Figure 
3.4.E), which agrees with the recently publication from Nakamura et al where 
they showed no changes in speed or particle number in hiPSC-derived D5 and 
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D17 neurons (Nakamura et al. 2015). Further, it has been recently shown that 
the signaling endosome axonal transport dynamics do not changed between 
PMN taken from embryonic mice up until neurons taken from mice age 
13months (Sleigh and Schiavo 2016). Therefore taken together the studies 
suggest axonal transport is a process that matures early in development and 
persists unchanged during ‘youth’.    
 
Next we compared transport speed in the iPSC-derived MNs to primary mouse 
cultures. We show that the signaling endosome axonal transport dynamics are 
comparable in primary mouse neurons (PMN taken from embyros day 12.5-
14.5 and cultured in vitro for 5-7days) to our iPSC-derived MNs (D3/17), both 
again have an average speed of ∼2µm/s and top speeds were shown up to 
∼5µm/s (Figure 3.4.F). This importantly demonstrates our in vitro differentiation 
is of comparable maturity to in vivo neural development and that the axonal 
transport profile we see in the hiPSC-derived MNs is reflective of neurons with 
matured signaling endosome axonal transport. In addition to gaining insights 
into neuronal function and maturation status, we have importantly established 
an assay that can later be exploited to address controversies in the role of 
axonal transport in disease and/or development. 
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Figure 3.4; Functional validation of motor Neurons  
A) iPSC-derived motor neurons generate action potentials at D17 in culture. A 
representative trace from a cell recorded during current injection (-1, 0, 1, 2, 3 pA) to 
evoke action potentials. B) Action potentials were blocked by TTX (-5, 0, 5, 10, 15 pA 
steps). C) Representative Calcium traces from D17MNs in response to ATP, Glutamate 
and KCL. D) Measurement of Calcium response to ATP, Glutamate and KCL (N=3+ 
biological replicates). Graph shows the % of cells stimulated at NPCs (n=66 cells), 
D3MN (n=68 cells) and D17MN (n=125 cells). At D17MNs, 98% of our cultures 
responded to KCl and glutamate stimulation, but not to ATP. E) Trace to show the 
speed and frequency of axonal transport in MN at days 6 and 19 in culture. N=2 
biological replicates, with 3 technical replicates per time point). F) Trace to show axonal 
transport of hiPSC-derived MN at D37 compared to primary mouse neurons. 
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Differentiation of spinal cord Astrocytes from hiPSCs using a 
monolayer culture system 
I next turned to develop a differentiation protocol for regionally defined spinal 
AC from hiPSCs. (Figure 3.5.A) I have used findings from our lab’s previously 
published methods (Gupta et al. 2012) to guide the development of robust a 
protocol. In a similar way to neuronal development, AC differentiation can be 
divided into several stages, first beginning with neuronal conversion and 
patterning and finishing with terminal differentiation and maturation. As with 
neuronal specification, AC subtype diversity is specified early on during 
development during the patterning of neural precursors (Krencik et al. 2011), 
therefore we can utilize the same approaches as previously descripted for 
motor neurogenesis for both neural induction and patterning.  
 
After neural conversion and patterning there is an additional step required for 
the propagation of neural precursors to form gliogenic precursors.  This is 
necessary in order for the cell intrinsic mechanism described above, known as 
the gliogenic switch, to occur. When using human neural stem cells or fetal 
tissues differentiation of AC often requires serum, and the capacity to expand is 
limited. However I propagate NPCs in maintenance media supplemented with 
10ng/µl FGF, without the need for serum and can expand NPC populations into 
large quantities of GPCs. Finally, the synergistic interaction between JAK-
STAT and smad signaling have been shown to promote astrocytic 
differentiation (Gupta et al. 2012) so I have targeted both pathways during the 
terminal differentiation phase.   
 
To summarise the approach; I carry out neural induction with dual smad 
inhibition (10µM SB431542 and 1µM Dorsomophin) for 10days, followed by 
8days patterning with 0.5µM RA and 1µM Purmorphamine then propagation of 
spinal motor neural precursors for a minimum of 60days in 10ng/µl FGF.  
Gliogenic precursors are then terminally differentiated for a minimum of 2weeks 
in 10ng/µl BMP4 (acts through smad transcription factor family) and 10ng/µl 
LIF (activates the JAK-STAT pathway).  
 
To validate the protocol I have carried about both immunocytochemistry and 
RNA sequencing. As highlighted earlier a major issue for AC characterisation is 
that markers for maturity and specificity are poorly defined. Consequently, I 
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have used both GLAST general astrocytic marker and GFAP for ICC staining. 
(Figure 3.5.C) At D28AC our culture is >70% GFAP +ve and >90% GLAST +ve 
(Figure 3.5.D).  
 
For RNAseq analysis of AC compared to hiPSCs, I have used an array of 
additional markers of differing maturational stages to show relative up-
regulation of astrocytic genes (VIM, NF1A to represent GPCs, and ALDH1L1, 
Acquaporin4, GLAST and GFAP to represent ACs) and down regulation of 
pluripotency markers (Pou5f1, Nanog, PODXL, Lin28A and NR5A2) (Figure 
3.5.E). It is notable that is changes still occurring between D14 and D28 AC 
marking an increase of transcriptional maturation. At the later stage of AC 
terminal differentiation (D28) the expression of VIM and ALDH1L1 appears 
whilst GFAP, GLAST (SLC1A3) and AQP4 expression is reduced.  
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Figure 3.5; Generating AC in monolayer culture 
A) Schematic to show the differentiation strategy employed for spinal cord 
astrogliogenesis. Stages include; iPSC=induced pluripotent stem cells, NPCs = spinal 
neural precursors, GPCs = Gliogenic precursors, AC = Astrocytes. B) Representative 
phase contrast images of 5 stages throughout differentiation. C) Representative 
immunocytochemistry images of i) GFAP (red) and DAPI (blue), and ii) GLAST (green) 
and DAPI (blue). D) Quantitative immunocytochemistry of selected cellular markers 
GFAP and GLAST. N=2+ independent inductions. Error bars represent mean ± SEM. 
E) Heatmap showing classic cell-type specific gene expression from iPSC and two 
stages of AC cellular populations (technical repeats plotted individually, n=2-4 per time 
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point). Points represent normalized FPKM values that are log2 transformed and mean-
centered.  
Astrocyte differentiation after accelerated neuronal precursor 
specification 
Since I have adapted the neural conversion and patterning phases of the MN 
protocol in order to achieve faster and more efficient progenitor specificity, I 
asked if spinal AC be made from this adapted protocol. Therefore I have 
applied the same concepts to our AC differentiation protocol; I use 3 
compounds to synchronize neural induction for 7 days followed by 11days 
patterning (7days with 0.5µM RA and 1µM Purmorphamine plus 4days with 
0.1µM Purmorphamine only), propagation and terminal differentiation phases 
remain as before (Figure 3.6.A).  
 
Following these changes I have validated cellular populations at gliogenic 
precursor stage and after terminal differentiation to AC (D28). To characterize 
the presence of gliogenic precursors I used NF1A and 3CB2 staining between 
day60-70 in FGF (Figure 3.6.B); generally, precursors committed to the AC 
lineage and immature AC are characterized by the expression of the 
transcription factor NFIA (Deneen et al. 2006). I found that 99.5% expressed 
NF1A and 76.1% expressed 3CB2 (Figure 3.6.C), reflecting highly pure 
population of GPCs. Further, after terminal AC differentiation I show the 
cultures are 71.5% GFAP +ve and 96.22% GLAST +ve (Figure 3.6.E). 
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Figure 3.6; Astrogliogenesis from an adapted pMN domain specification protocol 
A) Schematic to show our differentiation strategy for astrogliogenesis, after 
incorporating the first few stages of accelerated MN protocol. B) Representative 
immunocytochemistry images of i) NFIA (green), DAPI (blue) and ii) 3CB2 (red), DAPI 
(blue). Scale bar 5µM. C) Quantitative immunocytochemistry of selected cellular 
markers of GPCs; NFIA and 3CB2. ICC was carried out after propagation for 59days, 
n=3+ on independent inductions. Error bars represent mean ± SEM. D) Representative 
immunocytochemistry images of i) GFAP (red), DAPI (blue) and ii) GLAST (green), 
DAPI (blue). E) Quantitative immunocytochemistry of selected cellular markers of ACs; 
GFAP and GLAST. ICC was carried out at D14AC, n=3 on independent inductions. 
Error bars represent mean ± SEM. 
Functional characterization of iPS-derived Astrocytes 
For functional validation, in collaboration with Minee Choi, Zhi Yao and Sonia 
Gandhi, we have assessed the cytosolic calcium response to physiological 
calcium stimuli. Minee Choi stimulated GPC and AC cultures after 14 and 28 
days of terminal differentiation with ATP, KCL and glutamate. We confirmed 
that 98% of cells exhibited calcium waves in response to local application of 
ATP, but not to KCL and glutamate (Figure 3.7.B), as previously reported 
(Abramov, Canevari, and Duchen 2003; Guthrie et al. 1999). This suggests our 
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AC cultures are highly enriched at day 14 and are maintained through to day 
28. 
  
Figure 3.7; Functional characterization of iPSC-derived AC, Calcium response  
A) Representative calcium trace of D28AC after treatment with ATP, Glutamate and 
KCL. B) Measurement of the % of cells stimulated by ATP, Glutamate and KCL (N=3 
biological repeats/independent inductions). Graph shows the % of cells stimulated at 
GPCs (n=73 cells), D14AC (n=107 cells) and D28AC (n=113 cells). AC cultures show 
>98% cytosolic calcium responsds to ATP but not KCl.  
RNAseq validation of the accelerated MN and AC protocols 
In addition to immunocytochemical validation, we conducted RNA sequencing 
to further confirm the differentiation of ACs from the accelerated protocol. I 
prepared RNAseq libraries from two biological lines in duplicate (n=4) for 
terminally differentiated ACs (D28) and compared gene expression to 
pluripotent cultures and terminally differentiated MNs (D17) (Figure 3.8.A). I 
analyzed the mRNA expression (RPKM values) of established cell type specific 
markers for pluripotency (POU5F1, Nanog and LIN28), MNs (Chat, NEFH, 
Islet1, Olig2, Vacht) and ACs (AQP4, GFAP, GLAST). These cell-type specific 
markers were present in the predicted cell types confirming their identity. Also 
low/undetectable expression was seen in alternative fates emphasizing the 
purity of the cultures. Further, I plotted relative candidate gene expression 
across these cell types (iPSC, MN and AC) (Figure 3.8.B). 
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Figure 3.8; RNAseq validation of hiPSC-derived MN and AC 
A) Heatmap showing classic cell-type specific gene expression from iPSC, MN and AC 
cellular populations (n=2, each with 2 technical repeats, per time point). Points 
represent normalized RPKM values that are log2 transformed and mean-centered. B) 
Representative normalized RPKM values of cell-type specific genes. Error bars 
represent mean RPKM values ± SEM. 
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Transcriptional analysis of astrogliogenesis in hiPSCs 
Background 
Since there is currently a lack of reliable astrocytic markers, it is undeniably 
valuable to explore the genetic expression of ACs, in order to try to identify 
novel and reliable candidate markers for classifying sub populations of ACs - 
depending on their morphology, activation and maturational status. To date 
there have been few studies that have explored the global transcriptional profile 
of ACs, and even fewer have investigated the transcriptional signature 
throughout astrogliogenesis. However, recently genome wide studies of cell-
type-specific populations have become more available due to improved 
methods of generating purified populations of selected cell types (here the 
purification of ACs) and advances in genome wide methodologies (discussed 
separately in the Introduction). 
 
In 2008 microarray analysis of purified cell types from mouse brain neurons, 
oligodendrocytes and ACs revealed ALDH1L1 as a new candidate AC marker, 
that has a much broader expression pattern than GFAP (Cahoy et al. 2008). 
Although this helped to improve our detection of ACs (and distinguishes them 
from oligodendrocytes and neurons), it did not provide information on astrocytic 
development or diversity.  
 
In 2013, 5 time-points were selected throughout differentiation of ACs from 
hPSCs (both hiPSC and hES); NPC, day14, day21, day28 (onset of 
astrogliogenesis) and day35 and analysed by microarray analysis (Shaltouki et 
al. 2013). Analysis supported differentiation strategies showing stage-specific 
lineage gene markers up-regulated in specified cell types and highlight several 
genes enriched in AC (GFAP, S100B, APQ4, NFIX). Additionally, comparison 
to the murine AC transcriptional profile allowed confident detection of more AC 
specific genes (GLAST, ALdhL1, SLC25A18, SLC4A4, ATP1A2). Further, the 
importance of known regulators and the identification of novel markers and 
regulators of astrogliogeneis was touched upon (CHD protein 5, NFIA, NFIX, 
and OMG).   
 
Moreover in 2014, a study again used microarrays to compare iPSC-derived 
NPCs to primary human fetal ACs. They showed immature ACs express high 
levels of GFAP and factors from NFI family and also highlighted the importance 
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of Notch, TGFb, MAPK and growth factor programs in AC development and 
maintenance (Malik et al. 2014). However, using only two time points taken 
from two different model systems, means further work is needed to validate the 
findings.  
 
Lastly in 2015 RNA sequencing was used to compare the transcriptional 
signatures of fetal and mature, human and mouse primary ACs, using human 
neurons and oligodendrocytes as control.  While similarities were seen 
between human and mouse populations many differences were detected 
between gene expression profiling and functional characteristics of human and 
mouse ACs. They characterised gene expression of human ACs and showed 
AC exist in at least two distinct developmental stages; immature/fetal 
proliferative and mature/postnatal (Zhang et al. 2016).  
 
In summary, a mixture of model systems and methods have been used to 
explore global gene expression in ACs. Two major gaps in the research to date 
are; 
1/ The limited transcriptional characterisation throughout astrogliogenesis. 
2/ Comparative transcriptional analysis of iPSC-derived glia to primary human 
tissue.  
Thus, here I have sought to explore both these areas using hiPSC gliogenic 
derivatives.  
The transcriptional signature of neurogenic versus gliogenic 
precursors  
First I have explored the transcriptional differences between neurogenic and 
gliogenic precursors. It is well established that neuronal precursors are capable 
of multi-lineage differentiation that is partially temporally regulated. Young 
NPCs are primarily neurogenic and responsive to morphogenetic instruction, 
permitting generation of region specific neurons. On the other hand, their late 
counterparts exhibit a loss in competence to be patterned into regionally 
defined neuronal subtypes, which coincides with the acquisition of gliogenic 
potential. Several studies have generated NPCs in vitro and demonstrate their 
ability to recapitulate key developmental properties, such as their multi-lineage 
differentiation potential and temporal responsiveness to morphogenic signals 
permitting the generation of region specific neurons and glia (Bouhon et al. 
2006; Elkabetz et al. 2008; Okada et al. 2008; Reubinoff et al. 2001). Within the 
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lab we have also recapitulated key aspects of human neurodevelopment in 
hiPSCs, including demonstrating sequential generation of neurogenic then 
gliogenic precursors and the temporal restriction of NPCs to respond to 
patterning cues which coincides with the acquisition of gliogenic potential 
(Unpublished data, not shown).  But to further explore differences between 
these two temporally distinct classes of hiPSC-derived NPCs that differ 
markedly in their developmental competence, I conducted RNA sequencing. I 
compared pluripotent cells, early NPCs (which were left propagating <30days) 
and Late NPCs (progenitors left propagating for <70days) (Figure 3.9).  
 
 
Figure 3.9; Schematic presentation of our strategy to generate Early and Late 
NPCs 
 
Experiments were carried out using 2 alternative approaches; 
 
1/ First I used NPCs cultured by Rickie Patani from hESCs using a suspension 
culture system. Early precursors were defined as those propagated for 30days 
and late NPCs as those left to propagate for 100days. RNA from these 
samples was extracted using Zymo direct-zol extraction kit and the rRNA was 
depleted using Qiagen’s generead kit. Next I carried out library preparation 
using the NEXTflex directional RNAseq kit.  
 
2/ Secondly I used NPCs that I had generated from hiPSCs using our 
monolayer culture system. Using a monolayer system means that signals 
applied will reach cells in a more homeogenous manner, therefore we predict 
that the gliogenic switch would occur sooner. For this reason I defined early 
NPCs as those propagated for 20-30days and late NPCs as those propagated 
for 70-80 days. RNA was prepared using the automated Promega extraction 
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machine/kit, then polyA RNA was selected before libraries were prepared using 
Illumina’s Truseq mRNA stranded RNAseq kit.  
 
Firstly, using approach 1, I use principle component analysis (PCA) to describe 
the variation among samples. PCA identifies principle components in the data, 
which are directions that highlight the maximum variation in the data. Usually 
PC1 and PC2 account for the majority of variation in the data (here PC1 and 
PC2 account for 94% of the variation in the dataset), therefore by plotting PC1 
versus PC2 it allows us to visualize how samples are clustered (shows 
similarities and differences in the data). I have shown separation between early 
and late NPC population using PCA (Figure 3.10.A). Next I have carried out 
differential expression analysis between the early and late NPC populations, 
this is represented using a volcano plot (Figure 3.10.B) and a bar plot to show 
the number of differentially expressed genes with log(fold change) >1.5 and p-
value <0.05; 13 genes are upregulated and 54 genes are down regulated in 
Late NPCs compared to their early counterparts (Figure 3.10.C). Interestingly I 
noticed that, of the down-regulated genes in Late NPCs, over 85% of them 
correspond to histone coding proteins (Figure 3.10.D & E). Further I carried out 
gene ontology analysis. Figure 3.11 displays a condensed list of the most 
significant GO terms associated with both up and down regulated genes, 
generated using revigo. Among the most significant down-regulated biological 
terms were chromatin silencing, protein complex assembly and methylation, 
more specifically histone H3-K27 trimethylation, H3-K27 methylation and H3-
K4 trimethlyation were highlighted. GO terms associated with molecular 
function and component parts also implicate a striking convergence on 
epigenetic changes in early and Late NPCs. Together with previous literature 
(Allen 2008; Y. Hirabayashi and Gotoh 2010; Majumder et al. 2013), this data 
suggest epigenetic regulation could play a primary role in the gliogenic switch. 
However due to heterogeneous culture system and suboptimal RNAseq 
approach I sought to replicate these results using an optimized approach.   
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Figure 3.10; RNA sequencing between Early-Late NPCs (approach1) 
A) Principle component analysis shows Early and Late NPCs are distinct populations, 
n=2. B) Differential expression of Early and Late NPCs. C) Number of up & down 
regulated genes with fold change >1.5 and p value <0.05. D) >80% of all down 
regulated genes are proteins from the histone family. E) Top 10 differentially expressed 
genes. 
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Figure 3.11; GO term analysis  
GO analysis of differentially expressed genes between early and Late NPCs (approach 
1) using GOrilla. Redundant terms were condensed using REVIGO. 
 
Shifting to experimental approach 2, I have shown that pluripotent, early and 
late NPCs cluster as distinct populations in Principal component analysis. 
There is a greater variation seen between pluripotent cells and neural 
precursors (≈70%), than between early and late NPC populations (≈22%), as 
expected. Moreover cell populations express cell type specific markers; I have 
used Pou5f1, Nanog, PODXL, NR5A2, Lin28A to mark pluripotency, Nestin & 
Pax6 as early NPC markers and NF1A, VIM for their late counterparts (Figure 
3.12).    
A) 
Up#regulated# Down#regulated#
GO#term# p)value# Enrichment#score# GO#term# p)value# Enrichment#score#
Biologi
cal#pro
cess# #
extracellular#matrix#disassembly# 4.83E)08# 43.48# chromatin#silencing# 9.87E)08# 39.92#response#to#endogenous#stimulus# 6.46E)05# 7.29# mucosal#immune#response# 2.18E)06# 99.8#glial#cell#migration# 6.24E)05# 153.03# protein)DNA#complex#assembly# 4.75E)23# 54.79#collagen#metabolic#process# 5.30E)07# 54.65# methylation# 5.61E)04# 10.11#
extracellular#structure#organization# 3.21E)07# 18.07#
cellular#component#organization#or#biogenesis# 1.43E)05# 2.18### ## # # ## # #
Molecu
lar#fun
ction# # peptidase#regulator#activity# 2.97E)04# 21.66#
protein#heterodimerization#activity# 5.02E)15# 19.51#enzyme#regulator#activity# 6.04E)04# 6.42# DNA#binding# 1.95E)10# 5.1#peptidase#activator#activity# 9.36E)04# 42.51# chromatin#DNA#binding# 4.29E)05# 19.47### ## # # ## # #
Compo
nent# part# # extracellular#matrix# 3.06E)08# 26.69# nucleosome# 4.38E)36# 121.19#vesicle# 3.00E)06# 3.55# macromolecular#complex# 4.59E)06# 2.33#collagen#type#VI#trimer# 1.88E)05# 255.06# extracellular#region#part# 1.30E)06# 2.92#
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Figure 3.12; RNAseq of Early and Late NPCs, approach 2 
A) Principle component analysis shows Early NPCs, Late NPCs and iPSCs as distinct 
cellular populations. B) Heatmap showing classic cell-type specific gene expression 
from iPSC, NPC and GPC cellular populations (n=3 technical repeats per time point). 
Points represent normalized FPKM values that are log2 transformed and mean-
centered. 
 
Next I carried out differential expression analysis between early and late NPCs. 
I show 1488 down regulated genes and 2050 up regulated genes with a 
log(fold change) >1.5 and p-value <0.05 in early versus late NPCs (Figure 
3.13.A & B). The larger changes observed between early and late NPCs in this 
data set compared to data generated using approach1 could be for several 
reasons; approach 2 uses an improved RNAseq methodology (discussed in 
chapter 4) and NPCs have been derived from an improved differentiation 
method which is a solely monolayer strategy – this ensures more homogenous 
signaling in culture therefore generates a less heterogeneous cellular 
population. Due to the large numbers of changed genes I have performed GO 
analysis and displayed only a selection of the top terms highlighted (a full list 
can be found in Appendix 8.3) (Figure 3.13.C). Many of the terms reflect NPCs 
cell fate potential, for example synaptic regulation, neuronal differentiation, 
microtubule motor activity and ion transport are down-regulated in Late NPCs, 
reflecting the loss of neuronal potential. This coincides with the up regulation of 
Ca+ handling genes (eg. S100B), growth factor binding, cytokine signaling (eg. 
BMP1,2,4, WNT1, LIF, TGFB1) and AC morphological transformation (integrin 
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and heparin binding), which are all processes implicated in glial differentiation 
(Cahoy et al. 2008). Additionally many GO terms highlighted to be up/down 
regulated in early versus late NPCs are consistent with my previous data set 
(approach 1) even though many individual genes are not replicated; there is 
drastic up regulation in genes contributing to the extracellular region (COL6A1 
is significantly up-regulated in Late NPCs in both data sets) and down 
regulated genes involved in DNA binding.  
 
Overall, taking both approaches combined, I have shown distinct transcriptional 
signatures of early and late NPCs that reflect their developmental potential. 
Key differences include changes in extracellular matrix composition, chromatin 
methylation, gene silencing, Ca+ handling and cytokine signaling.  However 
further experiments are required to define the timing and what regulates the 
switch between early and late NPCs. 
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Figure 3.13; Differential expression analysis between Early and Late NPCs from 
Approach 2 
A) Differential expression between Early and Late NPCs. B) Number of up and down 
regulated genes between Early and Late NPCs. C) GO term analysis (terms with the 
lowest dispensability displayed). !
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technical n=3) and performed RNA sequencing using Illumina’s Truseq 
stranded mRNA kits. Principle component analysis revealed segregation of 
samples depending on the number of days they have been propagated. I noted 
an increase in NPC separation between 40-60days of propagation (Figure 
3.14.A), which would suggest that the gliogenic switch occurs during this time 
window.  
 
I repeated RNAseq on NPCs propagated between day 40 and 70 days using 
an additional biological replicate (biological n=2, technical n=3). Principle 
component analysis showed that biological replicates are separated by PC2 
and that PC1 separated samples based on the duration NPCs were 
propagated in FGF, which confirms the main variation in NPCs is between 
those propagated between 40 and 60days (Figure 3.14.B). Using two biological 
replicates in parallel I noticed that for one line the largest variation is seen 
between day 40-50 and the other line between day 50-60. This highlighted that 
the cellular alterations underlying the gliogenic switch could occurs at slightly 
different times in each patient line. Thus, I next used just one biological line to 
focus in on 5day windows throughout NPC propagation between 40 and 
60days to study the sequence of molecular events throughout the gliogenic 
switch. I selected 1 line only because I wanted to limit the noise created by 
different cell lines that undergo the gliogenic switch at slightly different times, 
but of course it will be of upmost importance to validate any findings on 
additional biological lines.  
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Figure 3.14; Defining when the gliogenic switch occurs in our system 
A) Principle component analysis of NPCs propagated in culture for 20-80days 
(biological n=1, technical n=3). B) Principle component analysis of NPCs propagated in 
culture for 40-70days (biological n=2, technical n=3) 
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After carrying out RNAseq on precursors propagated for 40, 45, 50, 55 and 60 
days, I have again first carried out principle component analysis to visualize the 
data separation; increased separation is seen between day 40-55 (Figure 
3.15.A). Subsequently I have carried out differential expression analysis, using 
R package DEseq2, between each 5day time-point (day 40-45, 45-50, 50-55) 
(Figure 3.15.B). Next I performed GO analysis using differentially expressed 
genes with log(fold change) >1.5 and p-value <0.05 (Figure 3.16.A). I show 
there is a time line of transcriptional changes throughout the gliogenic switch 
(summary shown in Figure 3.15.C & D). As expected transcriptional changes in 
NPCs entering into gliogenic switch (Day45) begin with a down regulation of 
genes involved in neuronal differentiation and neural-specific functions, along 
with down regulation of genes involved in DNA binding and up regulation in 
genes controlling cellular adhesion, migration, locomotion, peptidase and 
cytokine activity.  Following, at Day50 there is up regulation of genes encoding 
growth factors but they are quickly down regulated at Day55 along with genes 
directing cytokine activity and locomotion. Also at Day55 Wnt signaling is up 
regulated. Moreover, there are continual changes in genes encoding 
components of the extracellular matrix and space throughout the gliogenic 
switch, from Day 40-55.  
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Figure 3.15; Identifying the sequence of transcriptional changes across the 
gliogenic switch  
A) Principle component analysis of NPCs propagated in culture for 40 – 60 days. B) 
Paired differential expression analysis between NPCs propagated between 40-55days 
(40-45days, 45-50days and 50-55days). C) and D) Map highlights the key themes 
associated with transcriptional changes at each time point, categorized into up and 
down regulated genes respectively.   
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Figure 3.16; GO analysis across the gliogenic switch 
Displays the top 5 up and down regulated GO terms associated with Molecular function 
at three time-points during the gliogenic switch; Day 40-45, day 45-50 and day 50-55.  
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in astrogliogenesis (Ca+ handling, JAK/STAT regulation) and have plotted their 
relative expression (RPKM values) across 6 time-points during NPC 
propagation in FGF from 20days to 80days (using 2 biological replicates). This 
shows a clear transcriptional switch between neural precursors, where genes 
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involved in neural specification, neural-specific functions, RA metabolism and 
GTPase activity are up-regulated and gliogenic precursors, where there are 
large changes in extracellular components and up regulation of genes that 
control Ca+ handling, JAK/STAT and cytokine signaling (Figure 3.17.A & B and 
Figure 3.18.F & G). In the middle of the switch (approximately day 50), we 
observe a transcriptional switch point; some neural pathways are still being 
down regulated while genes involved in astrogliogenesis are being to be up 
regulated. But also there are a few pathways that are uniquely up regulated at 
this ‘transition’ time point, including a subset of growth factors (IL11 and 
HBEGF) and genes controlling cellular adhesion (FN1), but their expression is 
reduced promptly after Day50 (Figure 3.17.F and Figure 3.18.A). Interestingly 
both genes that control growth factor activity and cellular adhesion are up 
regulated later on after the gliogenic switch as well as at Day50, however it 
appears that different genes within these pathways are up regulated at each 
stage. For example, at Day 80 growth factors IL31RA and LIF are expressed 
where as IL11 and HBEGF are up regulated at D50 (Figure 3.18.A & G). 
However we also observe CTGF expression peaks at both Day50 and Day 80 
suggesting there is some overlap in genes expressed both during and after the 
gliogenic switch (Figure 3.18.A).  
 
As expected, many pathways highlighted during this temporal analysis 
throughout the gliogenic switch overlap with the previously presented data that 
compared the differentially expressed pathways between extreme early and 
late NPCs. Pathways identified using both strategies, and using NPCs derived 
both from hiPSCs and hESCs, include those regulating extracellular matrix 
changes, peptidase activity and DNA binding (Figure 3.17.D & G). Conversely, 
several additional pathways that were differentially expressed between the 
extreme early and Late NPCs, did not appear in the top differentially expressed 
pathways highlighted during the refined gliogenic switch window (day 40-55). 
Two such processes were histone regulation and expression of genes 
associated with MHC protein complexes. This suggests these pathways could 
play a role in regulating changes that happen immediately before or after the 
largest alterations underlying gliogenic switch occur. To investigate this I have 
temporally explored the transcriptional changes of selected genes from these 
pathways, between early to late NPCs in 10day intervals. This showed that 
selected genes involved in histone regulation (HIST1H2BH, HIST1H4K and 
SUV39H1) are down-regulated across the gliogenic switch, but with the main 
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changes occurring early on (day 20-40) (Figure 3.17.C), and genes associated 
with the MHC complex (HLA-DRA, HLA-DPA1 and CIITA) are up-regulated 
shortly after the gliogenic switch (Day60+) (Figure 3.18.C). Both observations 
are consistent with the previous data that compared transcriptional changes 
between extreme early and late NPCs. Here the temporal analysis has now 
provided us additional insights into the timing of these pathways during the 
gliogenic switch; histone regulation appears to be an early signature whereas 
changes in the MHC complex occur after the gliogenic switch.   
 
Figure 3.17; mRNA expression of select genes within key pathways involved in 
the gliogenic switch. 
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Multiple bar plots to show selected example genes from key pathways highlighted in 
the gliogenic switch, n= 3+ technical repeats for each timepoint, except D20 n=2. Error 
bars represent mean ± SEM. The processes highlighted are; A) Retinoic acid (RA) 
metabolism (CYP26B1 and CRABP1) and neuronal differenitation (NEUROD1). B) 
Neural function and development (SLC6A5, CBLN2 and ROBO3). C) Histone 
regulation (HIST1H2BH, HIST1H4K and SUV39H1). D) DNA binding (BHLHE22, 
NHLH1, LHX4). E) GTPase activity (ATP1A2, RAP1GAP2, REM2). F) Cell adhesion 
(IGDCC3), migration (FN1) and locomotion (EDN2). G) Protease (CTSC) and 
peptidases (ADAM12 and MMP2). 
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Figure 3.18; mRNA expression of select genes within key pathways involved in 
the gliogenic switch. 
Multiple bar plots to show selected example genes from key pathways highlighted in 
the gliogenic switch, n= 3+ technical repeats for each timepoint, except D20 n=2. Error 
bars represent mean ± SEM. The processes highlighted are; A) First induction of 
growth factor and cytokine activity (CTGF, HBEGF and IL11). B) Cell adhesion 
(LGALS1, ANXA1 and CD44). C) and D) Extracellular matrix components, including 
Major histocompatibility complex type II (HLA-DRA, HLA-DPA1, CIITA) and 
collagen/integrin (COL6A3, COL6A2 and ITGA3). E) Ca+ handling (MATN2, TNC and 
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S100B). F) Regulation of JAK/STAT cascade (BMP4, IGFBP3 and IL32) and G) A 
second induction of growth factor and cytokine activity (IL31RA, LIF and NF2). 
 
Overall our approach provides the first in depth temporal transcriptional 
analysis across the gliogenic switch, which uniquely provides insights into the 
combinatorial timing of key pathways involved in the precursor fate transition. 
We observe two distinct phases of neural precursors; neural (NPCs) and Glial 
competence (GPCs), which is switched at approximately Day50 in our culture 
system/protocol, but there is some overlap between when neural pathways get 
switched off and gliogenic pathways on. Interestingly some of the highlighted 
pathways are observed to play roles at two distinct stages during the 
gliogenesis, for example growth factor activity was seen to peak at both day 50 
and day 80 in our culture system. These findings are consistent with a previous 
proposed model whereby signals first enable progenitor cells to establish 
competence for differentiation and then upon a second signal induction 
progenitors differentiate (e.g. BMP signaling) (Allen 2008). Here I propose the 
two peaks of growth factor activity we observe control the developmental 
competence of precursors and subsequently the differentiation of ACs. Further 
analysis and functional studies are required to define the precise mechanisms 
that underlie the temporally determined switch between neurogenic and 
gliogenic precursors.  
 
Lastly, one of the aims from this temporal analysis throughout the gliogenic 
switch was to guide optimal differentiation strategies for neurons and ACs from 
hiPSCs. We don’t observe the down-regulation of many neural 
differentiation/development/function genes until Day 40, suggesting that NPCs 
would be competent to undergo terminal differentiation to MNs until day 40. 
Further we explored key pathways with act synergistically to promote glial 
differentiation; neurotrophic cytokines (eg. LIF), JAK/STAT (IL32, LIF and 
IGFBP3) and BMP signaling (eg. BMP4). We observe that these pathways are 
up-regulated a while after the gliogenic switch has occurred, at Day 80 in our 
system. Hence suggesting that the optimal time for terminal AC differentiation 
would be after 80days of propagation in our culture system.  
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Comparing the transcriptional profile of hiPSC gliogenic 
derivatives to primary human fetal and mature purified astrocytes 
To date no one has compared the transcriptional signature of fetal and mature 
human ACs with hiPSC-derived ACs. Therefore here I compare the 
transcriptional profile of hiPSC-derived GPCs and ACs to human fetal and 
mature ACs. Evidence, in the form of gene expression and functional 
characterization to date would suggest that differentiation of ACs from hPSCs 
only generates immature ACs (Krencik et al. 2011; Roybon et al. 2013), for 
instance Shaltouki et al in 2013 described the properties and needs of iPSC-
derived ACs as similar to fetal ACs (Shaltouki et al. 2013). Therefore we predict 
that the transcriptional signature of our hiPSC-derived ACs will be closer to 
fetal immature ACs than to post natal mature ACs.   
 
Here I have compared mRNA expression levels of iPSCs, GPC and AC derived 
from control iPSCs (n=2 biological lines and technical n=2) to published 
RNAseq data from human fetal AC, mature AC and to control samples of iPSC-
derived MNs, and published data from Cortex, Endothelial, myeloid and 
oligodendrocytes samples(Zhang et al. 2016). I have used published gene lists 
for markers of endothelial cells, myeloid cells, oligodendrocytes, fetal and 
mature ACs (Zhang et al. 2016), in addition to known markers of pluripotency 
(Pou5f1, Nanog, PODXL, LIN28A & NR5A2), neuronal fate (SYN1, Syt1, 
VGLUT1, MAP2, NeuN, Tubb3, PSD95 & STMN2), MN specific markers 
(Islet1, Chat) and additional known genes involved in astrogliogenesis (VIM, 
MLC1, GFAP, FGFR3). I have plotted the corresponding individual RPKM 
values on a heatmap to show the relative expression of candidate markers 
across all samples (Figure 3.19). By plotting individual replicates the 
diversity/heterogeneity of individual AC populations is highlighted.  
 
I show clear separation of control populations (endothelial, cortex, myeloid, 
oligodendrocytes, iPSCs and iPSC-derived MN) from all samples from the glial 
lineage (iPSC-derived GPCs and AC, human Fetal and mature AC). The 
transcriptional profile between the astrocytic cellular populations also shows 
separation; firstly mature human ACs are separated from fetal AC and iPSC-
derived GPCs and AC by known mature AC markers (including APQ4, 
ALDH1L1, SLC14A1). iPSC-derived GPCs show up-regulation of all fetal AC 
markers suggesting a similar developmental status, where as iPSC-derived AC 
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have only a partial overlap with some fetal markers (TPX2, TNC, VCAM1, 
PTX3, TNFRSF19, FZR1, ZYX, PXDN) and in addition up-regulate several 
additional astrocytic markers that are distinct from the mature AC markers 
(VIM, MLC1, GFAP, FGFR3). This suggests that our iPS-derived ACs are in a 
transition phase between fetal and mature AC. A previous study in murine brain 
also finds MCL1 is exclusively detected in glia and an increase in MLC1 
expression occurs in the perinatal period (between fetal and postnatal AC 
phases) (Schmitt et al. 2003), with the highest levels found in gliogenic 
progenitor populations. This reinforces our iPSC-derived AC still maintain 
several characteristic of a proliferative immature gliogenic population and have 
not fully matured.  Again suggesting iPSC-derived AC are not fully matured is 
the expression of FGFR3, which is a specific gliogenic marker of the pMN 
domain that is up-regulated in proliferative cells and is seen to decrease as 
GFAP expression increases.  This confirms the specification of a spinal cord 
identity of our iPSC-derived gliogenic derivatives but due to marking only a 
subtype of AC (pMN domain) and its presence in oligodendrocytes, this marker 
cannot be used in isolation (Pringle et al. 2003).  
 
Moreover this transcriptional database can also be used to address 
controversial results in the field, for example the expression of S100B in the 
gliogenic lineage is so far not clear, many report it as a late mature marker of 
ACs (Raponi et al. 2007) but others detect its expression in immature and 
undifferentiated ACs (Shaltouki et al. 2013). Here I see S100B expression is 
highest in mature ACs suggesting it is in fact a late astrocytic marker, but 
importantly it cannot be used in isolation to characterize AC populations as it is 
also expressed in oligodendrocytes. 
 
  
! 117!
 
iP
SC
-
de
riv
ed
 
G
PC
s 
Fe
ta
l A
C
 
iP
SC
-d
er
iv
ed
 
AC
 
M
at
ur
e 
H
um
an
 
AC
 
iP
SC
 
iP
SC
-
de
riv
ed
 
M
N
 
 C
or
te
x 
O
lig
o-
de
nd
ro
cy
te
s 
M
ye
lo
id
 E
nd
o 
ES
AM
 
EC
AM
2 
R
U
N
X1
 
TM
EM
11
9 
G
FR
37
 
SO
X1
0 
SY
N
1 
M
G
LU
T1
 
M
AP
2 
N
EU
N
 
IS
LE
T1
 
C
H
AT
 
TU
BB
3 
PS
D
95
 
ST
M
N
2 
PO
U
5F
1 
N
AN
O
G
 
PC
O
X1
 
N
R
5A
2 
LI
N
28
A 
N
U
SA
P1
 
TO
P2
A 
W
EE
1 
E2
H
2 
KI
F2
3 
G
A8
2L
3 
C
C
N
B1
 
N
SM
1 
M
EL
K 
R
R
M
2 
LM
N
B1
 
C
EN
PF
 
TP
X2
 
TN
C
 
VC
AM
1 
PT
X3
 
TN
FR
SF
19
 
FZ
R
1 
ZY
X 
PX
C
N
 
VI
M
 
M
LC
1 
G
FA
P 
FG
FR
3 
N
F1
B 
SO
X9
 
SL
C
1A
3 
G
IA
1 
ED
N
R
B 
D
IO
2 
SL
C
4A
4 
AQ
P4
 
AL
D
H
1L
1 
N
TS
R
2 
M
T1
G
 
PP
P1
R
1B
 
EB
XO
2 
TP
D
52
L1
 
M
R
D
 
H
SD
17
B6
 
H
H
AT
1 
SL
C
14
A1
 
R
AN
BP
3L
 
G
JB
8 
W
IF
1 
C
LD
N
10
 
G
AB
R
G
1 
AG
XT
2L
1 
G
FC
5 
C
AB
LE
S1
 
G
LT
1 
S1
00
B 
En
do
th
el
ia
l m
ar
ke
rs
 
M
ye
lo
id
 m
ar
ke
rs
 
O
lig
od
en
dr
oc
yt
e 
m
ar
ke
rs
 
N
eu
ro
na
l m
ar
ke
rs
 
Pl
ur
ip
ot
en
cy
 m
ar
ke
rs
 
Fe
ta
l a
st
ro
cy
tic
 
m
ar
ke
rs
 
M
at
ur
e 
As
tro
cy
te
 
m
ar
ke
rs
 Pr
op
os
ed
 
tra
ns
iti
on
 s
ta
ge
 
be
tw
ee
n 
Im
m
at
ur
e 
& 
M
at
ur
e 
 a
st
ro
cy
te
 
m
ar
ke
rs
 
! 118!
Figure 3.19; Comparing the transcriptional signature of hiPSC-derived AC to 
purified human fetal and mature astrocytes 
A) Heatmap to show candidate gene expression of iPSCs and their MN, GPC and AC 
derivatives, compared to human purified populations of fetal astrocytes, mature 
astrocytes, oligodendrocytes, cortex, myeloid and endothelial samples. Each block 
represents 1 technical replicate, with each sample having > n=2. Points represent 
normalized RPKM values that are log2 transformed and mean-centered. 
 
To conclude these results demonstrate the distinct maturational stages in 
astrogliogenesis and compare our differentiation strategy in hiPSCs to human 
development. GPCs show high transcriptional similarity to fetal proliferative 
ACs, but iPSC-derived AC do not mirror the maturation stage of postnatal 
mature AC, instead they display a distinct transcriptional signature which we 
hypothesis is a transitional stage between fetal and post-natal mature ACs.  
 
Overall, I have shown a human model of astrogliogenesis from pluripotent 
cells, through NPCs followed by GPCs to terminally differentiated ACs. Using 
highly enriched sample populations I analyzed global gene expression 
signatures, which build upon previous microarray studies of both murine and 
human ACs and offer insights into the transcriptional profile of ACs. This 
database can be used to help identify new genes that are pivotal for 
astrogliogenesis and could be used to ascertain the purity of AC populations 
that are differentiated from NSCs. This information will be particularly useful for 
future studies of human ACs, aiding the large-scale production of 
homogeneous AC cultures for high throughput drug screens and for 
understanding neurological disorders resulting from AC dysfunction.  
Discussion 
The revolutionary discovery of hiPSCs (Takahashi and Yamanaka 2006) has 
provided an alternative model system to study both development and disease 
that has remarkable advantages over previous models, including being a fully 
humanized system and the potential to enable personalized medicine in the 
future. Here I have; 
• Described and functionally validated novel differentiation methods developed 
for the generation of spinal cord MNs and ACs - that I will later use study the 
underlying pathogenesis of MND.   
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• Recapitulated key developmental events in hiPSCs, such as sequential 
neurogenesis and gliogenesis 
• Defined a fine window when the gliogenic switch occurs in our culture system 
• Defined a temporal sequence of transcriptional events that occurs as NPCs 
lose the ability to become neurons and acquire gliogenic potential 
• Compared the transcriptional signature of our hiPSC-derived ACs to human 
samples to assess their developmental stage/maturity.  
The generation of spinal cord MNs and ACs 
I have built upon the Patani lab’s previous published work (Gupta et al. 2012; R 
Patani et al. 2011) by generating robust directed differentiation strategies for 
highly enriched, regionally defined and clinically relevant populations of both 
spinal cord MNs and ACs, in a fully defined, humanized culture system. A 
major advantage of using a monolayer approach has enabled the consistent 
generation of highly enriched cellular populations. Importantly, this removes 
issues of heterologous cell-cell signalling that are frequently observed in 
suspension culture systems.  
 
Briefly for MN generation I use dual smad inhibition and GSK3B signaling 
(CHIR99021) to synchronize neural conversion and have altered the timing of 
patterning with RA and Purmorphamine to increase the generation of spinal 
neural precursors specified. Using same logic I was able to accelerate terminal 
differentiation of MNs by treatment with compound E, which promotes 
synchronized exit from the cell cycle.  The same approach for generating spinal 
neuronal precursors was used for astrogliogenesis, then BMP4 and LIF 
signaling was utilized to promote terminal differentiation. To summarise the 
novelty of the protocols I have developed i) they are fully monolayer based, ii) 
we do not use additional growth factors such as BDNF and GDNF, and iii) we 
use dorsomorphin instead of LDN during neural induction. All phases of the 
protocol have been optimized to ensure they are time efficient, generate highly 
pure populations of cells (which is particularly important for the 
application/analysis of genomic techniques I use later in this thesis) and that 
they mirror key developmental processes in vivo.  
 
Separately, I have explored the temporal regulation of early and late NPCs by 
analyzing the transcriptional signature at selected time points throughout the 
propagation of NPCs. These findings (discussed more below) guided the 
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optimization of robust protocols for neurons and glia from hiPSCs. In particular 
the timing of the gliogenic switch steered the timing of NPC propagation; the 
maximum time limit for propagation of neurogenic precursors could be defined 
(40days) and the minimum time NPCs should be propagated before gliogenic 
precursors can be efficiently terminally differentiated into ACs (60-80days).  
 
Moreover I have comprehensively validated the protocols at transcriptome-wide 
and functional levels in a stage specific manner. This has provided important 
insights into the maturity of derived cell types. For functional characterization of 
derived MNs we have collaboratively carried out several assays in parallel, 
including electrophysiology profiling, calcium response and axonal transport. It 
is important to note that although these enable us to investigate neuronal 
function they have not allowed us to distinguish MN specific functions. For this 
we will need to carry out co-culture with muscle or inject samples into the 
developing neuroaxis (eg. of a chicken). However separately, these 
investigations have resulted in establishing several assays in hiPSC-derived 
neurons that can later be exploited to address controversies in disease and/or 
development (although this is not addressed in this thesis). For example both 
neural synaptic activity and the efficiency of long-range communication caused 
by defects in axonal transport constitute major pathogenic mechanisms in 
neurodegenerative disorders (Alami et al. 2014; Devlin et al. 2015; Wainger, 
Kiskinis, Mellin, Wiskow, Steve, et al. 2014). Deficits in axonal transport have 
been identified at a pre-symptomatic stage in the SOD1G93A mouse model of 
MND (Bilsland et al. 2010) but have not yet been followed up in a human 
clinically relevant system. The early appearance of transport defects in the 
SOD1G93A mouse suggests axonal transport may play an important role in 
MND pathogenesis but it is not clear if this is the causative mechanism of MN 
degeneration or a secondary pathogenic event in MND. This can be elucidated 
by temporally analyzing hiPSCs throughout differentiation and maturation. 
Additionally, neural hyperexcitability followed by a progressive loss in synaptic 
activity has been shown in MND, in particular using hiPSCs carrying mutations 
in C9ORF72 and TARDBP (Devlin et al. 2015). We can now followed up and 
validate these findings using electrophysiology profiling of MNs derived from 
additional clinically relevant hiPSC lines.  
 
Finally it is important to highlight there is a huge cellular diversity present in the 
human motor system, which presents with differential vulnerability in different 
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neurodegenerative diseases. The majority of iPSC strategies to date, including 
ours, have focused on deriving MNs generically but comparatively few studies 
have characterized the motor neuronal subtype diversification (Zirra, Wiethoff, 
and Patani 2016). I have briefly begun to look at the MN subtype specified by 
our protocols. HOXB4 staining and RNAseq analysis of the HOX genes 
confirmed our MNs are specified to the cervical region of the spinal cord. Also 
FOXP1, a HOX cofactor that also regulates MN subtype diversity, indicates 
50% of our cultures are limb innervated MNs of LMC. However much further 
analysis is needed to fully define the subtypes of MNs derived from this 
protocol. In the future characterizing and elucidating new efficient protocols for 
subtype specific MNs will have important implications for more accurate models 
for studying disease and drug discovery.  
Defining the transcriptional landscape of the gliogenic switch and 
astrogliogenesis 
Until recently due to technical limitations, there has been a lack in 
understanding of genome-wide transcriptional status of iPS cells and their 
derivatives. In particular the gene expression profiles of ACs have been 
relatively poorly defined despite their importance in the nervous system and 
roles in disease. The role of ACs depends upon their maturity, reactivity and 
regional specificity therefore it is essential we improve our characterization, 
validation and specification stratergies. Here I have begun to systematically 
define the transcriptional landscape of astrogliogenesis, which can in the future 
guide improved protocol development and characterization.  
 
Firstly, I have explored the transcriptional regulation underlying the gliogenic 
switch by analyzing samples at selected intervals throughout the propagation of 
NPCs. I have narrowed down the window in which the gliogenic switch occurs 
in our culture system and begun to dissect the time line of regulatory events 
underlying the switch. I show a down-regulation of neuronal specific genes 
occurs (Day40) prior to the up-regulation of astrocytic-specific genes (Day80). 
Further within the transition period in between these two distinct phases we 
observe proteases, genes influencing cellular adhesion and migration, selected 
growth factors and cytokines are all up regulated. However further analysis and 
functional studies are required to determine the precise mechanisms by which 
the gliogenic switch is regulated, including dissecting the interaction of both 
extrinsic and intrinsic mechanisms. Understanding the molecular machinery of 
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the gliogenic switch will be able to guide the manipulation of relevant cell types 
(neurons and glia) in culture, enabling us to improve our strategies for 
generating the respective cell types.  
 
Further I have characterized the equivalent maturity status of our iPSC 
gliogenic derivatives by comparing their transcriptional signature to human fetal 
and mature ACs. This is important as the use of hiPSC-derivatives to model 
late-onset diseases is a wide concern in the field - typically patients do not 
develop symptoms until later in life, which implicates age is a vital component 
for disease onset and progression. We observe hiPSC-derived GPCs display a 
transcriptional signature of comparable maturity to human fetal ACs. 
Unsurprisingly though hiPSC-derived ACs transcriptional profile did not match 
that of human mature ACs. Instead they are observed to express some overlap 
with fetal AC markers (TPX2, TNC, VCAM1, PTX3, TNFRSF19, FZR1, ZYX, 
PXDN), in addition to several unique AC markers that were not defined in the 
transcriptional signature of mature ACs (VIM, MLC1, GFAP, FGFR3).  This 
suggests our hiPSC-derived ACs are in a  ‘transition’ phase between fetal and 
mature ACs. Although hiPSC-derivatives have proved not to be equivalent to 
mature adult cells, they still hold several advantages over other model systems 
to study neurodegenerative disease and ideally should be used in conjunction 
with other model systems (eg. in vivo models and postmortem tissue), to 
uncover robust disease mechanisms. Importantly hiPSCs overcome critical 
species differences, mutations are present at pathological doses, in theory any 
cell type can be generated in unlimited quantities and it is possible to 
temporally study how diseases evolve and progress.  
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Chapter 4; Optimizing genomic techniques to 
study RNA regulation 
As discussed in the chapter 1, there is strong evidence to suggest that RNA 
regulation plays a role in the pathogenesis of MND and I will later explore the 
contribution of defective RNA regulation in our hiPSC VCP-related MND model 
system, using RNA sequencing to study transcriptional changes and iCLIP to 
explore the possibility of altered protein-RNA complexes. However, iPSC 
technology is both very expensive and time-consuming, so although it can 
provide a limitless resource of human, patient specific cells, the amount of 
material available for experiments is restricted. It is therefore crucial to optimize 
downstream experimental methods first. Here I have comprehensively 
evaluated multiple RNAseq approaches and iCLIP modifications.  
RNA sequencing 
There are many different methods to prepare libraries from RNA samples for 
high-throughput sequencing but all follow a core workflow. Libraries can be 
created from the total RNA or from a selected subpopulation, for example from 
mRNA only (to calculate abundance and novel features of the coding 
transcriptome) or from transcripts of interest (by targeting selective pathways).  
 
Approximately 80% of cellular RNA is ribosomal, which is not translated, 
instead it functions as a scaffold and/or enzyme of the ribosomes. We chose to 
remove this abundant RNA before library preparation and deep sequencing to 
maximize the uniquely mapping reads. There are several methods for removing 
rRNA before library preparation; the most common are rRNA depletion (which 
targets selected rRNA molecules for removal but preserves information of non-
adenylated, non-coding, and regulatory RNAs) or PolyA selection (capture of 
all mRNA). Further there are many approaches for RNAseq library preparation 
but on the whole they follow the same principles; for stranded RNAseq the 
overall stages are;  
1/ Fragmentation – to make RNA optimal size for sequencing 
2/ first strand synthesis – uses dNTPs, and Actinomycin D to prevents spurious 
DNA-dependent synthesis, while allowing RNA-dependent synthesis, 
improving strand specificity. 
3/ second strand synthesis – uses a selective chemical marking (often dUTP) 
on the second strand 
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4/ Adenylation and adapter ligation – fragments are adenylated prior to the 
addition of an adapter. The adapters contain a unique 6 nucleotide 
sequence/barcode to allow for multiplexing of samples 
5/ second strand degradation and PCR amplification - UTP-marked strand is 
selectively degraded by Uracil-DNA-Glycosylase prior to PCR amplification.  
6/ Quantification and sequencing – Libraries are accurately quantified and 
quality is checked using the bioanalyser before sequencing. 
Here, I have tested the preparation of the RNA itself and several cDNA library 
preparation kits. 
RNA preparation 
To prepare samples for RNA sequencing, RNA is first extracted then the 
quantity and quality must be checked. For RNA extraction I compared the 
Zymo Direct-zol miniprep kit, Qiagen RNeasy extraction kit and the Promega 
Maxwell automated machine with simplyRNA cells kit. I found that the Zymo 
Direct-zol gave a consistently higher yield of RNA compared to the Qiagen 
RNeasy kit (data displayed in Appendix 8.4), however the Promega Maxwell 
automated machine gave the most consistent RNA yield (data displayed in 
Appendix 8.4). Samples from each experiment batch were selected at random 
to run on the bioanalyser to assess RNA quality. For downstream applications 
only samples with RIN scores >7.5 were used.    
Generead rRNA depletion and NEXTflex directional RNAseq 
approaches 
We first decided to deplete rRNA using the qiagen Generead rRNA depletion 
kit (input of 1-5ug). This works by the hybridization of specific oligonucleotide 
probes that are complementary to the large (18s, 28s), small (5s, 5.8s), and 
mitochondrial (12s, 16s) rRNAs. The RNA:DNA hybrid is recognized by an 
antibody and the resulting antibody-hybrid complex is efficiently captured on a 
protein G bead. These beads can then be separated from the sample, 
removing the rRNA in the process. After rRNA depletion, RNA quantity is again 
checked.   
 
I have tested several approaches for RNAseq library preparation, including 
unpublished methods produced within the lab and commercial kits. Among 
others, I trialed the NEXTflex directional RNAseq kit (10-100ng input) (Figure 
4.1.A). This kit has two main advantages, firstly it uses random primers used 
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for first strand synthesis, which reduces bias compared to oligo dT primers and 
it provides strand specific information (therefore this can be more confidently 
integrated with iCLIP data later on).  
 
There were many issues I encountered when using the NEXTflex library 
preparation kit. Firstly I routinely see a strong adapter dimer product (approx. 
100 bp), which is stronger when the RNA input is lower (or is lost throughout 
the library preparation) (Figure 4.1.B). After ligation of the adapter and again 
after PCR amplification, ampureXP beads were used to purify the library. 
These work by reversibly binding DNA in the presence of crowding agent - 
binding is dependent on the concentration of crowding reagent and ratio of 
beads to DNA, which in turn determines the size of fragments eluted. The 
NEXTflex protocol recommended using an equal ratio of beads to sample 
whereas I have tested a higher ratio of beads:product in an attempt to remove 
the unwanted adapter product. I used a ratio of 4:5 during the clean up step 
after the adapter ligation to remove the small products (<150bp) and was able 
to remove the unwanted adapter dimer (Figure 4.1.B). However altering the 
bead ratios caused the fragment sizes to be larger than that is optimal for 
sequencing (Figure 4.1.C). Additionally as a result of having low amount of 
product, we are using a greater cycle number than recommend in PCR 
amplification (18 versus 15 recommended). Over-amplification can introduce 
PCR artifacts and is not optimal for sequencing.  
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Figure 4.1; Library preparation using rRNA depletion and the NEXTflex RNAseq 
approach 
A) Schematic representation of the NEXTflex RNAseq method. B) Libraries post-PCR 
amplification. Lane 1 shows a library that was purified post-PCR using the standard 
NEXTflex protocol. An adapter by-product is highlighted at approximately 100bp. Lane 
2 shows a library that was purified post-PCR using an altered approach (decreased 
ampureXP bead ratio) to remove the adapter by-product. C) Bioanalyser traces of 
libraries 1 and 2 respectively. Traces show that altering the ampureXP ratio during the 
final clean up has knock on effect on the library distribution and average fragment sixe.  
 
Once the RNAseq libraries generated using the NEXTflex library preparation kit 
were sequenced and mapped we used several tests to check the quality of our 
data. Unfortunately we found further issues with our approach. Firstly there is 
high proportion of rRNA contamination (Figure 4.2.C) suggesting we need to 
improve our method of ribosomal RNA removal.  I also noticed there was a 
high percentage of intergenic reads and only a small fraction of exonic (Figure 
4.2.B). This is unexpected and suggests there could be a potential DNA 
contamination in library preparation. In addition we looked at the number of 
reads found on each the sense and antisense strand (Figure 4.2.A). This again 
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is unexpected as the reads are mixed between strands (ranging from <5% to 
>45% on each sense/antisense strand). Finally, looking across all samples 
(either in the same experiment, same processing batch or taking the total 
samples in database) I see a huge variability in the quality, mainly in the % of 
exonic reads and the strandedness. 
 
 
Figure 4.2; Post-sequencing quality checks of libraries produced using the 
NEXTflex RNAseq method 
A) Box plot representation of the average percentage of reads assigned to the sense 
and antisense strand (taken as an average across 123 samples). B) Pie chart 
displaying the percentage of reads aligned to exonic, intronic or intergenic regions 
(numbers calculated as an average across 123 samples). C) Plot displaying 
percentage of reads aligning to rRNA, Individual samples/replicates are plotted.  
 
All together as a result, we would need to carry out very deep sequencing to 
get a suitable number of reads for downstream analysis. RNAseq is an 
important tool for my projects therefore I needed to ensure the method is 
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reliable, reproducible and high quality. After consideration I did not think this 
approach was worth pursuing so I turned to exploring alternative methods/kits.  
PolyA selection and Illumina Truseq methods 
Since Illumina is a leader in sequencing technologies I chose to test out 2 of 
their RNA sequencing kits; Truseq stranded mRNA and the Truseq access kit 
(Figure 4.3.A). The two approaches are suited to generating libraries from 
different amounts of input material (Truseq stranded mRNA requires an input of 
0.1-4ug total RNA and the Truseq access kit required 10ng total RNA). The 
Truseq mRNA kit uses PolyA selection as a method to remove abundant rRNA. 
This is done using poly-T oligo attached magnetic beads to select mRNA in two 
rounds of purification. On the other hand the Access kit uses the total RNA to 
create a template library, from which the coding regions are captured and 
sequenced using probes to the known coding regions.  
 
 
Figure 4.3; Library preparation using PolyA selection and Illumina Truseq 
RNAseq methods 
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A) Schematic representation of both the Truseq stranded mRNA and Truseq Access 
approaches. Representative bioanalyser traces of libraries produced using B) Truseq 
mRNA and C) Truseq Access kits respectively.  
 
I have tested and produced successful libraries from both Illumina approaches. 
Both the Truseq mRNA and Access kits were shown to generate libraries of a 
significantly higher quality than I previously saw with the NEXTflex approach. 
Firstly during library preparation I see a consistent normal distribution of 
fragments around 300bp (Figure 4.3.B & C). After sequencing and mapping to 
hg19 the quality of reads had dramatically improved; the % of strandedness 
was >90%, there was a high proportion of exonic read >75% and there was no 
contamination of rRNA (Figure 4.4.A, B & C). 
 
Figure 4.4; Post-sequencing quality checks of libraries produced using the 
Truseq stranded mRNA RNAseq method 
A) Box plot representation of the average percentage of reads assigned to the sense 
and antisense strand (taken as an average across 66 samples). B) Pie chart displaying 
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the percentage of reads aligned to exonic, intronic or intergenic regions (numbers 
calculated as an average across 66 samples). C) Plot displaying percentage of reads 
aligning to rRNA, Individual samples/replicates are plotted.  
 
For this thesis the Truseq stranded mRNA kit has been used the standard 
method. A few exceptions that have been generated using the Illumina access 
kit (where there is very limited input material available) and NEXTflex kit are 
clearly marked. 
 
Individual nucleotide crosslinking and immunoprecipitation 
(iCLIP) and non-radioactive modifications 
Individual nucleotide crosslinking and immunoprecipitation (iCLIP) has been a 
powerful method to study protein-RNA interactions. It allows us to study post-
transcriptional regulation controlled by RBPs and uncover transcriptome wide 
maps of the RNA binding sites of an RBP at nucleotide resolution. However the 
technical aspects of iCLIP remain challenging and are one of the major 
limitations to its widespread use. A common aspect to all varieties of CLIP is 
the use of phosphorus-32 (P32) to label the protein-RNA complexes, which 
restricts application to institutions in which radioactive work is practicable. This 
was previously the case with northern blotting and in-situ hybridisations too 
(Cassidy and Jones 2014; S. W. Kim et al. 2010) .  
 
The current iCLIP protocol utilizes antibodies immobilized on magnetic beads 
to separate the RBP-of-interest from sample lysates. Next an on-bead 3’ linker 
ligation is then undertaken prior to SDS-PAGE analysis (Huppertz et al. 2014). 
This is also similar for HITS CLIP (Moore et al. 2014), whilst in PAR-CLIP the 
adapter sequences required for PCR amplification are incorporated  after  
SDS-PAGE  analysis (Hafner et al. 2010). Irrespective of the linker ligation, 
complexes are labeled with P32 prior to SDS-PAGE in all approaches. This 
way the protein-RNA complexes will be separated according to molecular 
weight and can be visualized. The resulting autoradiograms can subsequently 
be used to stringently isolate only the appropriate complexes associated with 
the RBP-of-interest.  Moreover, in theory SDS-PAGE has an  additional  benefit  
that it  allows  ready  removal  of  free RNA that may be stick to the beads 
during immuno-precipitation, and could contaminate the resulting cDNA 
libraries,  although this has not been experimentally evaluated. Labeled 
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samples proceed through multiple steps until the radioactive signal is 
eliminated, and this requires P32-designated apparatus until such steps are 
reached (Huppertz et al. 2014). Additionally, work with P32 has its own 
inherent risks and environmental impacts.   
 
Here I have investigated the application of three non-radioactive adaptations to 
the iCLIP protocol under the supervision of Dr. Chris Sibley. We use the 
previously CLIP studied heterogeneous nuclear ribonucleoprotein C (hnRNP C) 
as a model RBP to evaluate these non-radioactive approaches to circumvent 
the radioactive step during the current iCLIP protocol. The standard iCLIP 
procedure was followed except a few alterations after immuno-purification and 
on-bead linker ligation (Figure 4.5). 
 
1/ ‘Blind-cutting’ of protein-RNA complexes after SDS-PAGE separation.  
Previously several RBPs have been studied within the lab such as TIA1, 
TDP43, FUS and hnRNPC where autoradiographs have confirmed that single 
RBPs, or dimers of these RBPs, are immuno-purified specifically with no 
contaminating RBPs (König et al. 2011; Rogelj et al. 2012; Tollervey et al. 
2011; Ule et al. 2010). Under such scenarios we hypothesise that it may be 
possible to purify RBPs in the absence of an autoradiograph through size 
selection based on molecular weight marker alone. Here no P32-labelling of 
RNA was undertaken and samples were subjected to SDS-PAGE. No 
autoradiograph was produced and instead the protein-RNA complexes were 
cut from the nitrocellulose membrane by using the protein molecular weight 
ladders as guides for both the lane positioning and for the expected size of 
hnRNP C (Blind cut).  
 
2/ Elimination of SDS-PAGE analysis altogether – direct Proteinase K (PK) 
treatment. 
If free RNA stuck to the beads is minimual at the point of SDS-PAGE, then we 
hypothesized purification may be possible to in the absence of SDS-PAGE 
through proteinase-K digestion of the immuno-precipitated complexes directly 
off the magnetic beads. Here there was no P32-labelling of RNA, no SDS page 
and samples were subjected to on-bead proteinase-K digestion and 
subsequent RNA extraction and reverse transcription as usual.  
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3/ The use of an Atto663-labelled linker instead of P32 labelling. 
Finally we have tested the use of a non-radioactive adapter, so the protein-
RNA complexes can still be visualized. The non-radioactive adapter selected 
needs to be highly sensitive and detect low yields since UV cross-linking is 
expected to cross-link <1% of the total RBP-RNA contacts under the conditions 
employed in iCLIP (Ule et al. 2003). Further, it would need to not interfere with 
the reverse transcription reaction, which uses the adapter as a reverse 
transcription primer binding site. An atto633-labelled adapter was selected to 
test, with fluorescence properties 633nm excitation and 657nm emission. 
Instead of the standard on-bead ligation of iCLIP linker, the Atto633-labelled 
linker was ligated, enabling visualisation of protein-RNA complexes using a 
phosphoimager (Fuji FLA-2000) rather than autoradiograph. The resulting 
images were used to produce a cutting-mask and guide the isolation of protein-
RNA complexes of interest. To aid size determination a near-infrared ladder 
was used. The iCLIP procedure was rejoined after isolation of the protein-RNA 
complexes from the membrane.  
 
 
Figure 4.5; Schematic to show 3 alternative non-radioactive iCLIP approaches 
tested 
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Comparing the non-radioactive adaptions 
Firstly I compared the Atto633-labelled linker and p32 visualisation during 
library preparation. I found that the Atto633 linker retains the ability to monitor 
RBP-RNA complexes and the visualisation, on both the autoradiograph and 
phosphoimage, importantly confirms the RBP contaminant-free nature of the 
hnRNPC immuno-precipitations (Figure 4.6.A & B). 
 
Next I show the production of cDNA libraries from all 3 alternatives methods 
and using the standard P32 labelling at similar levels of PCR amplification, 
demonstrating that all adaptations to the iCLIP method are capable of 
producing high-throughput sequencing compatible libraries (Figure 4.6.C). 
Importantly we see that the Atto633 linker did not interfere with downstream 
preparation of the libraries nor the library complexity.  
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Figure 4.6; Library preparation using the standard iCLIP and 3 alternative non-
radioactive iCLIP approaches  
A) Autoradiograph after 1hour exposure showing RNA-protein complexes isolated after 
immunoprecipitation of hnRNPC and RNase treatment following the standard iCLIP 
method. 2 control samples (prepared using either no UV or no antibody) and 1 sample 
treated with high RNase are shown. B) Fluro-image of protein-RNA complexes ligated 
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to a modified adapter containing a flurophore, Atto663. Image is read immediately 
using a Fuji FLA-2000 phosphoimager. C) Post-PCR amplification of medium and high 
cDNA fragments prepared from standard iCLIP, Atto633, Blind cut and direct 
proteinase K approaches. 
 
Following, I have assessed the cross-link clusters (position of each cluster and 
amount of binding within each cluster) for hnRNPC. Comparison of the cross-
link cluster reproducibility of these libraries revealed that 2 of the proposed 
alternative non-radioactive iCLIP methods (the Atto633 adapter and Blind 
cutting) had a good correlation to the standard iCLIP protocol and to a 
previously published hnRNPC library (König et al. 2011) (Figure 4.7). However 
this did not hold true for the direct PK treatment. We observed that the direct 
PK digestion approach had the poorest correlation to the standard iCLIP 
approach (R2 =0.65 and compared to published iCLIP data R2 =0.52) (Figure 
4.7), a finding we attribute to contaminating free RNA that is not appropriately 
removed with bead wash-steps alone. Thus, whilst it may be possible to 
produce iCLIP libraries using this approach, a compromise is made to the 
quality and resolution of the data.  The blind cut based on molecular weight 
markers produced highly reproducible libraries relative to the standard iCLIP 
approach (R2=0.89), demonstrating this approach could be considered when 
there is no alternative available, however it still remains preferable to visualize 
RBP-RNA complexes prior purification such that evaluation of other RBP 
contaminants and the RNase digestion patterns can be appropriately 
assessed.  Finally the Atto633-adapter, produced highly reproducible clusters 
that mirrored those produced with the standard iCLIP procedure (R2 =0.84) and 
to previously published data (R2 =0.76). Moreover, this approach retains the 
ability to monitor protein-RNA complex  migration  patterns  during  SDS-
PAGE, and  can  be easily  adapted  with  alternative  fluorophores  to  suit  
institutional  capabilities.  
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Figure 4.7; Reproducibility of cross-link clusters 
Multiple scatterplots display the correlation between hnRNPC cross-link clusters 
(positions and size) identified using different iCLIP approaches; standard iCLIP, 
Atto633 adapter, Blind cutting, Direct PK treatment and also to published iCLIP data 
(Konig et al, 2010). R2 values shown.  
 
To demonstrate the applicability of this method, we have replicated previously 
published analysis of hnRNPC that requires high integrity data (König et al. 
2011). hnRNPC has previously been characterized to bind to uridine tracts 
(König et al. 2011). Thus I have sought to test the reproducibility of this by 
analyzing the sequences immediately surrounding the crosslink site. First using 
weblogo I have plotted the proportion of each nucleotide located immediately 
surrounding crosslink site (in a 20nt window) (Figure 4.8.A). Both the Atto633 
adapter and blind cut approaches shows T base enrichment similar to we 
observe with standard iCLIP method and in previously published hnRNPC 
iCLIP data. Conversely the direct PK treatment method failed to produce a 
striking T enrichment around hnRNPC’s binding sites. Secondly I have 
performed further sequence analysis by analyzing pentamer enrichments 
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immediately surrounding hnRNPC’s crosslink sites (again in a 20nt region). 
The top enriched pentamer for all iCLIP approaches is TTTTT (Figure 4.8.B). 
As before there is high correlation of the pentamer sequence enrichment 
between the standard iCLIP and Atto633-adapter approach (R2=0.97), but 
correlations are relatively poor between direct PK treatment and Blind cut 
approaches compared to the standard iCLIP approach (R2=0.18 and R2= 0.36 
respectively) (Figure 4.8.B). The standard iCLIP does not correlate that highly 
to previously published iCLIP data (R2=0.34). I hypothesize this is due to 
increase in library complexity with the latest standard iCLIP data due to 
improvements in the method over past 5years. Perhaps surprisingly, the 
pentamer scores generated from the blind cut approach are highly correlated to 
previously published data (R2=0.97). I reason that this is due to a reduced 
library complexity of both the blindcut and previous iCLIP data compared to the 
standard iCLIP protocol we are currently using.  
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Figure 4.8; Sequence analysis surrounding hnRNPC binding sites 
A) Weblogo plots showing the relative nucleotide frequency around the binding sites 
(position 0) of hnRNP-C. B) Scatterplot plots display the correlation of pentamer 
enrichment seen within a 20nt window surounding hnRNPC’s binding sites, identified 
using multiple iCLIP approaches; standard iCLIP, Atto633 adapter, Blind cutting, Direct 
PK treatment and also to published iCLIP data (Konig et al, 2010). R2 values shown 
and highest enriched pentamer highlighted in red.  
 
Finally we assessed cross-link positioning for a previously studied gene, CD55 
(König et al. 2011). We see crosslink nucleotides identified using the standard 
iCLIP, non-radioactive Atto633-adapter and Blind cut approaches are 
comparable to previously published data; they are present along the entire 
length of CD55 pre-mRNA and accumulate around the alternative exon (Figure 
4.9.A, B & C). Direct PK treatment does not reproduce this crosslinking pattern 
and shows non-specific binding, therefore in agreement with the previous 
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correlation analysis we conclude direct PK treatment results in inaccurate, 
compromised data. Further we note, as in previously published data, hnRNPC 
binds within Alu elements (Zarnack et al. 2013). We show the % of binding to 
Alu elements is comparable for all alternative approaches and to previously 
published data (ranging between 24.4% using the Blind cut method and 14.2% 
using the non-radioactive adapter. The average across methods is 18.1%±3.6) 
(Figure 4.9.D).  
 
 
Figure 4.9; Reproducing hnRNPC crosslinking to CD55 
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A) Global view of hnRNPC cross-linking to CD55; crosslinking nucleotides are present 
along the entire length of CD55 pre-mRNA. B) Zoomed in crosslinking positions, C) 
crosslinking accumulation around the alternative exon and within Alu element. D) % 
binding to Alu elements.  
 
To conclude, the Atto633-labelled linker and blind cut approaches reproduced 
cross-link positioning and the subsequent findings of previous radiolabelled 
libraries (binding to U tracts and alu elements). However the Atto633 adapter 
will be the preferred approach to use because it has the advantage over the 
Blind cut approach of visualising the protein-RNA complexes. 
Discussion 
The complexity of gene expression and regulation demands the highest 
sensitivity for measuring transcripts and detecting changes in abundance and 
structure. Since the advent of NGS, the use of unbias transcriptome-wide 
analysis has become increasingly accessible and even over the past decade 
there has been substantial progress in genomics technologies (including in 
library construction, sequencing and data handling/analysis). This is reviewed 
elsewhere (König et al. 2012; Metzker 2010). Here we have evaluated several 
RNA sequencing and non-radioactive iCLIP approaches to ensure we select 
the best methods for future projects.  
 
The vast number of recently published RNAseq studies highlights it as the 
preferred tool for the deepest levels of transcriptomic investigation. A simplified 
data analysis workflow, coupled with improvements in throughput and cost, 
makes RNAseq an accessible and affordable solution for transcriptome 
research. Here I have tested various RNAseq methods side by side to refine a 
highly reproducible, reliable approach for future studies. The first RNAseq 
approach trialed was the Qiagen rRNA depletion followed by NEXTflex 
directional RNAseq kit. This unfortunately proved problematic at various 
stages; it did not work efficiently with low input material and resulted in high 
percentage of rRNA and intergenic reads and unclear strand distribution. On 
the other hand both the Truseq RNAseq approaches used showed consistently 
good quality data; libraries were composed of optimal size fragments for 
sequencing, they had the ability to create libraries from low input material, the 
results generated had a low percentage of rRNA reads, normal library 
distribution, and high proportion of strandedness and exonic reads. Importantly 
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we have also set up an analysis pipeline for handling large quantities of 
RNAseq data systematically and efficiently (see Methods). 
 
Moreover iCLIP has provided a crucial tool for research in protein-RNA 
interactions, but the wider application has been limited by the need for 
radiolabelling in order to carefully select protein-RNA complexes of interest. 
Here I have contributed to the lab’s published iCLIP work by developing and 
comparing several alternative non-radioactive iCLIP approaches. The use of an 
Atto633-labelled linker has proved successful in reproducing crosslink 
positioning of the previously characterized RBP, hnRNPC, while also 
preserving the capability to visualize protein-RNA interactions. hnRNPC is a 
highly abundant protein therefore further experiments are required to fully 
evaluate the sensitivity of Atto663 linker, for example testing other less 
abundant proteins that usually require longer exposure to radioactive isotope in 
the standard iCLIP approach.  
 
In addition, testing a ‘Blind cut’ alternative to iCLIP has been of paramount 
importance in context of recent expansion in ENCODE data. ENCODE is a 
collaborative initiative to comprehensively annotate all functional sequences in 
the human genome and provides the data generated in an open resource. One 
arm of the project collects information on Protein-RNA interactions, which is 
generated using the eCLIP method (Diehl and Boyle 2016). eCLIP 
methodology, developed only a couple of months ago, bases its core principles 
on standard iCLIP approach but utilizes two novel adapters to circumvent an 
inefficient circularization step (Van Nostrand et al. 2016). This maintained 
nucleotide resolution of data and resulted in a reduced amplification rate and 
therefore reduced duplicate reads, an enhanced success rate and a protocol 
suitable for large-scale use. Nonetheless eCLIP abolishes radiolabelling at the 
expense of being able to visualize protein-RNA complexes and proceeds with a 
‘Blind cutting’ approach to isolate the protein-RNA complexes of interest. To 
date it has not be evaluated how this effects quality and complexity of the 
resulting libraries generated. Here we show that Blind cutting is able to produce 
high quality data, comparable to the standard and non-radioactive approaches 
tested side-by-side however this has only been explored for a widely studied 
protein (hnRNPC) which we know can be cleanly immunoprecipitated. Further 
comparative tests should be carried out using a variety of RBPs to fully assess 
the wide application of this approach.  
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Earlier this year another study also presented a non-radioactive alternative 
iCLIP approach, irCLIP (Zarnegar et al. 2016). They reported the use of an 
infra-red dye conjugated and biotinylated ligation adapter in replacement of the 
iCLIP adapter and P32 labeling. This had comparable ligation efficiency, the 
infra-red imaging was highly sensitive and reduced the visualization time 10-
100 fold. In addition the same study further optimized each stage to produce a 
simplified protocol requiring far less input material than before. Together, the 
removal of radio-labeling and the enhanced efficiency of methodology will 
enable CLIP based technology to be used more widely throughout the scientific 
community. Given its sensitivity it will facilitate the detection of non-canonical 
RBPs that are weakly expressed or only bind in limited conditions, which other 
CLIP methods have struggled to do to date.  
 
To conclude we have established robust, effective and consistent functional 
genomic methodologies that firstly I will utilize to later address the hypothesis 
that RNA regulation is defective in VCP-related MND, but also will be of value 
to the wider scientific community.  
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Chapter 5; Characterizing the earliest pathogenic 
events in VCP related MND 
So far research on VCP and associated diseases has been done using 
overexpression, KO or KD models in non-human and/or non-neuronal cells 
(Buchan et al. 2013; Ju et al. 2009; Rodriguez-Ortiz et al. 2013; Yin et al. 
2012). While both animal and cell-based models have provided invaluable 
insights into MND pathogenesis, such model systems may not precisely 
capture the human clinical pathophysiological state. Consequently, there is a 
need for accurate characterization of how VCP mutations affect human motor 
neurons, in the context of MND. Increasing recognition of glial involvement in 
MND, through either cell autonomous or non-cell autonomous mechanisms, 
also raises the question of their contribution in the context of VCP mutations. 
To begin to address these issues in VCP-related MND research, we employed 
patient-specific iPSCs and directed differentiation strategies to both spinal cord 
MNs and ACs. This approach accurately approximates human pathophysiology 
while bypassing the need for artificial overexpression, knock down or knock out 
studies. 
Aims 
Here I will use patient specific VCP-mutant hiPSC and their neural derivatives, 
to characterize the presence of a range of phenotypes and when these 
phenotypes arise during the differentiation and maturation of both spinal cord 
motor neurons (MNs) and astrocytes (ACs). The phenotypes investigated have 
been selected based on previous studies of VCP’opathies, neurodegeneration 
and in particular on MND. More specifically I ask; 
 
1. Do VCP neural derivatives show selective vulnerability? 
2. Using RNAseq, which transcriptional pathways discriminate VCP mutant 
from Control? 
3. Do we detect selected phenotypes in our VCP model that have previously 
been described in MND? In particular: 
• Mitochondria dysfunction 
• ER stress 
• Oxidative stress 
• Synaptic defects 
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4. When is the earliest pathogenic event detected in our hiPSC model of VCP-
MND? 
5. What is the sequence of events in MNs and ACs?  Do gene expression 
changes arise before cytoplasmic events? 
6. Are early events different in MNs and ACs? 
The experimental plan 
To explore the pathogenic events in our VCP-related MND model, I here 
considered the role of both ribostasis, using RNA sequencing and cytoplasmic 
organellar dysfunctional, using an array of imaging technologies. In order to 
assess the earliest pathogenic events detected I analyzed control and VCP-
mutant hiPSC neural derivatives throughout differentiation (Figure 5.1). After 
pluripotency I selected 4 stages during differentiation and maturation of motor 
neurons; neutrally inducted precursors (NI), patterned neural precursors 
(NPCs), early motor neurons (d3 MN) and mature motor neurons (d17 MN), 
and also 3 stages during astrogliogenesis; Gliogenic precursors (GPC’s), 2 and 
4 weeks after terminal astrocyte differentiation (d14 or d28 AC). 
 
Figure 5.1; Experimental time-course schema 
All VCP hiPSC lines and one control line were provided through collaboration 
with Dr. Selina Wray; she used established reprogramming methods to 
generated iPSCs from two patients with the VCP mutations R191Q (2 clones) 
and R155H (2 clones) and from one healthy control. iPSC clones all expressed 
the pluripotency markers OCT4, Tra1-81 and SSEA4 and exhibited a normal 
karyotype. VCP mutations were confirmed by Sanger sequencing. An 
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additional iPSC line (ND41866*C), derived from a matched healthy control, was 
employed as another comparator from Corriell.  
 
iPSC line Mutation 
present 
Method of 
reprogramming 
Age of 
Donor 
Age at 
disease 
onset 
Sex of 
Donor 
Control 1 
(JOM) 
None Episomal 78 - Male 
Control 2 
(ND41866*C) 
None Retroviral  64 - Male 
VCP mutant 1 
(CB1E) 
R155H Episomal 43 40 Female 
VCP mutant 2 
(CB1D) 
R155H Episomal 43 40 Female 
VCP mutant 3 
(GL1B) 
R191Q Episomal 42 36 Male 
VCP mutant 4 
(GL1A) 
R191Q Episomal 42 36 Male 
 
VCP mutant cultures recapitulate cell specific selective 
vulnerability, a key aspect of MND pathogenesis 
 
We first questioned whether key pathological aspects of MND were 
recapitulated in our model system. In MND, there is a selective vulnerability of 
motor neurons to neurodegeneration, therefore we began with a cell type-
specific and VCP mutation-dependent cell survival assay across a timecourse 
of motorneurogenesis and astrogliogenesis.  
 
Firstly this was tested using immunocytochemistry on VCP and control derived 
MNs at D17. We used the marker caspase3 to depict cellular apoptosis (Figure 
5.2.A). Analysis, carried out by Andras Lakatos, showed that number of 
caspase3 positive cells was increased by over 2 fold in VCP MNs compared to 
control (Figure 5.2.B). Further, in collaboration with Zhi Yao, Minee Choi and 
Sonia Gandhi, we optimized and employed an automated high throughput 
method for assessing cell death based on a PI/Hoechst assay. Cells needed to 
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be plated as single cells and analysed at approximately 70% confluency 
(15,000 cells were plated per well of a 96well plate). Zhi Yao stained cultures 
with Hoechst and PI, which enabled us to respectively count the total number 
of cells (total number of nuclei) and the number of cells with a loss of 
membrane integrity, which reflected cellular death. We analysed the 
percentage of cell death at 3 time points in MN development (NPC, d3 MN, d17 
MN) and 3 time points in AC development (GPC, d14 AC, d28 AC). This again 
showed a selective vunerability of VCP mutant MNs at D17, the basal level of 
cell death was 22.47%±9.31% in control MNs vs 52.23% ±1.61% in VCP 
mutant MNs (n= 2 control clones and 3 mutant clones from 2 patients, p < 0.05, 
2-way ANOVA) (Figure 5.2.D). Additionally we observed a trend of increased 
cell death in the VCP mutant neuronal cultures at earlier time points (both NPC 
and d3 MN) although this did not meet statistical significance. Notably, turning 
our attention to control and VCP mutant ACs or GPCs, we did not find a 
significant difference in cell death (Figure 5.2.F). Overall we show a cell-type 
specific and mutation-dependent cell survival vulnerability in VCP MN’s but not 
in ACs. 
! 147!
 
 
Figure 5.2; VCP mutant MN display a selective vulnerability 
A) Representative images of Control and VCP mutant MNs stained with Caspase-3 
(green) and DAPI (white). Images acquired on 20x objective. B) Quantification of the 
number of cells +ve for Caspase-3. C) Representative images from the high-throughput 
analysis of Hoechst (blue) and PI (red) staining in control and VCP mutant MNs(d17), 
and E) for control and VCP mutant ACs (d28). Images acquired on 20x objective. D) & 
F) Quantification of percentage of PI positive cells in control and VCP mutant cells 
across a motor neuron (NPC, d3MN, d17MN) and astrocyte (GPC, d14AC, d28AC) 
time-course . N=3, Error bars represent mean ± SEM. 
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Is RNA regulation disrupted in VCP-related MND? 
As rationalized previously, I next explored the hypothesis that RNA regulation 
is disrupted in VCP-related MND. I have analyzed the transcriptional signature 
of both control and VCP-mutant iPSC neural derivatives across differentiation 
using RNA sequencing. Unlike other differentiation methods for hiPSCs, which 
requires prior purification of cultures, our strategy yielded highly enriched 
cellular populations consistently and efficiently, enabling us to accurately use 
RNA sequencing to begin to unravel underlying molecular pathogenic 
mechanisms in selected cell types.  
 
I generated libraries from Control and VCP mutant samples across the 
differentiation of motor neurons (iPSC, NI, NPC, d3MN, d17MN) and astrocytes 
(GPC, d14AC, d28AC), using the Truseq stranded mRNA kit. All samples used 
went through tight quality checks before analysis (see Methods for further 
details).  
 
I firstly carried out principle component analysis using both Control and VCP 
mutant samples throughout motor neuron differentiation (Figure 5.3.A). The 
segregation pattern supports our differentiation strategy and also highlights that 
Control and VCP Mutant populations becomes increasingly segregated during 
neuronal differentiation, and is most prominently seen after terminal 
differentiation to Motor Neurons. Moreover, I performed differential expression 
analysis on each stage of motorneurogenesis (iPSC, NI, NPC, d3MN &d17MN) 
between control and VCP mutant samples (Figure 5.3.B). This also showed 
that as cells differentiate towards a motor neuron fate there is a greater number 
of differentially expressed genes and also an increase in significance (p-value) 
of the differential expression.  
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Figure 5.3; Transcriptional profile throughout motor neuron differentiation of 
Control and VCP mutant cells 
A) Principle component analysis separates samples by differentiation stage 
(Pluripotent, NPC, MN) and after terminal differentiation of MNs we also see separation 
of control and VCP mutant samples (d3/17MNs). Individual biological replicates plotted. 
B) Differential expression analysis between control and VCP mutant samples at 5 
stages throughout motor neuron differentiation (Pluripotent, NI, NPC, d3MN and 
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d17MN). Arrow indicates p=0.001. A minimum of biological n=2/technical n=3 for each 
condition (genotype and differentiation stage) was used.  
 
Focusing on terminal MN’s (D17), where the greatest transcriptional changes 
are seen between VCP mutant and control samples, there are 206 differentially 
expressed mRNA, 127 up-regulated and 79 down regulated (using a threshold 
of log(FC)>1.5, and p-adj >0.05). I performed gene ontology analysis on the 
differentially expressed genes at D17MNs (Figure 5.4.A). Among the terms 
highlighted there is a strong enrichment of terms related to synaptic functions 
down regulated in VCP mutant MNs, including ion channels, gated channels 
and transmembrane transporter activities suggesting there could be a loss of 
synaptic function in VCP-mutant MNs. On the other hand, cell cycle regulation, 
microtubule motor activity, and DNA/Protein binding are up-regulated in VCP-
mutant MNs.  
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Figure 5.4; GO analysis in d17MNs 
Top 5 GO terms for biological function, molecular function and cellular component 
associated with differentially expressed genes in control and VCP mutant d17MNs. 
Analysis carried out on differentially expressed genes that have log(fold change) >1.5 
and padj <0.05. 
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!! !! !! !! !! !! !! !!
m
ol
ec
ul
ar
!fu
nc
Ho
n!
protein!binding! 186.34! 8.90E506!!
substrate5speciﬁc!
transporter!acHvity! 14.35! 8.68E505!
DNA!binding! 57.77! 4.23E506!!
transmembrane!
transporter!acHvity! 13.23! 3.31E505!
sequence5speciﬁc!DNA!
binding!transcripHon!factor!
acHvity! 22.48! 3.34E505!!
substrate5speciﬁc!
transmembrane!
transporter!acHvity! 12.23! 2.48E505!
sequence5speciﬁc!DNA!
binding! 13.57! 8.03E506!!
ion!transmembrane!
transporter!acHvity! 11.32! 2.48E505!
chromaHn!binding! 8.74! 2.44E505!! channel!acHvity! 5.66! 8.68E505!
regulatory!region!DNA!binding! 7.18! 8.90E506!!
metal!ion!transmembrane!
transporter!acHvity! 5.61! 4.11E505!
regulatory!region!nucleic!acid!
binding! 7.18! 8.90E506!! ion!channel!acHvity! 5.5! 8.68E505!
transcripHon!regulatory!
region!DNA!binding! 7.05! 8.90E506!! gated!channel!acHvity! 4.5! 3.31E505!
structure5speciﬁc!DNA!
binding! 4.57! 4.23E506!! ion!gated!channel!acHvity! 4.5! 3.31E505!
microtubule!motor!acHvity! 2.15! 3.34E505!! caHon!channel!acHvity! 4.08! 8.68E505!
!! !! !! !! !! !! !! !!
ce
llu
la
r!c
om
po
ne
nt
!
microtubule!cytoskeleton! 25.03! 1.20E514!! membrane! 114.08! 5.96E511!
chromosome! 16.94! 2.26E528!! membrane!part! 84.15! 4.17E509!
chromosomal!part! 14.28! 8.39E528!! intrinsic!to!membrane! 71.14! 5.23E510!
spindle! 7.16! 2.69E522!! integral!to!membrane! 69.75! 6.29E509!
condensed!chromosome! 4.81! 9.84E532!! cell!periphery! 56.65! 7.19E514!
chromosome,!centromeric!
region! 4.62! 2.21E526!! plasma!membrane! 55.3! 4.10E513!
kinetochore! 3.27! 3.66E523!!
intrinsic!to!plasma!
membrane! 16! 1.58E507!
spindle!pole! 2.98! 2.52E513!!
integral!to!plasma!
membrane! 15.39! 1.58E507!
condensed!chromosome,!
centromeric!region! 2.76! 4.86E527!! neuron!projecHon! 12.88! 5.23E508!
condensed!chromosome!
kinetochore! 2.6! 7.85E527!! synapse!part! 7.03! 5.26E508!
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I next turned my attention to the transcriptional profile of VCP mutant ACs. 
Again I performed principle component analysis for both control and VCP 
mutant samples throughout AC differentiation, which showed segregation of 
samples dependent upon differentiation status (pluripotent, NPC and terminally 
differentiated AC) (Figure 5.5.A). Although we did not detect a cell autonomous 
selective vulnerability in VCP mutant ACs we did see some changes in RNA 
levels between control and VCP mutant ACs (Figure 5.5.B). We detected 156 
differential expressed genes (p-value <0.05, log(fold change) >1.5); 93 up-
regulated and 63 down-regulated mRNAs (Figure 5.5.C).  
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Figure 5.5; RNA sequencing of Control and VCP mutant astrocytes 
A) Principle component analysis separates samples by differentiation stage 
(Pluripotent, NPC, AC). Individual biological replicates plotted. B) Differential 
expression analysis between control and VCP mutant astrocytes. C) Bar plot to show 
the number of differentially expressed genes between Control and VCP mutant 
samples, comparison between MN and AC samples. Analysis carried out using a 
minimum of biological n=2/technical n=3 for each condition (genotype and 
differentiation stage). 
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Following, I performed GO analysis on the differentially expressed genes 
(log(fold change) >1.5 and p-value <0.05) (Figure 5.6.A). Among the terms 
associated there is a strong emphasis on genes involved in extracellular matrix 
and cell-to-cell signaling which raises several hypothesis; 
• VCP-mutant ACs play a non-cell autonomous role in MND.  
Astrocytes release, among other factors, extracellular matrix proteoglycans and 
remodeling factors that promote neuronal survival and maturation. In MND it 
has been shown that for SOD1 mutations, astrocytes release factors that are 
toxic to MNs. More recently it has also been shown that in disease astrocytes 
release an increase factors leading to a developmental syndrome (Krencik et 
al. 2015). Further work needs to be carried out to establish if this could also be 
a pathogenic mechanism underlying VCP related MND.  
• VCP-mutant AC have different reactivity than control AC. 
Astrocyte reactivity influences cell-to-cell communications, cytoskeletal 
changes, extracellular matrix and released factors therefore it is possible that 
the changes in gene expression we see in VCP-ACs are due to an altered state 
of reactivity (Pekny and Pekna 2014)(Tyzack et al, 2016, in preparation). In the 
future more precise AC reactivity should be characterized and then this 
improved model could provide clarification into the reasons in cell-to-cell 
signaling/extracellular differences in VCP mutant ACs.  
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Figure 5.6; GO analysis of differentially expressed genes between Control and 
VCP mutant ACs 
Top 5 GO terms for biological function, molecular function and cellular component 
associated with differentially expressed genes in control and VCP mutant ACs. 
Analysis carried out on differentially expressed genes that have log(fold change) >1.5 
and padj <0.05.  
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Enrichment!
Score!
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Enrichment!
Score!
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p7value!
bi
ol
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!p
ro
ce
ss
!
regula<on!of!mammary!gland!
epithelial!cell!prolifera<on! 0.07! 0.0003!!
an<gen!processing!and!presenta<on!of!
pep<de!an<gen!via!MHC!class!II! 0.2! 3.71E715!
biological!adhesion! 3.16! 0.0003!!
an<gen!processing!and!presenta<on!of!
exogenous!pep<de!an<gen!via!MHC!
class!II! 0.2! 3.71E715!
cell!adhesion! 3.15! 0.0003!!
an<gen!processing!and!presenta<on!of!
pep<de!or!polysaccharide!an<gen!via!
MHC!class!II! 0.21! 3.71E715!
mammary!gland!epithelial!cell!
prolifera<on! 0.11! 0.0005!! response!to!interferon7gamma! 0.18! 6.24E714!
regula<on!of!epithelial!cell!
prolifera<on! 0.71! 0.0068!! regula<on!of!T!cell!ac<va<on! 0.29! 1.21E713!
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mammary!gland!epithelial!cell!
prolifera<on! 0.03! 0.0179!! !! !! !!
adult!locomotory!behavior! 0.24! 0.0508!! !! !! !!
stem!cell!prolifera<on! 0.05! 0.0508!! !! !! !!
!! !! !! !! !! !! !! !!
M
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<o
n!
cyclin7dependent!protein!
kinase!regulator!ac<vity! 0.08! 0.0053!! MHC!class!II!receptor!ac<vity! 0.01! 1.90E715!
cyclin7dependent!protein!
kinase!inhibitor!ac<vity! 0.05! 0.0405!! pep<de!an<gen!binding! 0.02! 0.0024!
drug!transporter!ac<vity! 0.06! 0.051!! an<gen!binding! 0.02! 0.0031!
protein!serine/threonine!
kinase!inhibitor!ac<vity! 0.08! 0.063!! pep<de!binding! 0.18! 0.0075!
symporter!ac<vity! 0.31! 0.063!! amide!binding! 0.19! 0.0075!
L7amino!acid!transmembrane!
transporter!ac<vity! 0.14! 0.0879!! cytokine!receptor!ac<vity! 0.05! 0.0086!
kinase!inhibitor!ac<vity! 0.17! 0.0879!! signal!transducer!ac<vity! 1.09! 0.0206!
ac<ve!transmembrane!
transporter!ac<vity! 0.86! 0.0879!! molecular!transducer!ac<vity! 1.09! 0.0206!
secondary!ac<ve!
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!
integral!to!membrane! 15.09! 0.0028!! lysosomal!membrane! 0.27! 1.02E714!
membrane!part! 18.18! 0.0028!!
ER!to!Golgi!transport!vesicle!
membrane! 0.08! 4.79E714!
intrinsic!to!membrane! 15.37! 0.0028!! ER!to!Golgi!transport!vesicle! 0.09! 1.14E713!
extracellular!region! 4.63! 0.0104!! vacuolar!membrane! 0.36! 1.51E713!
membrane! 24.67! 0.0133!!
clathrin7coated!endocy<c!vesicle!
membrane! 0.05! 3.94E715!
apical!part!of!cell! 0.85! 0.0208!! clathrin7coated!endocy<c!vesicle! 0.06! 7.89E715!
dystrophin7associated!
glycoprotein!complex! 0.07! 0.0237!! trans7Golgi!network!membrane! 0.06! 7.89E715!
apical!plasma!membrane! 0.59! 0.0301!! MHC!class!II!protein!complex! 0.03! 9.37E728!
axoneme! 0.26! 0.249!! MHC!protein!complex! 0.06! 1.71E722!
extracellular!matrix! 1.29! 0.3312!!
integral!to!lumenal!side!of!
endoplasmic!re<culum!membrane! 0.05! 3.94E715!
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SYT1 staining in VCP mutant MNs 
Since I observe that there are many synaptic associated proteins among the 
top down-regulated genes in VCP-MNs and additionally because VCP has 
been previously shown to interact with synaptic protein (H. F. Wang et al. 
2011), we collaborated with Andras Lakatos to explore the effect of  VCP 
mutations on MN synapse formation. To address this I immunolabeled both 
control and VCP mutant terminally differentiated motor neuron cultures (d17) 
with pre-synaptic marker, synaptotagmin1 (SYT1), and co-immunolabeled with 
neuronal and motor neuron markers, MAP2 and CHAT respectively (Figure 
5.7.A).  Next, using confocal microscopy Andras Lakatos identified areas of 
close acquisition between SYT1 and MAP2 staining, which we denoted as 
positive puncta on both the soma and dendrites of MNs (Figure 5.7.B & C). 
Only cells in clusters interconnected by axons, forming a network were 
analysed. SYT1 density on the soma was significantly reduced by 2-fold in 
VCP mutant lines (0.038±0.004 and 0.033±0.003 puncta/µm2; overall 
p<0.0001, Kruskal-Wallis test) when compared to control lines (0.062±0.005 
and 0.079±0.007 puncta/µm2). Similarly, dendritic SYT1 densities were 
significantly lower in the VCP mutant MN cultures (0.153±0.064 and 
0.138±0.058 puncta/µm2; overall p<0.0001, Kruskal-Wallis test) compared to 
control MNs (0.262±0.117 and 0.305±0.098 puncta/µm2).  
 
As we have previously shown VCP mutant MNs display increased cell death it 
is important to determine whether a reduction in SYT1 staining represents early 
MN dysfunction or loss of inter-connected neurons. To do this Andras Lakatos 
counted the number of Chat/MAP-2 positive neurons with intact DAPI stained 
nuclei in the analysed cell clusters (Figure 5.7.D). Also we compared the 
cellular composition across the controls and mutants samples by calculating 
the MN ratio (CHAT +ve versus CHAT –ve cells) across each cell line (Figure 
5.7.E). We showed that both the number of total neurons and the MN +ve 
ratios were comparable confirming that a reduction in SYT1 staining in VCP 
mutant MNs is not attributable to differential loss of VCP MNs. Thus, MNs have 
the same chance to establish the same number of synaptic connections in both 
Control and VCP groups. We conclude the reduction in SYT1 staining is not 
directly caused by the death of the presynaptic neuron in these cell groups, and 
that there is a pre-synaptic dysfunction before the post-synaptic cell dies. 
Further work is now required to dissected the causative mechanisms behind 
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the reduced SYT1 staining observed; what is the trigger or whether this is a 
developmental defect in VCP-MNs? 
 
Our findings add to other studies that also suggest a role for defective synaptic 
function in MND. For a while excitotoxicity has been considered to play a role 
neurodegeneration/MND(Bories et al. 2007; Kuo et al. 2005)(Wainger, Kiskinis, 
Mellin, Wiskow, Han, et al. 2014). However to define the presence and 
functional consequences of a synaptic defect in VCP mutant MNs requires 
further work.  
 
Figure 5.7; Synaptotagmin-1 staining in Control and VCP mutant MNs 
A) Maximum projection of Z-stack confocal microscopy images showing synaptic input 
(SYT-1 positive puncta are in red) on Chat (blue)/MAP-2 (green) positive MNs with 
intact nuclei (DAPI is white). B) and C) Analysis of SYT1 positive puncta in Control and 
VCP mutant-MNs on the Soma and the dendrites respectively. Graphs represent mean 
SYT1 density values defined by puncta / area on the MN soma (N=26-32 cells, Dunn’s 
test) and puncta per length for a main MN dendrite (n=26-32 dendrites, Dunn’s test) in 
two control lines (Ctrl1 and Ctrl2) and two VCP mutant lines (Mut1 and Mut2). D) Bar 
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graph demonstrates the mean number of total neurons in the different cell lines. E) Bar 
plot shows the mean ratio of CHAT positive (MNs) vs CHAT negative cells in each 
cluster, in the different cell lines. (N=3 cultures, ANOVA). Data represent mean+SEM. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Scale Bar: 25 µm. 
 
Live cell imaging in hiPSC-neural derivatives to explore 
defective cytoplasmic events in VCP-related MND 
Having confirmed a robust cell survival and synaptic phenotypes in VCP-
mutant MNs, we next searched for earlier pathogenic events in our VCP model. 
In collaboration we have looked at the dysregulated cytoplasmic events in 
VCP-related MND using both ICC and multiple live cell imaging assays. We 
assess samples across a complementary time-course to the RNAseq 
experiments and analyze a range of additional phenotypes rationalized by 
pathways previously implicated in MND (Cozzolino and Carri 2012; D’Amico et 
al. 2013; Ilieva et al. 2007; Kiskinis et al. 2014; S Sasaki 2010; Weiduschat et 
al. 2014); we systematically examine, across a time course, the possibility of 
mitochondrial dysfunction, ER stress, and oxidative stress in VCP-hiPSC 
derivatives. For these experiments I carried out all iPSC culture and neural 
differentiation, then mitochondrial function, oxidative stress and ER stress 
assays were carried out by Minee Choi and Zhi Yao.  
 
Live cell imaging is a powerful method to analyze cellular dynamics in a quick 
and accurate way. It allows us to study individual cells and follow them across 
time whilst analyzing particular events. Unlike ICC, there are no artifacts that 
can be induced due to the fixation process, however careful attention must be 
played to the health/function of cultures during imaging, as fluorescent 
illumination can be harmful. Using live cell imaging we are able to look at a 
range of functions in the cell such as mitochondria viability, activity of the 
electron transport chain (ETC) and ATP production, ROS production and 
calcium influx.  
Mitochondrial dysfunction 
In neurons oxidative phosphorylation is the main source of ATP/energy, so 
mitochondria being the cells power station play a vital role. Owing to a decline 
in mitochondrial function in aging it is thought that dysfunctional mitochondria 
could be potentially an important factor in age related neurodegenerative 
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diseases, hence there have been many studies analyzing their morphology and 
functional characteristics in MND pathogenesis. In VCP-mutant patient derived 
fibroblasts it has previously been shown that there is mitochondrial uncoupling 
leading to a reduction in ATP production/energy supply(Bartolome et al. 2013). 
This means the rate of electron transport in the respiratory chain is no longer 
linked to ATP production. The mitochondria’s membrane potential is critical for 
the production of ATP by respiration and any loss results in depletion of ATP 
and subsequent cell death.  
 
Mitochondrial membrane potential can be used as a general marker of 
mitochondrial health and it has previously been show to be reduced in VCP-
deficient cellular models and VCP mutant patient cells (Bartolome et al. 2013). 
Here we have explored whether there this is also seen in VCP mutant iPSC-
derived neural derivatives. To do this we have used TMRM, a fluorescent 
cationic dye that is cell-permeable and is actively taken up by the mitochondria 
to look at the mitochondrial membrane potential, an indicator of mitochondrial 
viability telling us about flow of H+ ions across membrane. (Figure 5.8A) We 
found a reduction in basal levels of mitochondrial membrane potential in VCP 
mutant d17 MNs compared to control (54.65±6.64% in VCP mutant compared 
to control 100%, n= 2 control lines and 3 mutant clones, p< 0.05) (Figure 5.8B). 
Interestingly we noted a trend to decreased mitochondrial membrane potential 
in the VCP mutant NPCs and d3 MNs, but this only reached significance in d17 
MN. We also found a decrease in the mitochondrial membrane potential in 
VCP d14 ACs compared to controls (72.47±2.09% vs 100% control, n=2 
control lines and 2 mutant clones, p<0.05, 2 tailed t-test). Interestingly this 
difference had resolved by the d28 AC timepoint, which may reflect the 
activation of endogenous compensatory mechanisms.  
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Figure 5.8; Mitochondrial dysfunction in VCP MNs 
A) Control and VCP mutant d17 MN and d28 AC loaded with TMRM;. Scale bar = 
20µm. B) Histogram showing decreased basal mitochondrial membrane potential in 
VCP mutant d17 MN and d14 AC compared to control cells. N=3 separate 
inductions/replicates (from n=2 control cell iPSC lines and n=3+ VCP mutant lines). 
Error bars represent mean ± SEM. C) Representative traces showing that, in both 
control and VCP mutant d17 MN, oligomycin did not affect mitochondrial membrane 
potential; rotenone induced partial depolarization and FCCP induced complete 
depolarization.  Y-axis scale represents the relative TMRM intensity before and after 
treatment, where 100% is the baseline TMRM intensity for each sample.  
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To further understand the cause of the reduced mitochondrial membrane 
potential in VCP mutant d17 MNs, we investigated a possible mechanism by 
which the mitochondrial membrane potential is maintained, by studying its 
sensitivity to a range of mitochondrial inhibitors. Zhi Yao and Minee Choi 
measured fluorescent intensity at baseline and after stimulus; we use three 
modulators of the electron transport chain (FCCP, oligomycin (complex V 
inhibitor) and rotenone (complex I inhibitor)). In control d17 MNs, inhibition of 
complex V by oligomycin did not lead to depolarization, while subsequent 
inhibition of complex I by rotenone produced a significant reduction in the 
TMRM signal, indicating a rapid loss of mitochondrial membrane potential 
(Figure 5.8.C). In contrast to other neurodegenerative models, the inhibition of 
complex V in VCP mutant d17 MNs did not cause mitochondrial depolarization, 
whereas inhibition of complex I produced marked reduction of mitochondrial 
membrane potential (Figure 5.8.C). This result suggests that both VCP mutant 
MNs maintain mitochondrial membrane potential largely through respiration.  
 
There are several hypotheses why Mitochondria dysfunction could cause the 
death of MNs, for example by an increased production of ROS leading to 
oxidative stress and activation of intrinsic apoptotic pathway and instrinic Ca+ 
buffering to prevent excitotoxicity. Therefore we next turn to investigate 
oxidative stress in VCP mutant neural derivatives.  
Oxidative stress 
Oxidative stress is a well-recognized feature in neurodegenerative diseases 
including in both sporadic and familial MND (Carrì et al. 2015; D’Amico et al. 
2013; Gandhi and Abramov 2012; Weiduschat et al. 2014). It occurs due to the 
imbalance of production of reactive oxidative species and antioxidant defenses. 
To date oxidative stress has not been implicated in VCP’opathies but, on top of 
oxidative stress being broadly implicate in MND, VCPs involvement with the 
mitochondria gives added reason to explore the possibility of oxidative stress 
playing a role in pathogenesis of VCP-related MND. Mitochondria are a target 
by oxidative stress (genetic, metabolic and environmental alterations from 
oxidative insult will make mitochondria less dynamic in responding to needs of 
the cell) and conversely mitochondria are also the main site of production of 
ROS. Therefore oxidative stress can result from impairment of mitochondrial 
function. As previously discussed we detect deficiency in mitochondrial function 
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in VCP mutant MNs at D17. Thus we next investigate the presence and timing 
of oxidative stress in VCP-neural derivatives (i.e. pre or post mitochondrial 
defects?).  To study it we have employed live fluorescent imaging of both ROS 
production and antioxidant levels.   
 
Minee Choi and Zhi Yao evaluated superoxide production by measuring the 
rate of oxidation of the dihydroethidium dye (DHE) as a ratio of the oxidised 
over the reduced form (representative traces), normalising the data to 
percentage values (Figure 5.9.A). We found that the VCP mutant d3 MNs and 
d17 MNs exhibited significantly higher rates of ROS production compared to 
control (d3 MN 189.9±30.4% vs 100% control, n=2 control lines and 3 mutant 
clones, n=3 repeats; d17MNs 187.3±42.7% vs 100% control, n= 2 control 
clones and 2 mutant clones, n=3 repeats). There was a modest increase in 
ROS production in the VCP mutant GPCs compared to control (164.3±29.6% 
vs 100% control, n=2 control clones and 2 mutant clones, n=3 repeats). 
Notably, there was no significant difference in ROS production between VCP 
mutant and control in the d14 and d28 ACs (Figure 5.9.B).  
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Figure 5.9; Oxidative stress in VCP MNs 
A) Representative traces and B) analysis showing increased ROS production rate in 
VCP mutant cells compared to control. N=3 replicates (from n=2 control cell iPSC lines 
and n=3+ VCP mutant lines). C) Control and VCP mutant d17 MN and d28 AC loaded 
with MCB, a glutathione indicator. Scale bar = 20µm. D) Histogram showing decreased 
GSH level in VCP mutant d17 MN but not NPC, d3 MN, GPC, d14 AC and d28 AC. 
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N=3+ separate inductions/replicates (from n=2 control cell iPSC lines and n=3+ VCP 
mutant lines). Error bars represent mean ± SEM.  
 
In order to confirm the presence of oxidative stress, it is necessary to 
demonstrate an imbalance between the production of ROS and the antioxidant 
defences. We therefore measured the levels of glutathione using the 
fluorescent indicator monochlorobiomine (MCB; representative images,Figure 
5.9.C). We showed that there is a significant decrease in the levels of 
glutathione in the VCP mutant d17 MNs only, and not in any other neuronal 
time point (50.16±8.0% vs 100% control, n = 2 control lines and 3 mutant 
clones from 2 patients, p<0.001) (Figure 5.9.D). Taken together these data 
implicate an early increase in the generation of ROS particularly in the MNs (at 
d3 and at d17), and this is associated with oxidative stress due to depletion of 
glutathione levels by d17 in culture. Therefore we observe oxidative stress 
alongside mitochondrial dysfunction in VCP-related MND, suggesting they 
influence each other causing a cascade of damage.  
 
Additionally we investigated glutathione levels in Control and VCP mutant 
GPCs and ACs. One function of astrocytes is to release glutathione to neurons 
to protect them & their mitochondria from oxidative stress. We see no 
significant alteration in glutathione levels at any time point suggesting AC 
themselves are not under oxidative stress themselves, however if MNs and 
ACs were co-cultured I hypothesize that we would observe a compensatory 
glutathione release in astrocytes to protective VCP mutant MNs, unless VCP 
mutant ACs have dysfunctional cell-cell communication.   
 
ER stress 
Finally we ask if ER stress plays a role in VCP-related MND. The pathology of 
MND (inclusions of misfolded, aggregated & toxic proteins), which is also 
replicated in VCP’opathies, indicates that a significant disruption to proteostasis 
has occurred. This is backed by previous research that has demonstrated 
evidence of ER stress, the role of the unfolded protein response (UPR) and 
defective protein clearance pathways (eg. Autophagy) in MND pathogenesis 
(Kiskinis et al. 2014; Moreno et al. 2013; Walker et al. 2013). Further VCP is 
known to function in ERAD, ER morphogenesis and ER translocation raising 
the hypothesis that a mutation in VCP will affect its ERs functions making the 
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ER vulnerable to insult. Together this provides strong rational to probe ER 
stress in VCP-neural derivatives.  
 
To begin to probe ER stress in VCP mutant neural derivatives we looked at 
whether VCP mutant neural derivatives exhibited greater sensitivity to an ER 
stressor than control cells. I treated cultures for 48hours with 0.1-10µM 
Tunicamycin (an ER stress inducer) and Zhi Yao used the automated high-
throughput microscope to calculate percentage cell death. NPCs, MNs, GPCs 
and ACs were analyzed. Significantly increased cell death is evident in VCP 
mutant d3 MNs compared to control (43.25±2.72% vs. 79.15±5.24%, n= 2 
control lines and 3 mutant lines, > 50,000 cells per condition), but not in ACs or 
NPCs suggesting a cell-specific vulnerability of MNs (Figure 5.10A). We also 
note that sensitivity to the ER stressor tunicamyin is initiated early after MN 
terminal differentiation, whether as the previous phenotypes studied have not 
shown statistical significance until a more mature MN stage. 
 
Moreover we assess calcium function as an additional marker for ER stress. 
Calcium dysfunction has been previously been shown to play a role in MND. 
Increased levels of calcium have been detected both SOD1 mice and sMND 
patients and have been shown to medicate neuronal toxicity (via 
TDP43)(Aggad et al. 2014). The two main stores of calcium in the cell are in 
the ER and the mitochondria. Here we have looked at ER calcium storage 
across motor neurogenesis using thapsigarin. Thapsigarin causes all ER 
calcium to be released, which can subsequently be captured by ATP (if not it 
will be taken up by the mitochondria). Minee Choi measured Ca+ release by 
evaluating the ratio of Fura2-am bound by Ca+ and free. Examining the ER 
calcium stores we found significant reduction in ER Ca+ storage VCP mutant 
d3MNs (63.7±2.4% of control, n= 2 control lines and 3 mutant lines) (Figure 
5.10B). This likewise suggests ER stress occurs at an early time-point after the 
terminal differentiation of MNs (d3 MNs) but further studies are required to 
understand if Ca+ regulation is involved in pathoegenesis. 
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Figure 5.10; ER stress in immature VCP-neuronal derivatives 
A) Histograms showing percentage of PI positive cells in control and VCP mutant NPC, 
d3 MN, GPC and d14 AC with or without 48 hours treatment with ER stressor 
Tunicamycin. Error bars represent mean ± SEM. B) Histogram showing thapsigagin 
induced calcium signal measured in calcium free media (n=2 control and 3 mutant 
clones). Error bars represent mean ± SEM. C) Western blot images and D) 
quantification of Bip/beta-actin and phospho-eIF2alpha/total eIF2alpha levels in control 
and VCP mutant NPC, d3 MN and d17 MN (n= one biological replicate & 3 technical 
replicates). Error bars represent mean ± SEM. Ei) Representative images show co-
localization of mitochondria (labeled by ATP5B, in green) and ER (labeled by PDI, in 
red) in control and VCP mutant d17 MN. The site of co-localization highlighted in 
yellow. Eii) Quantification of percentage of ER co-localized with mitochondrial in control 
and VCP mutant NPC, d3 MN and d17 MN (n= 1+ biological replicates & 3 technical 
replicates). Error bars represent mean ± SEM. 
 
Next to increase confidence in an early ER phenotype in VCP MNS Zhi Yao 
measured protein levels of two ER stress markers Bip and p-eIF2alpha across 
a motor neuron time-course (Figure 5.10.C).  In d3 and d17 MNs, we observed 
an increase in the expression of Bip and p-eIF2alpha in VCP mutant compared 
to control (Figure 5.10.D), further highlighting ER stress as an early event in 
VCP-related MND.  
 
Finally ER stress is associated with increased contact points between the ER 
and mitochondria. Therefore Zhi Yao next quantified the ER-mitochondrial 
contacts in MN cultures by measuring the co-localisation of a mitochondrial 
marker (ATP5b) and an ER marker (PDI) by immunocytochemistry (Figure 
5.10.E). There was no difference in the ER-mitochondrial contacts between 
VCP mutant and control NPCs or d3MNs. However we found a significant 
reduction in the ER-mitochondrial contacts in the control compared to the VCP 
mutant at d17 MNs (Figure 5.10.F). It is of no surprise that we see a reduction 
in ER-mitochondria contacts in the Control MNs during terminal differentiation 
because ER stress is known to play a role early on during neuronal 
differentiation (Liu et al. 2012; Zhang et al. 2007). However it is of interest that 
we see a relative increase in ER-mitochondria contacts in the VCP mutant at 
D17MNs, again implying the presence of ER stress.  
 
Taken together, these data provide evidence of significant ER stress in the 
VCP mutant MNs, which begins to manifest first biochemically and through 
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sensitivity to ER stress in d3 MNs, and progresses to an increase in ER-
mitochondrial contacts by d17 MNs. Again, no significant ER stress was 
detected in VCP-ACs, reinforcing a cell-type specific phenotype. 
 
Are transcriptional changes observed before corresponding cytoplasmic 
events occur? 
We next interrogated the RNAseq data set to see if gene expression changes 
show alterations in pathways highlighted in our VCP model through imaging.  It 
has recently been reported in mutant iPSC-derived MNs that ER stress 
response is a prominent transcriptional signature(Kiskinis et al. 2014). 
Therefore have examined gene expression changes in our VCP mutant MN 
cultures to address whether transcriptional changes precede cytoplasmic 
evidence of ER stress. We looked at several markers of ER stress including 
heat shock proteins, chaperonin subunits, protein disulfide isomerases and of 
the unfolded protein response. We find no clear evidence of transcriptional 
deregulation in VCP mutant NPCs or d3MNs leading to ER stress, therefore we 
conclude that this pathway is first activated in the cytoplasm (Figure 5.11.A).   
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Figure 5.11; Cytoplasmic ER stress response in VCP mutant MNs occurs before 
gene expression changes but Mitochondrial dysfunction and oxidative stress in 
VCP MNs are not preceded by coordinate gene expression changes. 
A) Gene expression in control and VCP mutant samples analysed across 3 time points 
in motor neurogenesis (iPSC, D3MN, D17MN). Normalized RPKM values of 
representative genes associated with ER stress displayed; unfolded response pathway 
(Bip, XBP1, PERK, Chop, ATF6), heat shock proteins (HSPA4L, DNAJC10), 
chaperonin subunits(CCT3, CCT7) and protein disulfide isomerases (PDIA6). d3MN is 
highlighted to represent the onset of cytoplasmic ER stress in VCP mutant MNs. N=3+ 
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technical repeats across a minimum of 2 biological repeats. Error bars represent mean 
± SEM. B) Gene expression in control and VCP mutant samples analyzed across 3 
time points in motor neurogenesis (iPSC, D3MN, D17MN). RPKM values of 
representative genes associated with mitochondrial dysfunction (SOD2, ACOT2, 
TMEM143, TMX4) and oxidative stress (GPX1, MT3, TXNRD2, CCS). d17MN is 
highlighted to represent the onset of cytoplasmic mitochondrial dysfunction and 
Oxidative stress in VCP mutant MNs. N=3+ technical repeats across a minimum of 2 
biological repeats. Error bars represent mean ± SEM. 
 
Moreover we next analyze the expression of several markers for the later onset 
phenotypes, including mitochondrial dysfunction, oxidative stress and synaptic 
defects. Again for mitochondrial dysfunction and oxidative stress we detect no 
transcriptional differences between control and VCP mutant MNs (Figure 
5.11.B). Conversely, we see a clear down regulation of several genes related 
to synaptic function in VCP mutant MNs including genes encoding voltage 
gated Ca+ channels, delayed rectifier and inward rectifier K+ channels, Na+ 
channels, glutamate receptors and genes associated with synaptic density 
(Figure 5.12). These transcriptional changes are detected at d17MNs 
suggesting that these are secondary pathological changes in VCP mutant MNs 
which are indeed orchestrated, at least in part, by their cognate transcriptional 
programs.  
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Figure 5.12; The transcriptional signature of VCP mutant MNs reflects synaptic 
dysfunction. 
Gene expression in control and VCP mutant samples analysed across 3 time points in 
motor neurogenesis (iPSC, D3MN, D17MN). Representative normalised RPKM values 
of genes encoding selected synaptic components (CACNB1, CACNB3 & CACNG2), K+ 
delayed rectifier channels (KCNA2, KCNA6, KCNB1, KCNH2 & KCNQ2), K+ inward   
rectifier channels (KCNJ3, KCNJ4, KCNJ5, KCNJ9 & KCNJ11), Na+ channels  
(SCN9A, SCN2A & SLC12A5), Synaptic density (DLG4 & SYNPO), Glutamate 
receptors (GRIN2A, GRM3, GRM7, GRIK2 & GRIK5). d17MN is highlighted to 
represent the onset of cytoplasmic mitochondrial dysfunction and Oxidative stress in 
VCP mutant MNs. N=3+ technical repeats across a minimum of 2 biological repeats. 
Error bars represent mean ± SEM. 
 
Overall we conclude that cytoplasmic ER stress response is a primary event in 
VCP mutant MNs that precedes transcriptional changes, but that gene 
expression is seen to contributes to secondary pathogenic events such as 
synaptic dysfunction. Our findings underscore the importance of our study in 
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detecting the earliest VCP mutation-related molecular events in ALS using 
hiPSCs. 
Attempts to reverse VCP-mutant phenotype in iPSC-derived 
MNs by manipulating ER stress pathway 
There have been many attempts to reverse the phenotypes seen in MND, 
including many using pharmacological treatments. Several have demonstrated 
an improved phenotype, for example UPR manipulators have been explored. 
Firstly the perk inhibitor (GSK2656157) which reinitiates translation during 
UPR(Moreno et al. 2013), Salubrinal which promotes translational arrest by 
inhibiting the phosphorylation of eIF2a(Kiskinis et al. 2014) or TUDCA a 
molecule that acts upstream of Perk.  
 
Since the earliest molecular event we have detected in VCP mutant MNs is an 
increase in ER stress we have tried to rescue VCP MNs by targeting the ER 
stress pathway using a perki inhibitor (GSK2656157) which reinitiates 
translation during UPR) (Moreno et al. 2013) and Salubrinal which promotes 
translational arrest(Kiskinis et al. 2014). For each treatment 2 different 
concentrations were trialed rationalized by previous studies (Perk at 1µM or 
10µM and Salubrinal at 50µM or 100µM), and the VCP mutant cell death 
phenotype monitored (Figure 5.13.A & B). I treated mature MN cultures for 
48hours (d15-d17MNs) and cell viability was then analyzed by Zhi Yao using 
an automated florescence microscope. At this stage we do not see any 
improvements in cell viability with either treatment, however we cannot rule out 
Perk or Salubrinal as potentially being viable candidates to modulate the 
phenotypes described in VCP mutant MNs yet as there are many variables 
involved and that still to be explored, such as dosage and timing of 
administration and treatment. I also note we observe a high variability in the 
data emphasizing the need for increased biological replicates to be used where 
possible in the future. Moreover we observe a slight trend that treatments 
increase cell death in the control MNs, which is an important control step that 
must also be addressed.  
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Figure 5.13; Attempt to rescue cell death in VCP MNs by manipulating ER stress 
pathways 
% Cell death of Control and VCP mutant D17MNs shown after 48hours treatment with 
A) Perk, at 1µM or 10µM and B) Salubrinal, at 50µM or 100µM. N=3+ technical 
repeats across a minimum of 2 biological repeats. Error bars represent mean ± SEM. 
Discussion 
Here I have begun to dissect cell specific mechanisms of disease in VCP-
related MND, using patient specific hiPSCs differentiated into MNs and ACs. 
Our efficient differentiation strategies for MN and AC, that I previously 
optimized, permitted a range of careful cellular phenotyping assays and RNA 
sequencing technology to systematically identify early VCP mutation-
dependent and MN selective phenotypes. We have characterized the presence 
of a range of phenotypes detected in mutant MNs, including mitochondrial 
dysfunction, oxidative stress, ER stress, synaptic dysfunction, changes in gene 
expression levels and cell death.  
 
Analysis throughout the differentiation of motor neurons has so far revealed 
that there is no differential vulnerability at earlier stages of MN differentiation 
(prior to NPCs) but upon terminal differentiation a robust phenotype is 
identified. To date the order of pathogenic events in MND has not been 
addressed. Using patient specific hiPSCs enabled us to model the timeline of 
events in VCP-related MND and we demonstrate that ER stress is a primary 
event in VCP mutant MNs. Further I confirm that it is not preceded by 
transcriptional deregulation within this pathway. These results build upon 
several other recent studies that express ER stress is an important event in 
MND. ER-stress related genes were shown to be upregulated in MNs in fMND 
mice before symptomatic stage (Saxena, Cabuy, and Caroni 2009) and also 
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noted in MNs derived from patient specific iPSCs (Kiskinis et al. 2014). In 
addition several studies link ER stress and TDP43 mislocalisation, the 
pathological hallmark of MND.  Cytoplasmic aggregates of TDP43 are known to 
induce ER stress in ALS, while ER stress itself has also been proposed to drive 
cytoplasmic TDP43 mislocalisation (S Sasaki 2010; Walker et al. 2013). At the 
moment we need further work to establish if TDP34 pathology can be 
recapitulated in our model of MND (see chapter 6 for further details) and 
therefore which of TDP43 mislocalization and ER stress is primary.  
 
Following ER stress we detect a deleterious spiral of events, mutation-
dependent cell viability, oxidative stress, mitochondrial dysfunction and 
reduced synaptic density. These pathways when all activated together can 
reinforce each other, causing a cascade of damage. ER stress has been 
shown to lead to mitochondria dysfunction and also to promote oxidative 
stress(Ilieva et al. 2007; Malhotra and Kaufman 2011). The ER is known to 
cooperate with the mitochondria to maintain cellular homeostasis through both 
structural and functional interactions. They work together to determine cellular 
fate under various pathophysiological conditions, for example pro-death 
pathways are regulated by Ca+ signalling between ER to mitochondria 
(Malhotra and Kaufman 2011). Here we show ER-mitochondria interactions are 
increased following ER stress in VCP-mutant D17MNs, which also coincides 
with when we observe mitochondria dysfunction. Mitochondrial dysfunction is 
also tightly linked to oxidative stress; a combination of reactive oxygen species 
(ROS) production and mitochondrial dysfunction can cause widespread protein 
oxidative damage, which may further overwhelm and impair cellular protein 
clearance pathways (Sitte et al. 1999). Chronic ER stress can in turn lead to 
cell death by mitochondria-dependent or independent mechanisms (Lindholm, 
Wootz, and Korhonen 2006; Malhotra and Kaufman 2011). Further work is 
needed to unravel the communication between the ER and mitochondria and 
oxidative stress pathways in VCP-related MND and the mechanism by which 
this causes cell death. 
 
Moreover I present a VCP mutation-dependent reduction in SYT1 density, 
which could represent perturbation of pre-synaptic MN terminals, MN 
autosynapses, interneuronal interactions or reflect post-synaptic pathology in 
MNs. This observed defect is supported by alterations in gene expression of 
many synaptic genes, ion channels and glutamate receptors. So far we have 
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not investigated the functional consequences of reduced synaptic density and 
altered synaptic gene expression in VCP mutant MNs. Current evidence from 
other MND studies presents basal MN hyperexcitability in several forms of 
familial MND (Devlin et al. 2015; Kiskinis et al. 2014). Further studies 
implicates that excessive glutamatergic synaptic activity in MND leads to an 
increase in Ca+ influx and cell death. Studies show that glutamatergic activity-
induced calcium influx is too much for the mitochondria and ER to handle 
resulting in ER stress or increased mitochondrial calcium uptake, 
depolarization and ROS production, therefore further enhances a downward 
cascade of events (Howland et al. 2002; Shaw et al. 1995). Additionally a link 
between ER stress and electrical activity has been demonstrated, suggesting 
that the burden of ER stress makes the VCP mutant MNs more susceptible to 
synaptic dysfunction (Kiskinis et al. 2014).  
Since we observed ER stress as an early pathogenic event in VCP-mutant 
MNs we began to test if the VCP mutant cell viability phenotype can be 
reversed by manipulating ER stress pathways. So far we found no 
improvement in cell viability after treatment with perk or salubrinal but much 
further testing needs to be carried out, including altering dosage and timing, 
before conclusions can be drawn. In addition an array of additional modulators 
will be tested including retigabine (Wainger, Kiskinis, Mellin, Wiskow, Han, et 
al. 2014), the VCP inhibitor vesnarinione shown to manipulate the NfKb 
pathway(Hotta et al. 2013), NRF2 activators shown to promote anti-oxidant 
defences(Gupta et al. 2012) and treatment with stains, since Simvastatin has 
been shown to promotes mitochondrial function (Chataway 2015). It is 
important to bear in mind that treatment with such compounds could not only 
have an effect on the cellular phenotype but also could influence cell-subtype 
diversity (Dalton, Lyons, and Lomvardas 2013) so this should also be 
monitored.  
Finally we observe that molecular events in VCP mutant motor neurons and 
astrocytes are different. So far we find no substantial evidence of VCP-
mutation related AC pathology, suggesting the VCP-mutant phenotype is 
specific to MNs. This is consistent with a recent study that also presents a 
neuronal but not AC mutation-dependent phenotype in mutant SOD1 iPSC-
derived MNs (Kiskinis et al. 2014). Conversely, a study exploring TARDBP 
mutations has observed a cell autonomous AC pathology (Serio et al. 2013) in 
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addition to MN pathology (Bilican et al. 2012), which leads us to propose there 
could be mutation-specific glial contributions in the pathogenesis of MND. 
Lastly, our findings do not exclude a non-cell autonomous role for VCP mutant 
ACs as they could exert deleterious effects on spinal MNs, as in the case of 
SOD1 ACs (Di Giorgio et al. 2008). We are currently investigating this 
hypothesis.  
 
As expected, throughout this work we have seen variation between cell lines. 
This highlights the desirability to use isogenic lines in future studies. We are 
currently replicating all work with an additional Control and VCP biological lines 
and are working towards generating isogenic lines by both introducing an 
R155C VCP mutation into a control line and correcting an R155C mutation in a 
disease causing line.  
To conclude, the in depth phenotyping of VCP-mutant hiPSC lines has 
provided important insights into the mechanisms underlying VCP-related MND, 
which has showed considerable over lap with previous studies in other familial 
and sporadic MND models. Further this work underscores the value of cellular 
phenotyping at different stages of iPSC lineage restriction to selected cell types 
of interest (MNs and ACs) to uniquely discriminate primary from secondary 
pathogenic events in MND.  
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Chapter 6; Characterizing TDP43 in VCP related 
MND 
Introduction: The RNA binding protein TDP43 
TAR DNA-binding protein (TDP43), molecular weight 43kDa, is classified as a 
heterogeneous ribonucleoprotein and is encoded by the TARDBP gene. It is a 
ubiquitously expressed, highly conserved protein and its features include 2 
RNA recognition motifs (RRM), two NLS at N-terminus, NES within RRM2 and 
a glycine-rich c-terminus (Gendron, Josephs, and Petrucelli 2010). TDP43 is a 
versatile protein that binds to both DNA and RNA (Buratti and Baralle 2001; 
Gendron, Josephs, and Petrucelli 2010; Tollervey et al. 2011).  
 
TDP43 functions to control different stages of protein production through its 
interactions with RNA and DNA. It acts at many stages during an RNA life 
cycle; including repression of transcription, RNA stability, alternative 
polyadenylation and alternative splicing (I.J.Huppertz 2015; E. B. Lee, Lee, and 
Trojanowski 2012). Hence it is no surprise that the majority of TDP43 is 
localized to the nuclear compartment.  
 
In addition, TDP43 has been found to bind to specific mRNA’s 3’UTRs 
(including its own) (Ayala et al. 2011; Tollervey et al. 2011) and has been 
shown to shuttle between the nuclear and cytoplasmic compartments (Ayala et 
al. 2008). Cytoplasmic TDP43 is particularly evident under cellular stress and 
up to 30% of TDP43 can be localized to the cytoplasmic compartment (Scotter, 
Chen, and Shaw 2015). Further it has been shown, using a variety of stressors 
(heat shock, ER, osmotic, and oxidative stress) and cell lines, that TDP43 co-
localises selectively with SGs (Colombrita et al. 2009; Dewey et al. 2010; 
Walker et al. 2013). Also similar to other hnRNP’s, TDP43 is involved in the 
formation of granules by forming protein-RNA complexes that sequester 
mRNA’s unneccessary for survival (Vanderweyde et al. 2013). This function of 
TDP43 emphasizing the importance of TDP43’s role under cellular stress.   
 
The RNA binding properties of TDP43 were first explored in 2001 where two 
distant RRM domains were described and TDP43 was seen to bind with 
increasing affinity to UG repeats >6nt long (Buratti and Baralle 2001). A decade 
later TDP43 binding targets were characterized on a genome wide scale in the 
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brain using iCLIP (Tollervey et al. 2011). Consistent with previous studies 
TDP43 showed preferential binding to UG tandem repeats or long clusters of 
UG-rich motifs and the majority of binding targets were found to be within 
intronic sites, representing the nuclear localization of TDP43.  
 
Another important function of TDP43, dependent on RNA binding, is to regulate 
its own protein levels. If TDP43 protein levels are too high they are toxic to cells 
but a lack of TDP43 is lethal to cells (Kraemer et al. 2010; Tsai et al. 2010). 
When cellular TDP43 is abundant it binds to its own 3’UTR resulting in 
alternative polyA site selection, which activates the use of a usually silent intron 
in its 3’UTR, followed by rapid degradation of TDP43 mRNA (Ayala et al. 
2011). A loss of this regulation is implicated in human neuropathology where 
TDP43 protein levels are seen to be increased (this is discussed further below).  
 
In addition, several pieces of evidence suggest that TDP43 plays a particular 
role in neuronal cells. Firstly TDP43 has been discovered to regulate the 
alternative splicing of genes implicated in neuronal development (DLC1, FZ3, 
KIF2A, KIF1B, AP2, TLE1, TNIK, UNC5C) and neuronal survival (CNTFR, 
MEF2D, MADD) (Tollervey et al. 2011). On top of this, TDP43 forms 
cytoplasmic mRNP granules that undergo bidirectional, microtubule-dependent 
transport in neurons (Alami et al. 2014). This enables the delivery of target 
mRNA to distal neuronal compartments and facilitates TDP43 to locally 
regulate RNA processing. Together this permits neuronal plasticity and 
development (dendritic branching, axonal growth). Finally, aberrant TDP43 
mislocalisation and aggregation is at the forefront of many neuronal diseases 
highlighting the importance of TDP43 functions within neurons (Gendron, 
Josephs, and Petrucelli 2010; J. O. Johnson et al. 2010; E. B. Lee, Lee, and 
Trojanowski 2012).  
TDP43 in MND 
TDP43 pathology is defined by cytoplasmic localization, aggregation, 
fragmentation and post-translational modifications, namely phosphorylation and 
ubiquitination (Manuela Neumann et al. 2006; Scotter, Chen, and Shaw 2015). 
Nuclear inclusions are also sometimes seen (Arai et al. 2006; Manuela 
Neumann et al. 2006). Collectively this is recognized as the pathological 
hallmark of MND (detected in >95% of patients), which since discovered in 
2006 sparked great interest in TDP43 pathology and has subsequently been 
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detected in other relative neurodegenerative disorders (Geser et al. 2009). 
These are collectively known as TDP43 proteinopathies (Liscica et al. 2008). 
Additionally TDP43 pathology is increasingly seen in normal aging population 
(over 65) (Geser et al. 2011) suggesting a broader role for TDP43 in aging and 
disease.   
 
The role of TDP43 pathology in disease pathogenesis is controversial and the 
features of TDP43 pathology have been extensive examined. 
Hyperphosphorylation of TDP43 is a recognized featured in disease (Arai et al. 
2006; Hasegawa, Arai, and Nonaka 2008; Manuela Neumann et al. 2006) but 
the role of phosphorylation is not established. One group hypothesized 
phosphorylation is a protective mechanism but others have shown it is required 
for toxicity and/or suggests that the phosphorylation negatively impacts 
TDP43’s degradation (H. Y. Li et al. 2011; Liachko, Guthrie, and Kraemer 
2011; Y.-J. Zhang et al. 2010). Moreover C-terminal TDP43 fragments are 
seen to be a major constituent of cytoplasmic inclusions owing to the presence 
of low complexity domain (responsible for protein interactions) and the removal 
of NLS enhances cytoplasmic distribution (I.J.Huppertz 2015; Nonaka et al. 
2009; Yong-jie Zhang et al. 2009). However TDP43 C-terminal fragmentation 
has not been shown to directly exert toxicity and is thought to be a secondary 
effect. Neuronal toxicity is associated with TDP43 mislocalisation, which can be 
driven by TARDBP mutations (Barmada et al. 2010), cellular stress (Colombrita 
et al. 2009; Dewey et al. 2010) or impaired degradation (van Eersel et al. 
2011). Similarly the cleavage of C-terminal TDP43 fragments is influenced by 
cellular stress, proteasomal inhibition and mutations in C-terminal domain of 
TARDBP (Scotter, Chen, and Shaw 2015). Additional biochemical analysis in 
disease has shown that aggregated TDP43 is ubiquitinated, making it relatively 
insoluble (Hasegawa, Arai, and Nonaka 2008).  
 
Even though TDP43 pathology is seen in the majority of patients with MND, 
mutations in the TARDBP gene are only responsible for 2% of cases (Scotter, 
Chen, and Shaw 2015). All disease-causing mutations discovered in TARDBP 
are found within the highly conserved glycine rich C-terminus (exon 6), with 
except to one FTLD/MND patient discovered to have the missense mutation 
A90V, which is located in between the two NLS (Winton et al. 2008). Additional 
mutations have been found in the non-coding region but these are thought to 
be benign. Many studies have used the discovery of a disease–causing 
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mutation hot-spot in TDP43 to serve as a platform for investigating 
pathobiology for TDP43; C terminus is involved in protein interactions and 
influences solubility and cellular localization (Ambrogio et al. 2009; Ayala et al. 
2008). In addition mutations have been discovered that affect phosphorylation 
of TDP43; 3 mutations have been found that could abolish phosphorylation 
sites but on other hand 9 mutations could enhance phosphorylation which in 
turn could augment TDP43 aggregation (Corrado et al. 2009; Kabashi et al. 
2008; Kühnlein et al. 2009).  
 
Although there has been extensive research of TDP43, its the role in disease is 
still not fully understood. It has been debated whether TDP43 in MND acts via 
a loss of function mechanism, mediated by nuclear clearance, RNA 
dysregulation or defective protein clearance, and/or gain of function mediated 
by aggregates or abnormal cytoplasmic function (E. B. Lee, Lee, and 
Trojanowski 2012). In a wider context, aggregation is seen across 
neurodegeneration suggesting that it plays a central role in neurodegenerative 
disease pathology. However it is still not clear what role inclusions play in 
disease pathogenesis; 1/ Are they the primary causative toxic species? Or 2/ 
are they just an innocent bystander (that occurs with another toxic event but 
themselves are not critical) or 3/ are they a protective mechanism to prevent 
cellular damage from misfolded/toxic proteins?  
TDP43 in VCP-related MND 
As touched on earlier, previous models of VCP related MND have recapitulated 
the pathological hallmark of MND (J. O. Johnson et al. 2010; Ju et al. 2009; M 
Neumann et al. 2007), suggesting VCP-related MND could share common 
mechanisms of pathogenesis with other TDP’opathies. In addition another 
study has explored the genetic interaction of TDP43 and VCP; in drosophila 
mutant VCP was shown to genetically interact with TDP43 resulting in an 
enhancement of the pathological phenotype (Ritson et al. 2010). The 
interaction was enhanced by the presence of a mutation in NLS of TDP43 and 
abolished by restricting TDP43 expression to the nucleus (Ritson et al. 2010). 
The findings presented imply that TDP43 is a mediator of toxicity initiated by 
disease-causing mutations in VCP rather than just an indicator of cytoplasm 
stress caused by disease but the mechanism underlying the interaction 
between TDP43 and VCP in disease is not fully understood.   
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Although key steps have been made, characterizing the role of TDP43 in MND 
is far from complete. Here I have studied TDP43 in VCP-related MND and 
begun to unravel the effect of VCP mutation on TDP43 RNA interactions.  
Modeling TDP43 proteinopathies 
To date there has been an array of TDP43 models generated that have all 
provided novel insights into the pathogenesis of TDP43-proteinopathies, 
including MND (Ayala et al. 2008; Bilican et al. 2012; B. S. Johnson et al. 2008, 
2009; Kraemer et al. 2010; Serio et al. 2013; Winton et al. 2009). However 
there is unfortunately a lack of models in the field that have recapitulated fully 
TDP43 pathology we see in MND; phosphorylation, ubiquitination, cleavage, 
cytoplasmic mislocalisation and aggregation, which could contribute to the lack 
of translated research in MND. 
 
Firstly yeast models have been an attractive system to use because they are 
easily manipulated (genetically). Both purified TDP43 and TDP43 
overexpression in yeast results in TDP43 aggregation, which was seen to be 
dependent on TDP43’s C-terminal domain (B. S. Johnson et al. 2008, 2009). 
However TDP43 C-terminal mutants are not shown to aggregate and remain in 
the nucleus (B. S. Johnson et al. 2008). This discrepency could be due to the 
availability of different binding partners influencing the transport system in 
yeast. Since some features of MND are recapitulated yeast models have been 
exploited to test modulators of TDP43 toxicity and aggregation, for example 
Pbp1 (orthologue of ataxin-2) was shown to enhance toxicity providing potential 
novel therapeutic targets (Elden et al. 2010). Overall the yeast system has 
provided indisputably valuable mechanistic insights into TDP43 pathology but it 
us unable to provide complexity introduced by the specialised neuronal cell-
signalling networks.  
 
Next studying endogenous or overexpressed TDP43 in mammalian tissue 
culture models has not recapitulated aggregation as yeast did; TDP43 remains 
soluble and predominantly localised to the nucleus (Baloh 2011; Winton et al. 
2009). But TDP43 has been manipulated to recapitulate pathology; TDP43 
mutations have targeted the nuclear localisation signal (Winton et al. 2009), 
RRM (Ayala et al. 2008), or C-terminal truncation (Nonaka et al. 2009), 
suggesting that altered TDP43 RNA binding, nuclear localization, or proteolytic 
cleavage can promote TDP43 aggregation.  
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Further, numerous animal models have been utilised to study TDP43. 
Transgenic, virus induced and KO mammalian models have all been 
generated. One example is the transgenic mouse with A315T mutation that 
shows ubiquitinated inclusions and c-terminal fragmentation however fails to 
show cytoplasmic mislocalisation (Wegorzewska et al. 2009). Other rodent 
models have recaptitulated cytoplasmic mislocalisation but observe insoluble 
TDP43 is only a minor component of pathological inclusions present (Baloh 
2011). Moreover KO models were generated to address the hypothesis that 
TDP43 acts via a loss of function in disease, however TDP43 KO models 
proved embryonic lethal (Kraemer et al. 2010). To avoid this conditional KO’s 
were generated but they do not show striking MND symptoms and present with 
defective body-fat metabolism (Chiang et al. 2010). In summary each model 
differs and recapitulates different features of typical TDP43-proteinopathies but 
one common feature across species (yeast, rats, mice, worms, flies and 
zebrafish) is that TDP43 overexpression is toxic. A more detail comparison of 
TDP43 animal models are reviewed elsewhere (Baloh 2011; Wegorzewska and 
Baloh 2011).  
 
Together this highlights the need for novel improved model systems to study 
MND and TDP43-proteinopathy. hiPSCs provide a unique advantage in that 
they enable investigation in a human system and that mutations are studied at 
their pathological dose.  
Aims  
Here I begin to uncover the role of the RBP TDP43 in the pathogenesis of 
VCP-related MND, using a humanized clinically relevant model system.  Firstly 
I address the localization of TDP43 in control and VCP-mutant hiPSC neural 
derivates. Next, I continue to explore the possibility of defective RNA regulation 
in VCP-related MND by studying Protein-RNA interactions of the candidate 
RBP TDP43 in hiPSC-derived patient specific MNs.  I addressed this by using 
a technique developed in the Ule lab, Individual nucleotide crosslinking and 
immunoprecipitation (iCLIP), to explore whether the composition of protein-
RNA complexes are changed in VCP-related MND. 
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Characterizing TDP43 localization in VCP hiPSC neural 
derivatives 
Previous studies using both in-vitro and in-vivo approaches have demonstrated 
TDP43 pathology in VCP related MND. To explore this pathological hallmark in 
our VCP mutant cultures, we examined the subcellular localization of TDP43 in 
patient specific hiPSC-neural derivatives.   
 
Moreover, several studies have linked TDP43 pathology with ER stress (S 
Sasaki 2010; Walker et al. 2013). Earlier we have shown that ER stress is an 
early pathogenic event in VCP mutant MNs that manifests shortly after terminal 
differentiation. Thus I reasoned that ER stress is associated with TDP43 
mislocalisation so I have chosen to explore TDP43 pathology at flanking time-
points of to this ER phenotype; in NPCs and D3MNs.  
TDP43 localisation in VCP hiPSC neural derivatives 
TDP43 staining in control NPCs shows 97.1±0.8% localization to the nucleus 
and 2.9±0.8% in the cytoplasm (n=2, from 1 biological line), compared to 
94.8±0.3% within the nucleus and 5.2±0.3% in the cytoplasm in VCP-mutant 
NPCs (n=4, across 3 biological lines) (Figure 6.1.A & C). (Ungrouped data for 
each biological line is displayed in Appendix 8.5) 
 
Shortly after terminal differentiation in D3MNs, control cultures display 
90.0±1.5% TDP43 localization in the nucleus and 10.0±1.5% in the cytoplasm 
(n=3 across 1 biological lines). Where-as the percentage of nuclear TDP43 in 
VCP-mutant cultures is reduced to 75.7±4.6% and the cytoplasmic TDP43 is 
reciprocally increased to 24.3±4.6% (n=4, across 2 patient lines) (Figure 6.1.B 
& D). Thus revealing a significant difference in TDP43 localization between 
control and VCP-mutant cultures in D3MNs but not at the NPC stage.  
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Figure 6.1; TDP43 staining in hiPSC-derived NPCs and MNs 
A & B) Representative images of Control and VCP-mutant NPCs and MNs 
respectively, stained with TDP43 (red) and merged with DAPI staining (blue). Scale 
bar: 20µm. C & D) quantification of TDP43 staining, displayed as % of TDP43 in the 
nucleus vs cytoplasm. (N=3 technical replicates from biological n=1 for control lines 
and n=2 for VCP mutant lines, 50+ cells counted per condition, two-way ANOVA). Error 
bars represent mean ± SEM. *p<0.05.  
 
TDP43 iCLIP in VCP hiPSC derived Motor neurons 
To date, RNA regulation of TDP43 has been studied in the human brain and in 
the context of FTLD (Tollervey et al. 2011).  iCLIP was carried out on human 
cortical post mortem tissue from 3 healthy control patients and 3 patients with 
FTLD (another TDP43-proteinopathy). TDP43 mRNA targets were identified on 
a genome wide scale in human neuronal tissue. This sites were then compared 
to those found in tissue from FTLD patients; the greatest number of changes 
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were found within intronic regions, which suggests the largest changes in 
TDP43 functions in FTLD are in the nucleus. Although this provides key 
insights into TDP43’s role under both control and disease conditions it is 
difficult to interpret cell specific functions due to a mixed sample population. 
Further, in combination with microarray experiments in SHSY5Y cells upon 
TDP43 KD, sites of alternative splicing in reduced TDP43 expression were 
identified. These results cannot be confidently interpreted in relation to disease 
yet as it is unresolved if TDP43 acts via GOF or LOF mechanisms in MND.  
 
TDP43’s RNA interactions have not been explored selectively in MNs, the cells 
most vulnerable in MND or on a genome wide scale in VCP-related MND. This 
is now possible due to optimized and highly pure differentiation protocols using 
patient specific hiPSCs and advancements in functional genomic techniques 
(both discussed in previous chapters). Here, I have carried out a focused high-
throughput iCLIP experiment using the candidate RBP, TDP43 in human iPSC-
derived MNs. Further, to probe the role of TDP43 in MND I have used patient 
specific VCP-mutant hiPSC-derived MNs to address whether TDP43-RNA 
complexes are altered in VCP-related MND. I carried out this first experiment 
on both control and VCP-mutant MNs at D17 MNs, as this is after the onset of 
a robust cell-type and mutation specific phenotype in VCP mutant MNs (see 
Chapter 5 for details). 
Library preparation  
Library preparation for CLIP protocols require a large number of enzymatic 
steps which all potentially affect the binding site detection. For this reason it is 
crucial to optimize the experimental conditions first. Within the lab we have 
recently refined each step of the iCLIP protocol (Huppertz et al. 2014) and on 
top of this, I have optimized the experiment specific conditions, such as the 
antibody of use. Here I have firstly used Proteintech TDP43 10782-2-AP 
antibody as previous studies in the lab (I.J.Huppertz 2015; Tollervey et al. 
2011). I next tested the partial RNase digestion conditions. This is importance 
to test for each specific experiment to ensure enzyme activity has not changed 
(overdigestion can decrease the number of identified sites). This can be 
observed on radioactive gel after immunopreciptation, RNase treatment and 
linker ligation (Figure 6.2.A). Additionally, the visualization of the 
immunoprecipitated RBP-RNA complexes helped to purify unbound RNA, 
enabled me to check the size of target RBP-RNA complexes correlates to 
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expected protein weight (TDP43 to be approx. 43kDa) and it allowed me to see 
the relative amount of RNA pulled down between conditions (by looking at the 
signal intensity). After 1 hour I noticed there was less RNA pulled down in the 
VCP-mutant MN sample 1, but after longer exposure complexes were clearly 
visualized so I continued with all samples noting a reduction in RNA within the 
one sample. The size of the dominant TDP43-RNA complex present 
corresponded to a single TDP43 molecule bound to the RNA. (At 
approximately 120kDa I observe IgG that blocks visualization; this will not 
impact complexes purified but causes a separation in the visualization. In future 
experiments I will use a reducing agent to disrupt the IgGs and make them run 
individually at 25, and 50 kDa). I isolated protein-RNA complexes, bearing in 
mind to cut slightly higher on the membrane to ensure all RNA-Protein 
complexes are extracted due to the IgG interference, and continued with the 
standard iCLIP library preparation method. PCR amplification was performed 
for 22 cycles across all samples (Figure 6.2.B).  
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Figure 6.2; Optimization of TDP43 iCLIP library preparation from hiPSC-derived 
MNs 
A) Autoradiograph showing protein-RNA complexes isolated after TDP43 
immunoprecipitation, taken after 1hour exposure. Region isolated for downstream 
library preparation is annotated by the red dotted lines. B) Post PCR gel (23cycles 
used). Medium (75-95nt) and High (95-200nt) fractions were obtained by cutting 
selected regions from cDNA gel. C) Table displays ratio of unique reads, only 
experiment attempt 3 has been further analyzed in this thesis.  
 
After sequencing I assess the complexity of the libraries by calculating the ratio 
of unique reads. My first experimental attempts using hiPSC-derived MNs 
revealed extremely high ratios of unique reads ranging between 58-258, which 
reflects poor complexity and would contain many duplicate reads due to over 
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sequencing (Figure 6.2.C). I hypothesized that this could be partially due to the 
small sample input from hiPSC-derived MNs (mean input was 0.08mg protein) 
therefore I repeated the experiment using ten times the input material 
(0.84mg). This did improve the complexity of the library generated, ratio of 
unique reads ranged from 14-38 (Figure 6.2.C). However I wanted to further 
improve the data quality before continuing with analysis. We reasoned that the 
immunoprecipitation could be improved by using an alternative TDP43 antibody 
(Sigma TDP43 SAB4200008). This was tested in the lab by Martina Hallegger; 
immunoprecipitations were carried out on HeK293 cells side by side with the 
previously used Proteintech antibody. The new sigma antibody revealed a 
much stronger signal on autograph after 1 hour exposure than previous 
Proteintech antibody, therefore I attempted iCLIP on hiPSC-derived MN for a 
third time using increased input material and the Sigma antibody. This resulted 
in a good library complexity and unique ratio scores between 1.8-2.5 (Figure 
6.2.C).  
 
TDP43 binding sites in iPSC-derived MN 
Firstly I have defined the clusters bound by TDP43 on a genome wide scale 
using both control and VCP-mutant samples. I then analyzed the correlation 
between the clusters bound in all samples (biological replicates and vs control 
and mutant conditions). Strong correlation was seen between all samples (R2 
values ranged between 0.96 to 0.98) (Figure 6.3). 
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Figure 6.3; Correlation between biological replicates 
Clusters were defined based on all samples, then Log(number of reads within each 
cluster) was plotted for each biological replicate. R2 value displayed.  
 
Although we have not seen TDP43 mislocalisation so far in VCP-mutant 
D3MNs I wanted to explore whether any alteration in protein localization could 
be detected with an alternative more sensitive technique and at a later stage of 
MN maturation. Therefore I have evaluated, at the genome-wide level, the % of 
TDP43 binding to different regions of the genome (3’UTRs, 5’UTRs, ORF, inter 
and intronic) for both control and VCP mutant groups, and compared my 
findings to previously published data. This was done using single hits that 
mapped to genome (Gsumtype files on icount provides the calculation 
summary of cDNA counts that map to different regions of genome). I find the 
genomic distribution of TDP43 binding was not altered between the control and 
VCP mutant MNs and, consistent with previous findings(Tollervey et al. 2011), 
the highest % of binding was found in introns (Figure 6.4.A). This also confirms 
the localization of TDP43 is predominantly nuclear (>70%). Since I do not 
detect TDP43 mislocalization at this point in VCP mutant MNs, this makes the 
downstream analysis simpler as we do not need to normalize for protein 
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localization (a change in protein localization would alter the binding targets due 
to RNA availability).  
 
 
 
Figure 6.4; TDP43-RNA interactions in iPSC-derived MN 
A) Genomic distribution of TDP43 binding, B) Weblogo logos displaying the sequence 
motif around crosslink sites genome wide, and C) Pentamer analysis, in human ESCs 
(published data), Control hiPSC-derived MNs and VCP-mutant hiPSC-derived MNs.  
 
TDP43 has previously been shown to bind to UG-rich regions in the genome 
(Buratti and Baralle 2001; Tollervey et al. 2011). To explore whether this finding 
is consistent in my current data I have first analyzed the proportion of each 
nucleotide seen surrounding binding sites using weblogo. I have plotted 10nt 
either side of the crosslink sites and show enrichment of T nucleotides, which is 
comparable for control, VCP-mutant MNs and to previous TDP43 iCLIP data 
from hESCs (Figure 6.4.B) (Tollervey et al. 2011). Next I performed further 
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sequence analysis of TDP43’s crosslink sites by analyzing pentamer 
enrichment around crosslink sites. I captured 30nt either side of each 
crosslinking site and excluded the region immediately surrounding the site -10 
to 10 (due to bias of UV crosslinking nucleotide preferences). I see that in both 
Control and VCP-mutant MNs TDP43 binds to UG rich sequences (enrichment 
score = 6.10 for control and 6.64 VCP-mutant MNs) (Figure 6.4.C).  
Differential Protein-RNA interactions of TDP43 in VCP mutant MN 
Next, I analyzed only the binding sites that were changed between control and 
VCP mutant MN samples. Using a threshold score of smoothed z>20, there are 
261 sites that are more bound in by TDP43 in VCP mutant MN and 463 sites 
that are less bound (Figure 6.5.A). The top changes in TDP43 binding include; 
Doublecortin (DCX = a microtubule associated protein involved in neuronal 
migration), NRG1 (Neuregulin 1 = a membrane glycoprotein involved in cell-cell 
signaling in growth and development), TSHD7A (thrombospondin type1 domain 
containing 7A = a neural protein involved in angiogenic patterning) and 
PHACTR3 (phosphatase and actin regulator 3 = is associate with the nuclear 
scaffold in proliferating cells), which are more bound in VCP mutant MNs 
compared to control. On the other side FXYD6 (Phosphohippolin = a 
transmembrane protein which affects activity of NA,K-ATPase), XPO1 (exportin 
1 = a cell-cycle-regulated gene & encodes a protein that mediates leucine-rich 
NES-dependent protein transport) and STX1B (syntaxin-1B = role in exocytosis 
of synaptic vesicles) are all less bound by TDP43 in VCP-mutant MNs. It is 
interesting to note that many of the top changed genes have neuronal specific 
functions.  
 
Following the detection of differential binding, functional consequences need to 
be elucidated. I have begun to look at the functional impact of TDP43 binding 
by combining iCLIP and RNAseq data to explore if differential binding of TDP43 
has any effect on RNA expression levels. Here I touch upon two preliminary 
examples; firstly STX1B is less bound by TDP43 in VCP-mutant MNs and the 
RNAseq shows a trend for reduced mRNA expression (Figure 6.5.B & C). This 
suggests that TDP43 acts on STX1B as an enhancer. On the other hand 
PHACTR3 is more bound by TDP43 but also suggests TDP43 acts in this 
situation as an enhancer, as our RNAseq data shows a trend towards higher 
mRNA expression in VCP-mutant cells (Figure 6.5.D & E). Neither of these 
sites/genes mentioned have significantly different mRNA expression levels in 
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VCP-mutant MNs compared to control. Further replicates and analysis need to 
be done to explore the trends observed and to understand the impact of 
differential TDP43 binding in VCP-mutant MNs.  
 
 
Figure 6.5; Differential TDP43 binding in VCP-mutant MNs 
A) Barplot displays the number of sites more and less bound by TDP43 in VCP-mutant 
MNs. B) Representative trace showing binding of TDP43 to STX1B and C) relative 
mRNA expression levels of STX1B in Control and VCP-mutant MNs. D) Representative 
trace showing TDP43 binding to PHACTR3 and E) relative mRNA expression levels of 
PHACTR3 in Control and VCP mutant MNs. (N=3+ technical repeats across 2 control 
lines and 3 VCP mutant lines), mean RPKM values plotted with error bars that 
represent ± SEM. 
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Genomic localization and Sequence Motif analysis of the differentially 
bound sites 
I have analyzed the genomic distribution of the differentially bound sites in VCP 
mutant MNs. This interestingly revealed the sites that less bound in the VCP 
mutant MNs have an enrichment within the 3’UTR (Figure 6.6.A). 3’UTR 
influences post-transcriptional regulation therefore suggest a level of gene 
expression regulation by TDP43 is lost in VCP-mutant MNs. The same effect is 
shown upon TDP43 C-terminal truncation; TDP43 binding is reduced in 3’UTRs 
and increased in intronic regions (I.J.Huppertz 2015). 
 
 
 
Figure 6.6; Genomic binding distribution and motif analysis of differential bound 
TDP43 sites in control and VCP-mutant MNs 
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A & B) Respective genomic distribution of sites more and less bound by TDP43 in VCP 
mutant MNs. C & D) Top sequence motif’s for the less and more bound sites by TDP43 
in VCP-mutant MNs respectively. C) Table displays the top 5 sequence motif’s and 
their correlating enrichment scores for both the more and less bound sites by TDP43 in 
VCP-mutant MNs 
 
To further explore possible underlying reasons for the change in binding 
localization, we performed motif analysis on the sites differentially bound. 
Interestingly we see that the sites that are increasingly bound by TDP43 in the 
VCP mutant MNs are enriched in U-rich motif’s, whereas the sites that are less 
bound by TDP43 in the VCP mutant are enriched in UG-rich motif’s (Figure 
6.6.B & C). Within the lab, we have begun to unravel the function of TDP43 
binding to U-rich regions. Ina Huppertz has replicated TDP43’s binding to U-
rich regions in Hela cells and has shown that U rich binding of TDP43 is 
abolished after truncation of TDP43’s LC domain (I.J.Huppertz 2015). This lead 
us to hypothesize that U-rich binding is specific to TDP43 and that TDP43 
binds to U-rich regions with the help of the LC domain, either directly or being 
forced through its stabilizing interacting partners. The data I have presented 
here adds to the current hypothesis, implicating that U-rich binding is relevant 
in MND.  
 
Significant further work will need to be untaken to determine 1/ the 
consequences of U rich binding, 2/ what interactions in the LC domain 
influence U rich binding seen? 3/ If this phenomena is broadly important to 
MND and other TDP43 proteinopathies?  
GO analysis of differentially bound sites 
In addition I have carried out GO term analysis on the differentially bound sites 
in VCP-mutant MNs, using all genes with a smoothed z-score >20 (Figure 6.7). 
I find that the sites that are less bound by TDP43 in VCP mutant MNs are those 
involved in cellular process regulation – this involves regulating the 
rate/frequency of processes at the cellular level (not single cell) so for example 
includes cell-cell communication. On the other hand among the top terms 
associated with increased TDP43 binding in VCP-mutant MNs is the regulation 
of neuronal differentiation and development. However at this stage it is not 
clear the functional implications of these binding sites.  
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Figure 6.7; GO analysis of differentially bound TDP43 sites in VCP-mutant MNs 
Table displaying top 10 GO terms associated with both more and less bound TDP43 
sites !
Discussion 
Here I have firstly investigated the presence of TDP43 pathology in patient 
specific VCP mutant hiPSCs. I detect a cytoplasmic mislocalisation of TDP43 in 
D3 VCP mutant MNs, a key pathological hallmark associated with MND. This 
correlates with the onset of ER stress in VCP mutant MNs and is detected prior 
to a cell death phenotype, which is observed at D17 (described in chapter 5). 
The relationship between TPD43 pathology and ER stress has been 
investigated before; Walker et al describe how ER stress induces the 
accumulation of TDP43 in the cytoplasm (Walker et al. 2013). Further 
experiments are required before we can determine whether this sequence of 
events (ER stress followed by TDP43 aggregation) is true in our model VCP-
related MND too. Moreover, previous studies have demonstrated that elevated 
levels of cytoplasmic TDP43 in MND correlate with cellular toxicity 
(Wegorzewska and Baloh 2011)(Barmada et al. 2010), I am currently exploring 
TDP43 pathology in D17MNs too (where we detect a selective vulnerability of 
VCP mutant MNs).  
 
As previously mentioned many cellular models of TDP43-proteinopathies fail to 
accurately recapitulate TDP43 pathology. Using hiPSCs we were able to 
recapitulate TDP43 mislocalisation, a key aspect of TDP43 pathology (Manuela 
Neumann et al. 2006), specifically in VCP mutant MNs. This emphasizes the 
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power of hiPSCs to be used as a model system to study MND. However it is of 
upmost importance for us to explore other aspects of TDP43 pathology in 
addition to mislocalisation such as ubiquitination, phosphorylation, protein 
levels and solubility. 
 
Next I have combined hiPSC methodologies with genomics to understand how 
VCP-mutations affect the composition of TDP43-RNA complexes in iPSC-
derived MNs. In agreement with previous work, I show that in hiPSC-derived 
MNs TDP43 binds to predominantly to intronic regions in the genome and has 
a preference to UG-rich sequences (Tollervey et al. 2011).   
 
Further I show there are differentially bound sites by TDP43 in Control and 
VCP-mutant MNs. Many of the sites less bound in VCP-mutant MNs lay within 
genes implicates in neuronal differentiation and development. This raises the 
hypothesis that neuronal development is altered in VCP mutant cells. This 
concept is reinforced by our previous findings (Chapter 5) showing 
synaptogenesis is defective in VCP mutant MNs and also by VCP’s interaction 
with NF1, a protein that if mutated causes neurodevelopmental disorder 
neurofibromatosis (Hsueh 2012). Under normal conditions VCP and NF1 
cooperate to regulate dendritic spine formation, but in VCP mutations this is 
abolished (H. F. Wang et al. 2011). Additional studies have also suggested a 
possible pathophysiological link between development and neurodegeneration 
(Lule, Ludolph, and Ludolph 2008). However, further work is needed to 
understand the mechanistic link between neural development and 
neurodegeneration and also what role the interaction between VCP and TDP43 
plays in both processes.  
 
Moreover, the differentially bound sites present a loss of TDP43 binding in sites 
located in 3’UTRs in VCP mutant MNs suggesting a partial loss of RNA 
regulation in VCP-related MND. The results also show an increase of TDP43 
binding to U-rich sequences in VCP-mutant MNs. The implications of U-rich 
binding are largely unknown but separately a study has shown that TDP43’s 
preference to U-rich sequences is lost upon truncation of TDP43’s LC domain 
(I.J.Huppertz 2015). The LC domain of TDP43 is also responsible for protein 
interactions and formation of granules. Granules are present in all 
neurodegenerative diseases, with TDP43 being a major component, including 
VCP-related MND (J. O. Johnson et al. 2010; M Neumann et al. 2007). This 
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suggests that TDP43’s function in MND are partially in the formation of 
granules, implemented via its binding to U-rich sites.  
 
Stress granules are usually highly dynamic and form under cellular stress 
where RBPs and capped mRNA molecules (stalled translation complexes) 
aggregate in a process to fine-tune protein expression under stress. VCP itself 
has been shown to be involved in stress granule dynamics (Buchan et al. 
2013), specifically functioning in the disassembly of stress granules. It has 
been suggested that when mutated this function of VCP is lost leading to 
persistent disease aggregates (Buchan et al. 2013), although we haven’t yet 
characterized this. I reason that in VCP-related MND, VCP-mutations do not 
disperse cellular granules, which I believe are partially formed via TDP43 
binding to U-rich sequences via its LC domain. All together it leads me to 
hypothesize TDP43 binding to U-rich sequences are less specific interactions 
than to UG-rich motifs, and that U-rich binding of TDP43 will be of relevance to 
MND. 
 
Also to note, TDP43 is highly conserved throughout species but also among 
human paralogues, which share a ‘common’ LC/glycine rich region (21% 
homology), for example with hnRNPA1. Interestingly several paralogues have 
also been implicated in MND, including hnRNPA2B1 and hnRNPA1 (Benatar et 
al. 2013; H. J. Kim et al. 2013). Therefore it is reasonable to suggest that other 
hnRNP’s may share similar functions to TDP43, perhaps via their LC domains, 
and could also play a role in MND. Additionally it has previously been shown 
that TDP43 binds up to 100 nucleotides away from UG repeats (Tollervey et al. 
2011) which further suggests co-operative binding could occur via its glycine 
rich region.  
 
To conclude this work has provided novel insights into the mechanism 
underlying RNA regulation in MND and into the characterization of TDP43 in 
VCP-related MND.  
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Chapter 7; General Discussion 
The pathogenic mechanisms underlying MND are so far not fully characterized, 
in particular there is very limited understanding of the sequence of pathogenic 
events. The research I have presented here underscores the value of using 
hiPSCs to model disease and has furthered our understanding of primary vs. 
secondary pathogenic events in VCP-related MND. 
Use of hiPSC to model neurodegeneration 
Over the past decade, the discovery of hiPSCs combined with advancements 
in neural differentiation strategies has revolutionized our ability to analyze 
patient specific material and thus model disease. This is of particular benefit to 
studying MND (and other neurodegenerative disorders) due to the 
inaccessibility of spinal motor neurons from patients. Additionally it opens up 
the doors for personalized medicine in the future.  
 
Previously long protocols and heterogeneous cellular yields have discouraged 
large-scale modeling of disease. Here I have refined differentiation methods for 
the generation spinal motor neurons and astrocytes that result in a high yield 
and a near homogeneous cellular population. This has been primarily achieved 
by the use of monolayer culture approach and compounds to synchronize exit 
from cell cycle. An additional block in the wide-spread use of hiPSC technology 
has been the expense. Here we have addressed this by eliminating the use of 
growth factors, such as BDNF and GDNF, and also by massively shortening 
our strategy for motoneurogenesis (51+ to 21days). Finally we have ensured 
our protocols closely mirror key in vivo developmental processes. These 
advancements provide the opportunity to maximally exploit hiPSC technology 
in the future. A few laboratories have already exploited hiPSC-derivatives in 
high-throughput screens; for example a recent study highlights the ability to use 
hiPSC-derived MNs in high-throughput imaging and drug screens (Burkhardt et 
al. 2013). They first accessed the presence of TDP43 pathology in 384-well 
format then secondly screened 1,757 compounds to search for any that would 
ameliorate the pathology observed (Burkhardt et al. 2013). Our rapid, high yield 
and reduced cost protocol would benefit this approach.  
 
Further, to date the majority of hiPSC-derived cells have been characterized by 
a handful of protein markers and function assays, however this doesn’t provide 
comprehensive functional maturity or cell-subtype information. Here we have, 
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in addition to standard ICC and multiple functional assays, carried out 
transcriptional profiling to validate our specified cellular population. This 
enables us to capture a snapshot of many cellular properties at once, for 
example expression of neurotransmission transporters, region specific genes, 
ion channels and signals controlling axonal branching, although we loose 
single cell resolution in this analysis. For selective cell types there is a 
particular lack of standardized cell-specific markers that encompass subtype 
specificity and maturational status. This is the case for astrocytes. Therefore 
here we sought to dissect the transcriptional signature throughout 
astrogliogenesis, using an unbiased approach, to objectively define novel 
reliable stage-specific markers. In addition we compared the transcriptional 
signatures of iPSC gliogenic derivatives to human AC tissue at two different 
maturational stages (fetal and adult) to gain insights into the maturation status 
of our iPSC-derivatives. Validation is required before we can confidently define 
a set of markers to establish cell identity throughout differentiation and 
maturation, and further assays are required to understand the heterogeneity of 
astrocytes.  
 
Finally, an important consideration for using hiPSCs to study of adult-onset 
diseases such as with neurodegenerative conditions, is the maturation status of 
iPSC-derivatives. Within the relatively short period of time in culture, we and 
others have observed, cellular phenotypes emerge in patient-derived neurons 
(H. Chen et al. 2014; Devlin et al. 2015; Wainger, Kiskinis, Mellin, Wiskow, 
Han, et al. 2014). Could this be due to in vitro induced stress and/or lack of 
supportive environment in vitro? Neuronal differentiation in vitro may not fully 
recapitulate neuronal development as it happens in vivo due to the absence of 
non-neuronal components in culture. Additionally previous studies have 
demonstrated cellular pathology often appears before symptom onset 
(sometimes developing over decades) (Bories et al. 2007; Kuo et al. 2005), 
which opens up the possibility of defects being detected early in 
development/maturation and thus hiPSCs would be a good system to explore 
this within. Moreover there have been several attempts to accelerate cellular 
maturity, namely by either co-culture with other tissue or by administration of 
specific factors (Miller et al. 2013; Zhang et al. 2016). Overall the meaning of 
the early phenotypes we detect using hiPSCs compared with those we observe 
at the end stage of disease (postmortem tissue) and events that occur in adult-
onset neurodegeneration, remains unresolved.  
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Dissecting the pathogenic events in VCP-related MND 
To date both defective protein homeostasis and RNA regulation have been 
implicated to play key roles in MND pathogenesis, however the individual role 
of each process is controversial. Manipulation of either protein homeostasis or 
RNA regulation has been shown to cause a forward feedback loop resulting 
relentless disease progression (Ling, Polymenidou, and Cleveland 2013), but 
the initiating event in MND remains elusive. The complete in vitro recapitulation 
of human MND pathology is challenging but in my PhD thesis I have presented 
to use of patient-specific hiPSC models to dissect the primary pathogenic 
events and to distinguish the onset of secondary events in VCP-related MND. 
 
VCP usually contributes to a myriad of cellular functions; including protein 
control, membrane turnover, protein degradation, cell cycle regulation and 
dendritic formation (Kim et al. 2014; Shih and Hsueh 2016; Vaz, Halder, and 
Ramadan 2013; Wang et al. 2011; Yamanaka, Sasagawa, and Ogura 2012) 
but currently the consequences of VCP mutations within human neuronal 
samples and in the context of MND are unknown/poorly defined. Thus we firstly 
employed an unbiased approach, RNA sequencing, to uncover pathological 
processes underlying VCP-related MND at the RNA level. Additionally we 
separately used a range of analysis techniques to address multiple organelle 
functions in cells carrying VCP mutations (eg. ER, mitochondrial and synaptic 
health). Using a combination of hiPSC technologies, RNA sequencing and 
collaboratively cellular imaging methods, we detect a clear phenotype in VCP 
mutant iPSC neural derivatives. Analysis throughout the differentiation of motor 
neurons reveals we first detect a phenotype shortly after terminal differentiation 
of neuronal precursors; ER stress is detected after 3 days of terminal 
differentiation and during neuronal maturation (day 3-17) several further striking 
phenotypes emerge; mitochondrial dysfunction, oxidative stress, synaptic 
defects and cellular vulnerability.  
 
Importantly, combining RNAseq and imaging analysis across a differentiation 
time course, we have been able to uncover that defects in cytoplasmic protein 
homeostasis arise before we detect defective RNA regulation. Further the later 
transcriptional profile of VCP-mutant MNs complimented a selection of the 
phenotypes detected through imaging, demonstrating at least some of the later 
events in VCP-related MND are coordinated by defects in RNA regulation. 
Together, for the first time these results have begun to untangle the web of 
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defective protein and RNA regulation in MND; they suggest that in VCP-related 
MND deregulated proteostasis occurs prior to the onset of defective RNA 
regulation.  
 
There is further controversy in MND research about the role of astrocytes in 
disease pathogenesis. For TDP43 mutations a cell autonomous role has been 
described for AC in MND (Serio et al. 2013). For SOD1 and C9ORF72 
mutations instead a non-cell autonomous role of AC has been described, but 
for TDP43 a non-cell autonomous role is debated (Di Giorgio et al. 2008; K. 
Meyer et al. 2014; Nagai et al. 2007; Serio et al. 2013; Tong et al. 2013). 
Overall research to date would suggest that the role of AC in MND may be 
mutation-specific. The role of VCP-mutant AC in MND has no yet been 
explored; therefore I have addressed this by probing VCP-mutant hiPSC-
derived ACs. So far we have not detected a robust cell autonomous role for 
VCP-mutant AC in VCP-related MND. This finding accentuates our confidence 
in the cell-specific vulnerability of VCP-mutant motor neurons we have 
detected. 
 
Finally we utilised iCLIP methodology to begin to look at underlying 
mechanisms of the RBP that constitutes the pathological hallmark of MND, 
TDP43.  The involvement of TDP43 in MND is undisputed. However, exactly 
how TDP43 elicits its effects are not clear; there is evidence supporting both a 
loss of function and gain of function for TDP43 (E. B. Lee, Lee, and 
Trojanowski 2012). Further, the onset of TDP43 pathology in MND in relation to 
the timing of additional phenotypes observed is yet to be disentangled. We 
have not yet managed to fully characterize TDP43 pathology in our model of 
VCP-related MND, however we have defined changes in TDP43 RNA-binding 
in MNs in the presence of VCP-mutations. Our results demonstrate many 
alterations occur in TDP43 binding to RNA’s involved in neuronal functions. It is 
challenging to combine high-resolution protein–RNA interaction maps (from 
iCLIP) with other high-throughput data, such as RNAseq, in order to elucidate 
the functions and dynamics of cellular protein–RNA interactions. Thus further 
analysis and validation needs be carried out to reveal the functional 
consequences of this differential TDP43 binding in VCP-mutant MNs.  
 
In addition, our TDP43 iCLIP data in VCP-mutant MNs shows that sequence 
specific binding is altered in the presence of VCP-mutations in MNs; a slight 
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decrease of UG-rich motifs coincides with a slight increase of U-rich motifs in 
the TDP43 iCLIP data produced from VCP-mutant MNs. Previous findings 
within the lab showed that U-rich binding is lost upon truncation of TDP43’s LC 
domain, which is responsible for protein-protein interactions (I.J.Huppertz 
2015). When taken together, this suggests that U rich binding depends on co-
operative protein-protein interactions with TDP43 and that these interactions 
could be of relevance in VCP-related MND. In spite of this, the wider 
implications of TDP43 binding to U-rich sites in MND are yet to be explored. 
A proposed model of pathogenesis in VCP-related MND 
Combining my findings so far I propose a model for pathogenesis in VCP-
related MND (Figure 7.1). I propose that ER stress, along with TDP43 
pathology, are among the earliest pathogenic events, occurring at the onset of 
terminal MN differentiation. We next simultaneously observe mitochondrial 
dysfunction and oxidative stress in VCP-mutant MNs, which in turn we propose 
reinforce each other’s activation. Recently it has been shown that TDP43 
pathology, particularly pTDP43, accumulates at the mitochondria, triggering 
mitochondria dysfunction (W. Wang et al. 2016), thus supporting the sequence 
of events we observe. Separately VCP-mutations cause a synaptic dysfunction, 
which in part is orchestrated by deregulated RNA. Taken together, this results 
in selective vulnerability in VCP-mutant MNs. Nevertheless I must reinforce, 
further investigations need to be carried out before we can present a fully 
comprehensive model of VCP-related MND with high confidence. This model I 
propose can be used to design further investigations.  
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Figure 7.1; Proposed model of pathogenesis in VCP-related MND 
A) Control MN and AC. B) Proposed pathogenic pathways contributing to 
selective vulnerability of VCP-MNs.  
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Future Plans 
In my PhD thesis I have presented many unresolved questions, thus here I 
propose several ways in which we can address these points in the future.  
Overcoming genetic variability when working with patient-specific 
cells 
A considerable challenge in modeling neurodegeneration using hiPSC remains 
in the heterogeneity of different cell lines. A major source of variation is genetic. 
This arises firstly from differences in the genetic background between different 
individuals and secondly can occur between hiPSC clones from the same 
individual.  Here we have found it a challenge to dissect pathogenic events in 
mutant hiPSCs due to variation seen between cell lines. These problems can 
be addressed by the use of genome editing technologies, such as CRISPR 
(Clustered Regularly Interspaced Short Palindromic Repeats), to produce 
isogenic lines.  
 
The CRISPR system is a microbial nuclease system that can be implemented 
in mammalian cells by co-expressing the bacterial Cas9 nuclease along with 
the guide RNA (Cong et al. 2013; Jiang et al. 2013). This method works by the 
induction of a double strand break (DSB) in the DNA at the site of target, which 
are repaired by one of two general repair pathways: non homologous-end 
joining (NHEJ) – where insertion or deletion often occurs leading to frameshift 
or a premature stop codon, or Homologous Recombination (HR) where the 
DSB is repaired using a donor DNA as a template so you can insert your 
desired sequence/mutation. Isogenic lines can be generated by either 
introducing a disease-causing mutation into control patients cell lines or by 
correcting a mutation in a disease-causing cell line. This substantially reduces 
genetic heterogeneity.  
 
As with most things, this approach has its disadvantages. The majority of 
neurodegenerative conditions, including MND cases, are sporadic, and 
research has shown that both the genetic and environmental factors contribute 
to neurodegeneration. However, the roles and interactions of genetic and 
environmental elements in disease pathogenesis remain elusive. Since the 
environmental contributions in neurodegeneration are unclear, only genetic 
factors are recapitulated in current disease models. Further the genetics 
underlying sporadic cases remains to be elucidated and it is not possible to 
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make isogenic controls from patients with sporadic disease. Therefore the 
approach we currently adopt in the laboratory is to first gain insights into 
disease pathogenesis by studying models with known disease-causing 
mutations, then see if findings can be replicated in samples from other disease-
causing mutations and sporadic cases.  
Rescuing the VCP phenotype 
One of our next goals is to rescue our VCP mutant hiPSCs. We will attempt to 
modulate the phenotype using both pharmacological and genetic approaches. 
There are many pharmacological treatments that have already been shown to 
improve phenotypes seen in MND or neurodegenerative disease model; this 
includes retigabine (Wainger, Kiskinis, Mellin, Wiskow, Han, et al. 2014), the 
VCP inhibitor vesnarinione shown to manipulate the NfKb pathway(Hotta et al. 
2013), UPR manipulators firstly the perk inhibitor (GSK2656157) which 
reinitiates translation during UPR (Moreno et al. 2013), Salubrinal which 
promotes translational arrest by inhibiting the phosphorylation of eIF2a 
(Kiskinis et al. 2014) or TUDCA a molecule that acts upstream of Perk, and 
treatment with statins, since Simvastatin has been shown to promotes 
mitochondrial function (Chataway 2015). We find ER stress plays a primary 
role in VCP-related MND thus we will first test modulators of the ER stress 
pathway, including Perk inhibitor and Salubrinal.  
 
Separately we will use the CRISPR platform to perturb ER stress, the primary 
pathogenic pathway in our model system, to try and reverse the primary and 
secondary phenotypes. It is important to note that pertubation of ER stress 
pathway could influence cell-subtype diversity in addition to effecting the 
cellular phenotype (Dalton, Lyons, and Lomvardas 2013). Thus we will assess 
both subtype selection and cellular health, including cellular viability and 
mitochondria function, using cellular imaging and RNAseq as readouts. 
Further dissecting the underlying molecular mechanisms in VCP-
related MND 
Although we have demonstrated the sequential onset of pathogenic events in 
VCP-related MND, further studies are required to definitively show the 
causative sequence of events. After 17 days of terminal motoneurogenesis we 
detect striking mitochondria dysfunction, ER stress, oxidative stress, selective 
vulnerability and synaptic defects. All mentioned pathways are intricately linked 
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and often work to reinforce each other (Barmada et al. 2010; Carrì et al. 2015; 
Colombrita et al. 2009; Ilieva et al. 2007; Malhotra and Kaufman 2011; Walker 
et al. 2013), therefore it is no surprise we detect them in parallel. In order to 
unravel the precise course of disease progression we will analyze events in 
across shorter windows of time, eg. every 24hours throughout terminal 
motoneurogenesis. Further we can induce each phenotype individually (by 
adding pharmacological stressors or using genome editing technology) and 
analyze the phenotypic consequences on the other interlinked pathways.  
Non-cell autonomous mechanisms of injury in VCP-related MND 
Although traditionally neurodegenerative conditions, such as MND, have been 
viewed as neuron-specific it is increasingly recognised that glia may contribute 
to disease pathogenesis. Here we have not detected a robust cell autonomous 
role for astrocytes in VCP-related MND, however non-cell autonomous 
mechanisms of injury in VCP-related MND remain unevaluated. To assess this 
we are analysing both control and mutant, MN and AC co-cultures and also 
using transwell culture supports, which enable a continuous exchange of 
soluble factors between AC and MNs. 
Common mechanisms in MND 
After fully characterising and establishing a pathogenic model for MND caused 
by VCP mutations it is important to next explore if the underlying mechanisms 
are mutation (VCP) or disease (MND) specific. Within the lab we are 
addressing this by analysing hiPSC-derivatives from patients carrying 
mutations in SOD1 (a cytoplasmic antioxidant, where the main function is to 
convert superoxide, which is highly reactive, to hydrogen peroxide/oxygen), 
and FUS (FUS is an RBP located in the nucleus and is involved in many stages 
of RNA processing).  Both SOD1 and FUS mutations do not recapitulate the 
typical TDP43 pathology seen in >95% of MND cases, but it would be 
interesting to see if there are any shared pathways or highlighted events that 
could be generically targeted (eg. UPR/autophagy). This can then be tested by 
pharmacological rescue or genetic manipulation in these additional mutant 
lines. Further we are currently carrying out transcriptional analysis of post 
mortem samples from sporadic and C9ORF72-mutant MND patients to again 
see if any common pathways are highlighted across different genetic models of 
MND.  
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Chapter 8; Appendix 
8.1 Enriched monolayer spinal motor neurogenesis protocol 
 
Preparation TIMING ~ 1day 
1. For iPSC culture, coat cell culture plates with 150µg/ml Geltrex (diluted in 
DMEM media) and leave to incubate at 37°C for 1 hour. Pre-coated plates 
can be used for up to 7days if kept sterile at 4°C.  
2. Thaw a vial of iPSCs by rotating quickly between your hands and adding 
media (pre-warmed to room temperature) drop-wise. Transfer the 
suspension to a 15ml falcon and dilute in 10ml media. Spin for 1min at 
1000g at room temperature. Resuspend the iPSCs in 2ml Essential 8 
media and add directly into 1well of a pre-coated geltrex 6well plate. Shake 
the plate side-to-side and back-and-forth to evenly distribute the cells. 
Leave the plate at 37°C overnight (Cell attachment can be checked after 
leaving to settle for a minimum of 20minutes).   
TIP – Can add Y27632 into essential 8 medium to improve cell survival during 
thawing.  
 
iPSC cultures TIMING ~ 1week 
3. The following day after thawing check the iPSC colonies have settled and 
are healthy. Carry out a full media change and remove the Y27632 
supplement if added.  
4. Continue feeding iPSC cultures daily with 2ml fresh Essential 8 media to 
expand iPSC colonies.  
5. Cultures should be passaged prior to contacting with each other. Passage 
iPSC on a 6well plate by removing the media, adding 1ml EDTA and 
leaving to incubate for 5minutes at 37°C. After 5minutes check colonies 
have begun to lift under the microscope, then aspirate EDTA and collect 
cells using a p1000 in 1ml essential 8 media. Cells can be split across 
several wells of a 6well plate and expanded as much as required.  
TIP – Good quality cultures at this stage are essential in order to maximize 
success in differentiation - ensure there is minimal cell death and iPSC 
colonies are pure (no contaminating cells present). 
6. The day before you start neural induction, cells need passaged to achieve 
100% confluency onto fresh geltrex-coated plates. 
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TIP – This is usually achieved by passaging 3 semi-confluent wells of a 6well 
plate into 1 well.  
 
Neural Induction TIMING ~ 7days 
7. Before beginning neural induction check iPSCs are 100% confluent, but 
that they are not growing on top of each other.  
8. Feed daily with 2ml neural induction media for a total of 7days. During this 
time a neuroepithlial sheet will form.  
9. After 7days of neural induction the neuroepithelial layer should be lifted 
and re-plated. First prepare laminin-coated plates at dilution 10-20µg/ml  
and incubate at 37°C for 4hours. 
10. Lift the neuroepithlial sheet by adding 350uL dispase into each well 
containing 2ml neural induction media and leave to incubate at 37°C.  
Check the plate after 10minutes and then every 1-2 minutes for the 
neuroepithlial sheet to lift. 
11. Once lifted, collect the sheet using a p1000 and add into a 15ml falcon 
containing 10ml neural maintenance media. Spin for 2 minutes at 500g.  
12. Aspirate media and carefully add a fresh 10ml neural maintenance media 
to wash the cells (dispase is not inactivated by media so needs to be 
thoroughly washed away). Spin again for 2minutes at 500g.  
 
Patterning TIMING ~ 11days 
13. Gently re-suspend the cells in spinal cord patterning media, as to minimize 
breaking up cellular clumps, and dry plate onto laminin coated plates. (Dry 
plating helps with cellular attachment.) 
TIP – Usually 1 well of neural induction can be placed into 2wells after 
washing. Cells should not be plated too sparsely or be broken up too much 
at this stage.  
14. 1hour after dry plating, add 2ml spinal cord patterning media to each well.  
15. For 7days feed daily with 2ml spinal cord patterning media. RA and 
Purmorphamine will act respectively to caudalise and ventralise neural 
precursors to the pMN domain. 
16. After 7days passage neural precursors. Usually this can be done simply by 
using a p1000 to collect neural precursors but if needed EDTA can also be 
used to lift precursors from the plate. Add collected cells to a 15ml falcon 
and spin for 1minute at 1000g.  
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17. Re-suspend the pellet in secondary patterning media and gently triturate 
before dry plating onto fresh laminin-coated plates (laminin coating at 10-
20µg/ml in DPBS). Again after approximately 1hour add 2ml media to each 
well.  
18. Feed daily for an additional 3days with secondary patterning media.  
 
Propagation TIMING ~ 0-30days 
TIP – To increase yield and facilitate easier plating of neurons at a single cell 
level, precursors should be propagated in FGF for a maximum of 30day. 
This stage is not essential and can skip directly to terminal differentiation.  
19. Passage NPCs by removing the media, adding 1ml EDTA and leaving to 
incubate for 5minutes at 37°C. After 5minutes aspirate EDTA and collect 
cells using a p1000 in 1ml propagation media.  
20. Plate precursors on geltrex coated plates.  
21. Feed 3 times weekly with propagation media and passage weekly. 
Gradually break up precursors further each time they are passaged. 
 
Terminal differentiation and maturation TIMING ~ 3+days 
TIP – Replate before terminal differentiation to the cell density and plates 
required for analysis. Neurons do not passage well after terminal 
differentiation of 5+ days.  
22. Prepare Laminin coated plates (20-40µg/ml in DPBS) as required for 
downstream analysis (eg. 96well format, coverslips etc).  
23. Passage NPCs by removing media, add 1ml accutase and incubate for 
3minutes at 37°C. 
24. Check the cells are lifting under the microscope, then collect them using a 
p1000 and neural maintenance media. Add into a falcon with 10ml neural 
maintenance media and spin for 1minute at 1000g.  
25. Re-suspend the precursors in terminal differentiation media and plate onto 
laminin-coated plates. 
26. Feed 3 times weekly during terminal differentiation. 
 
Table 8.1; Troubleshooting 
 
Step Problem Possible reasons Solution 
5 Contaminating • Influence of cell- To clean up a mixed 
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cells present in 
between iPSC 
colonies 
cell contact 
(Ensure cells 
are passaged at 
the correct time 
to avoid this in 
future - i.e. don’t 
let cultures over 
grow) 
• Cells are not 
receiving the 
correct signals 
(Can double 
check all 
reagents are in 
date, active and 
that the media 
has been made 
up correctly). 
culture where the 
majority of cells are 
pluripotent colonies - 
passage harshly and 
after a couple of 
passages only 
pluripotent cells 
should remain.  
 
To clean up 
pluripotent colonies 
that have been “taken 
over” by another cell 
type – pick pluripotent 
colonies and replate. 
7 iPSCs have not 
reached 100% 
confluency 
• Too few cells 
plated 
If small gaps are 
observed between 
cells, feed with 4ml 
essential 8 media and 
check confluency 
again after 24hours. If 
100% confluent then 
begin neural induction 
as per step 8. If there 
are large gaps 
between cells then 
passage again for 
neural induction and 
plate more cells than 
previous attempt. 
10 Neuroepithlial 
sheet lifting early  
• Beginning with 
over confluent 
cells before 
Advise to start again 
! 211!
induction 
• Toxicity possible 
induced by 
CHIR99021 
13-15 NPCs die off • Neuroepithlial 
sheet broken up 
too harshly or 
left in dispase 
too long 
Start over again from 
neural induction but 
do not break the cells 
up or plate too 
sparcely at stage 13. 
They need cell-to-cell 
signaling at this stage. 
15 Cells will not 
attach 
 Feed the precursors in 
suspension; gently 
aspirate half the 
media and replace 
with fresh. Replate as 
described after 7days 
of patterning.  
Attachment should be 
more efficient once 
the cells are broken 
up further.  
Additionally you can 
increase 
concentration of 
laminin used to 1:50 
to improve 
attachment. 
26 MNs begin to lift 
from the plate 
during terminal 
differentiation 
• Laminin-coating 
dried out or not 
concentrated 
enough 
• Excessive 
movement of 
the plate can 
disturb the MNs 
As long as it is not too 
late (i.e. the majority 
of each MN is 
attached to the plate 
but you notice the 
edges are peeling) 
spike additional 
laminin into the media 
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to improve adherence. 
Also carry out half 
media changes to 
reduce impact of 
feeding on the MNs.  
 
 
 
8.2 Enrichment of MNs before and after propagation of NPCs 
 
 
Figure 8.2; The percentage of MNs specified before and after the propagation of 
NPCs. 
Quantitative ICC of SMI32 shows the percentage of MNs specified after 17days of 
terminal differentiation starting with either NPCs (D0) or NPCs that have been 
propagated for 25days prior to terminal differentiation. 
 
8.3!GO!analysis!for!differentially!expressed!genes!between!Early!and!
Late!NPCs!!
Table 8.1 
Full list of GO terms associated with differentially expressed genes highlighted between 
early and Late NPCs with Log(Fold change) >1.5, p-value <0.05 and enrichment 
score>2.  
NPCs D0 Propagated D25
0
25
50
75
100
 
%
 +
ve
 c
el
ls
MNs Specified
Stage terminal 
differentiation began from 
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Up#regulated#in#Late#NPCs# ## Down#regulated#in#Late#NPCs#
GO#term# Descrip:on# P;value#
Enrichme
nt#score## ## GO#term# Descrip:on# P;value#
Enrich
ment#
score#
GO:0004872# receptor#ac:vity# 4.51E;25# 2.32## GO:0099600#
transmembrane#
receptor#ac:vity# 1.77E;18# 2.65#
GO:0060089#
molecular#transducer#
ac:vity# 4.51E;25# 2.32## GO:0038023#
signaling#receptor#
ac:vity# 2.43E;17# 2.49#
GO:0004871# signal#transducer#ac:vity# 3.77E;21# 2.08## GO:0004888#
transmembrane#
signaling#receptor#
ac:vity# 8.89E;17# 2.6#
GO:0038023# signaling#receptor#ac:vity# 7.25E;21# 2.4## GO:0022836#
gated#channel#
ac:vity# 1.26E;16# 3.57#
GO:0099600#
transmembrane#receptor#
ac:vity# 2.44E;20# 2.46## GO:0022838#
substrate;speciﬁc#
channel#ac:vity# 7.03E;16# 3.15#
GO:0004888#
transmembrane#signaling#
receptor#ac:vity# 1.61E;19# 2.47## GO:0005261#
ca:on#channel#
ac:vity# 1.55E;15# 3.59#
GO:0005509# calcium#ion#binding# 6.57E;14# 2.1## GO:0005216# ion#channel#ac:vity# 1.80E;15# 3.12#
GO:0005201#
extracellular#matrix#
structural#cons:tuent# 3.04E;12# 4.87## GO:0004872# receptor#ac:vity# 2.14E;15# 2.18#
GO:0005125# cytokine#ac:vity# 1.01E;11# 3.89## GO:0060089#
molecular#
transducer#ac:vity# 2.14E;15# 2.18#
GO:0019838# growth#factor#binding# 1.71E;10# 3.18## GO:0022803#
passive#
transmembrane#
transporter#ac:vity# 3.04E;14# 2.91#
GO:0061134#
pep:dase#regulator#
ac:vity# 1.72E;09# 2.9## GO:0015267# channel#ac:vity# 3.04E;14# 2.91#
GO:0030246# carbohydrate#binding# 3.69E;09# 2.52## GO:0004930#
G;protein#coupled#
receptor#ac:vity# 1.64E;12# 3.28#
GO:0030414# pep:dase#inhibitor#ac:vity# 7.90E;09# 3.24## GO:0046873#
metal#ion#
transmembrane#
transporter#ac:vity# 8.35E;12# 2.71#
GO:0005539#
glycosaminoglycan#
binding# 1.41E;08# 2.71## GO:0015079#
potassium#ion#
transmembrane#
transporter#ac:vity# 3.01E;11# 4.19#
GO:0004866#
endopep:dase#inhibitor#
ac:vity# 1.80E;08# 3.22## GO:0005267#
potassium#channel#
ac:vity# 4.23E;11# 4.57#
GO:0005518# collagen#binding# 2.64E;08# 3.67## GO:0015075#
ion#
transmembrane#
transporter#ac:vity# 2.07E;10# 2.03#
GO:0005126# cytokine#receptor#binding# 5.45E;08# 2.58## GO:0022843#
voltage;gated#
ca:on#channel#
ac:vity# 2.33E;10# 4.27#
GO:0050840#
extracellular#matrix#
binding# 7.75E;08# 3.91## GO:0022834#
ligand;gated#
channel#ac:vity# 2.58E;10# 4.11#
GO:0061135#
endopep:dase#regulator#
ac:vity# 1.50E;07# 2.95## GO:0015276#
ligand;gated#ion#
channel#ac:vity# 2.58E;10# 4.11#
GO:0008083# growth#factor#ac:vity# 1.70E;07# 3## GO:0022891#
substrate;speciﬁc#
transmembrane#
transporter#ac:vity# 3.18E;10# 1.96#
GO:0002020# protease#binding# 3.28E;07# 2.91## GO:0022832#
voltage;gated#
channel#ac:vity# 3.47E;10# 3.62#
GO:0004930#
G;protein#coupled#
receptor#ac:vity# 4.53E;07# 2.3## GO:0005244#
voltage;gated#ion#
channel#ac:vity# 3.47E;10# 3.62#
GO:0008201# heparin#binding# 4.86E;07# 2.68## GO:0005249#
voltage;gated#
potassium#channel#
ac:vity# 3.64E;10# 5.15#
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Up#regulated#in#Late#NPCs#con5nued..# ## Down#regulated#in#Late#NPCs#con5nued..#
GO#term# Descrip5on# P<value#
Enrichm
ent#
score## ## GO#term# Descrip5on# P<value#
Enrichm
ent#
score#
GO:0005178# integrin#binding# 9.79E<07# 2.84## GO:0008324#
ca5on#transmembrane#
transporter#ac5vity# 5.36E<10# 2.2#
GO:0001664#
G<protein#coupled#receptor#
binding# 1.42E<06# 2.29## GO:0015077#
monovalent#inorganic#
ca5on#transmembrane#
transporter#ac5vity# 4.27E<09# 2.58#
GO:0005161#
platelet<derived#growth#
factor#receptor#binding# 3.10E<06# 5.57## GO:0022890#
inorganic#ca5on#
transmembrane#
transporter#ac5vity# 1.38E<08# 2.2#
GO:0048407#
platelet<derived#growth#
factor#binding# 3.23E<06# 7.04## GO:0008188#
neuropep5de#receptor#
ac5vity# 3.01E<08# 7.75#
GO:0004896# cytokine#receptor#ac5vity# 4.13E<06# 3.75## GO:0005231#
excitatory#extracellular#
ligand<gated#ion#
channel#ac5vity# 3.43E<08# 5.43#
GO:0004867#
serine<type#endopep5dase#
inhibitor#ac5vity# 4.47E<06# 3.55## GO:0005230#
extracellular#ligand<
gated#ion#channel#
ac5vity# 4.84E<08# 4.69#
GO:0019955# cytokine#binding# 6.42E<06# 3.18## GO:0030594#
neurotransmiPer#
receptor#ac5vity# 5.63E<08# 4.93#
GO:0044548# S100#protein#binding# 6.53E<06# 5.85## GO:0005179# hormone#ac5vity# 1.89E<07# 5.22#
GO:0004222#
metalloendopep5dase#
ac5vity# 8.05E<06# 2.68## GO:0071855#
neuropep5de#receptor#
binding# 2.36E<07# 7.51#
GO:0003823# an5gen#binding# 9.83E<06# 3.73## GO:0001077#
transcrip5onal#
ac5vator#ac5vity,#RNA#
polymerase#II#core#
promoter#proximal#
region#sequence<
speciﬁc#binding# 2.30E<06# 2.39#
GO:0019199#
transmembrane#receptor#
protein#kinase#ac5vity# 1.55E<05# 2.73## GO:0030553# cGMP#binding# 3.90E<06# 9.3#
GO:0004714#
transmembrane#receptor#
protein#tyrosine#kinase#
ac5vity# 1.85E<05# 2.97## GO:0001640#
adenylate#cyclase#
inhibi5ng#G<protein#
coupled#glutamate#
receptor#ac5vity# 6.59E<06# 10.85#
GO:0008237# metallopep5dase#ac5vity# 1.96E<05# 2.19## GO:0008528#
G<protein#coupled#
pep5de#receptor#
ac5vity# 9.89E<06# 3.92#
GO:0001968# ﬁbronec5n#binding# 2.01E<05# 4.02## GO:0001653#
pep5de#receptor#
ac5vity# 1.40E<05# 3.81#
GO:0050839#
cell#adhesion#molecule#
binding# 2.49E<05# 2.11## GO:0005251#
delayed#rec5ﬁer#
potassium#channel#
ac5vity# 1.81E<05# 5.79#
GO:1901618#
organic#hydroxy#compound#
transmembrane#transporter#
ac5vity# 2.72E<05# 4.23## GO:0008066#
glutamate#receptor#
ac5vity# 3.05E<05# 4.88#
GO:0017171# serine#hydrolase#ac5vity# 3.54E<05# 2.6## GO:0015464#
acetylcholine#receptor#
ac5vity# 3.98E<05# 7.23#
GO:0005544#
calcium<dependent#
phospholipid#binding# 3.78E<05# 3.37## GO:0001228#
transcrip5onal#
ac5vator#ac5vity,#RNA#
polymerase#II#
transcrip5on#
regulatory#region#
sequence<speciﬁc#
binding# 4.64E<05# 2.01#
GO:0004620# phospholipase#ac5vity# 4.76E<05# 2.79## GO:0015081#
sodium#ion#
transmembrane#
transporter#ac5vity# 4.65E<05# 2.88#
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Up#regulated#in#Late#NPCs#con5nued..# ## Down#regulated#in#Late#NPCs#con5nued..#
GO#term# Descrip5on# P<value#
Enrich
ment#
score## ## GO#term# Descrip5on# P<value#
Enrich
ment#
score#
GO:0015291#
secondary#ac5ve#
transmembrane#transporter#
ac5vity# 5.41E<05# 2.06## GO:0034617#
tetrahydrobiopterin#
binding# 7.18E<05# 10.85#
GO:0042056# chemoaMractant#ac5vity# 8.39E<05# 4.6## GO:0003777#
microtubule#motor#
ac5vity# 7.34E<05# 2.89#
GO:0004252#
serine<type#endopep5dase#
ac5vity# 9.02E<05# 2.87## GO:0004114#
3',5'<cyclic<nucleo5de#
phosphodiesterase#
ac5vity# 9.56E<05# 4.82#
GO:0008236# serine<type#pep5dase#ac5vity# 9.43E<05# 2.51## GO:0022824#
transmiMer<gated#ion#
channel#ac5vity# 9.56E<05# 4.82#
GO:0016641#
oxidoreductase#ac5vity,#ac5ng#
on#the#CH<NH2#group#of#
donors,#oxygen#as#acceptor# 9.46E<05# 5.12## GO:0022835#
transmiMer<gated#
channel#ac5vity# 9.56E<05# 4.82#
GO:0005160#
transforming#growth#factor#
beta#receptor#binding# 1.37E<04# 3.4## GO:0005246#
calcium#channel#
regulator#ac5vity# 1.15E<04# 4.25#
GO:0004859# phospholipase#inhibitor#ac5vity# 1.59E<04# 6.7## GO:0004889#
acetylcholine<ac5vated#
ca5on<selec5ve#channel#
ac5vity# 1.18E<04# 7.75#
GO:0005534# galactose#binding# 2.38E<04# 8.04## GO:0004112#
cyclic<nucleo5de#
phosphodiesterase#
ac5vity# 1.52E<04# 4.57#
GO:0038024# cargo#receptor#ac5vity# 2.68E<04# 3.02## GO:0022841#
potassium#ion#leak#
channel#ac5vity# 2.91E<04# 6.78#
GO:0048306#
calcium<dependent#protein#
binding# 3.54E<04# 2.68## GO:0016594# glycine#binding# 2.91E<04# 6.78#
GO:0016298# lipase#ac5vity# 3.87E<04# 2.4## GO:0005184#
neuropep5de#hormone#
ac5vity# 3.32E<04# 8.68#
GO:0008227#
G<protein#coupled#amine#
receptor#ac5vity# 4.98E<04# 5.75## GO:0030551# cyclic#nucleo5de#binding# 5.00E<04# 3.95#
GO:0055102# lipase#inhibitor#ac5vity# 4.98E<04# 5.75## GO:0004497# monooxygenase#ac5vity# 5.76E<04# 3.06#
GO:0042605# pep5de#an5gen#binding# 4.98E<04# 5.75## GO:0042165#
neurotransmiMer#
binding# 5.87E<04# 5.01#
GO:0008028#
monocarboxylic#acid#
transmembrane#transporter#
ac5vity# 5.00E<04# 3.45## GO:0001972# re5noic#acid#binding# 6.05E<04# 6.03#
GO:0016638#
oxidoreductase#ac5vity,#ac5ng#
on#the#CH<NH2#group#of#
donors# 7.00E<04# 4.02## GO:0043138#
3'<5'#DNA#helicase#
ac5vity# 6.05E<04# 6.03#
GO:0050431#
transforming#growth#factor#
beta#binding# 7.00E<04# 4.02## GO:0022842#
narrow#pore#channel#
ac5vity# 6.05E<04# 6.03#
GO:0001618# virus#receptor#ac5vity# 9.24E<04# 2.68## GO:0022840# leak#channel#ac5vity# 6.05E<04# 6.03#
GO:0008528#
G<protein#coupled#pep5de#
receptor#ac5vity# 9.24E<04# 2.68## GO:0042166# acetylcholine#binding# 6.05E<04# 6.03#
## ## ## ## ## GO:0070405# ammonium#ion#binding# 7.05E<04# 3.77#
## ## GO:0005272# sodium#channel#ac5vity# 7.09E<04# 4.22#
## ## GO:0031406# carboxylic#acid#binding# 7.70E<04# 2.03#
## ## GO:0004517#
nitric<oxide#synthase#
ac5vity# 7.81E<04# 10.85#
## ## GO:0004118#
cGMP<s5mulated#cyclic<
nucleo5de#
phosphodiesterase#
ac5vity# 7.81E<04# 10.85#
## ## GO:0008401#
re5noic#acid#4<
hydroxylase#ac5vity# 7.81E<04# 10.85#
## ## GO:0005222#
intracellular#cAMP#
ac5vated#ca5on#channel#
ac5vity# 7.81E<04# 10.85#
## ## GO:0043177# organic#acid#binding# 8.65E<04# 2.01#
## ## GO:0047555#
3',5'<cyclic<GMP#
phosphodiesterase#
ac5vity# 9.24E<04# 7.23#
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8.4!Comparing!the!RNA!yield!from!multiple!RNA!extraction!methods!!
Table 8.2  
  Extraction method (ug extracted per sample) 
Randomly 
selected 
samples Qiagen Rneasy 
Zymo Direct-zol 
miniprep  
Promega Maxwell 
simplyRNA cells 
1 7.47 9.06 19.645 
2 6.99 13.68 19.705 
3 4.41 11.31 16.81 
4 9.03 7.98 16.58 
5 2.22 7.62 17.68 
6 4.14 8.79 11.14 
7 7.65 11.454 21.435 
8 5.97 17.544 21.58 
9 9.66 21.969 18.205 
10 6.87 17.853 18.155 
  
 ! !
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8.5!TDP43!localization!in!Control!and!VCP!mutant!D3MNs!!
!
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Figure 8.3; Ungrouped Control and VCP mutant TDP43 staining for individual cell 
lines in d3MNs  
A) Representative images of Control and VCP-mutant d3MNs stained with TDP43 (red) 
and merged with DAPI staining (blue). B) Quantification of TDP43 staining, displayed 
as % of TDP43 in the nucleus vs cytoplasm. C) Percentage of TDP43 staining in the 
cytoplasm for Control and VCP mutant d3MN grouped data (Biological n=2 for control 
lines and n=4 for VCP mutant lines, two-way ANOVA). Error bars represent mean ± 
SEM. ! !
! 219!
References 
 
1. Abramov, Andrey Y, Laura Canevari, and Michael R Duchen. 2003. 
“Changes in Intracellular Calcium and Glutathione in Astrocytes as the 
Primary Mechanism of Amyloid Neurotoxicity.” The Journal of Neuroscience 
23(12): 5088–95. 
2. Aggad, Dina, Julie Vérièpe, Arnaud Tauffenberger, and J Alex Parker. 2014. 
“TDP-43 Toxicity Proceeds via Calcium Dysregulation and Necrosis in Aging 
Caenorhabditis Elegans Motor Neurons.” The Journal of Neuroscience 
34(36): 12093–103. 
3. Alami, Nael H et al. 2014. “Axonal Transport of TDP-43 mRNA Granules in 
Neurons Is Impaired by ALS-Causing Mutations.” 81(3): 536–43. 
4. Allen, Nicholas D. 2008. “Temporal and Epigenetic Regulation of 
Neurodevelopmental Plasticity.” Philosophical transactions of the Royal 
Society of London. Series B, Biological sciences 363(February 2007): 23–
38. 
5. Almeida, Sandra et al. 2013. “Modeling Key Pathological Features of 
Frontotemporal Dementia with C9ORF72 Repeat Expansion in iPSC-
Derived Human Neurons.” Acta Neuropathologica 126(3): 385–99. 
6. Ambrogio, Andrea et al. 2009. “Functional Mapping of the Interaction 
between TDP-43 and hnRNP A2 in Vivo.” Nucleic Acids Research 37(12): 
4116–26. 
7. Amoroso, Mackenzie W et al. 2013. “Accelerated High-Yield Generation of 
Limb-Innervating Motor Neurons from Human Stem Cells.” The Journal of 
Neuroscience 33(2): 574–86. 
8. Arai, Tetsuaki et al. 2006. “TDP-43 Is a Component of Ubiquitin-Positive 
Tau-Negative Inclusions in Frontotemporal Lobar Degeneration and 
Amyotrophic Lateral Sclerosis.” Biochemical and Biophysical Research 
Communications 351(3): 602–11. 
9. Ayala, Youhna M et al. 2011. “TDP-43 Regulates Its mRNA Levels through 
a Negative Feedback Loop.” The EMBO journal 30(2): 277–88. 
10. Ayala, Youhna M. et al. 2008. “Structural Determinants of the Cellular 
Localization and Shuttling of TDP-43.” Journal of Cell Science 121(22): 
3778–85. 
11. Baloh, Robert H. 2011. “TDP-43: The Relationship between Protein 
Aggregation and Neurodegeneration in Amyotrophic Lateral Sclerosis and 
Frontotemporal Lobar Degeneration.” The FEBS journal 278(19): 3539–49. 
12. Baltz, Alexander G. et al. 2012. “The mRNA-Bound Proteome and Its Global 
Occupancy Profile on Protein-Coding Transcripts.” Molecular Cell 46(5): 
674–90. 
13. Barmada, Sami J. et al. 2010. “Cytoplasmic Mislocalization of TDP-43 Is 
Toxic to Neurons and Enhanced by a Mutation Associated with Familial 
Amyotrophic Lateral Sclerosis.” The Journal of Neuroscience 30(2): 639–49. 
14. Baron, Desiree M et al. 2013. “Amyotrophic Lateral Sclerosis-Linked 
FUS/TLS Alters Stress Granule Assembly and Dynamics.” Molecular 
neurodegeneration 8(1): 30. 
15. Bartolome, Fernando et al. 2013. “Pathogenic VCP Mutations Induce 
! 220!
Mitochondrial Uncoupling and Reduced ATP Levels.” Neuron 78: 57–64. 
16. Bembich, Sara et al. 2014. “Predominance of Spliceosomal Complex 
Formation over Polyadenylation Site Selection in TDP-43 Autoregulation.” 
Nucleic acids research 42(5): 3362–71. 
17. Benatar, Michael et al. 2013. “Motor Neuron Involvement in Multisystem 
Proteinopathy: Implications for ALS.” Neurology 80(20): 1874–80. 
18. Bilican, B. et al. 2012. “Mutant Induced Pluripotent Stem Cell Lines 
Recapitulate Aspects of TDP-43 Proteinopathies and Reveal Cell-Specific 
Vulnerability.” Proceedings of the National Academy of Sciences 109(15): 
5803–8. 
19. Bilsland, Lynsey G et al. 2010. “Deficits in Axonal Transport Precede ALS 
Symptoms in Vivo.” 107(47): 1–6. 
20. Blokhuis, Anna M. et al. 2013. “Protein Aggregation in Amyotrophic Lateral 
Sclerosis.” Acta Neuropathologica 125: 777–94. 
21. Bories, Cyril, Julien Amendola, Boris Lamotte D’Incamps, and Jacques 
Durand. 2007. “Early Electrophysiological Abnormalities in Lumbar 
Motoneurons in a Transgenic Mouse Model of Amyotrophic Lateral 
Sclerosis.” European Journal of Neuroscience 25(2): 451–59. 
22. Bouhon, Isabelle a et al. 2006. “Embryonic Stem Cell-Derived Neural 
Progenitors Display Temporal Restriction to Neural Patterning.” Stem cells 
24(8): 1908–13. 
23. Bramham, Clive R, and David G Wells. 2007. “Dendritic mRNA*: Transport , 
Translation and Function.” 8. 
24. Buchan, J. Ross, Regina Maria Kolaitis, J. Paul Taylor, and Roy Parker. 
2013. “XEukaryotic Stress Granules Are Cleared by Autophagy and 
Cdc48/VCP Function.” Cell 153(7): 1461–74. 
25. Budini, Mauricio, and Emanuele Buratti. 2011. “TDP-43 Autoregulation: 
Implications for Disease.” Journal of Molecular Neuroscience 45(March): 
473–79. 
26. Buratti, Emanuele, and Francisco E. Baralle. 2001. “Characterization and 
Functional Implications of the RNA Binding Properties of Nuclear Factor 
TDP-43, a Novel Splicing Regulator of CFTR Exon 9.” Journal of Biological 
Chemistry 276(39): 36337–43. 
27. Burkhardt, Matthew F. et al. 2013. “A Cellular Model for Sporadic ALS Using 
Patient-Derived Induced Pluripotent Stem Cells.” Molecular and Cellular 
Neuroscience 56: 355–64. 
28. Cahoy, JD et al. 2008. “A Transcriptome Database for Astrocytes, Neurons, 
and Oligodendrocytes: A New Resource for Understanding Brain 
Development and Function.” Culture 28(1): 264–78. 
29. Calder, Elizabeth L et al. 2015. “Retinoic Acid-Mediated Regulation of GLI3 
Enables Efficient Motoneuron Derivation from Human ESCs in the Absence 
of Extrinsic SHH Activation.” The Journal of Neuroscience 35(33): 11462–
81. 
30. Caldwell, Maeve A et al. 2001. “Growth Factors Regulate the Survival and 
Fate of Cells Derived from Human Neurospheres.” Nature biotechnology 
19(5): 475–79. 
31. Camus, Anne, Aitana Perea-Gomez, Anne Moreau, and Jérôme Collignon. 
2006. “Absence of Nodal Signaling Promotes Precocious Neural 
! 221!
Differentiation in the Mouse Embryo.” Developmental Biology 295(2): 743–
55. 
32. Carrì, Maria Teresa, Cristiana Valle, Francesca Bozzo, and Mauro 
Cozzolino. 2015. “Oxidative Stress and Mitochondrial Damage: Importance 
in Non-SOD1 ALS.” Frontiers in cellular neuroscience 9(February): 41. 
33. Cassidy, Andrew, and Julia Jones. 2014. “Developments in in Situ 
Hybridisation.” Methods 70(1): 39–45. 
34. Chambers, Stuart M et al. 2009. “Highly Efficient Neural Conversion of 
Human ES and iPS Cells by Dual Inhibition of SMAD Signaling.” Nat 
Biotechnol 27(3): 275–80. 
35. Chaolin Zhang and Robert B. Darnell. 2011. “Mapping in Vivo Protein-RNA 
Interactions at Single-Nucleotide Resolution from HITS-CLIP Data.” Nature 
biotechnology 29(7): 607–14. 
36. Chataway, Jeremy. 2015. “Simvastatin in Patients with Progressive Multiple 
sclerosis–Authors’ Reply.” The Lancet 384(9947): 952–53. 
37. Chen, Hong et al. 2014. “Modeling ALS with iPSCs Reveals That Mutant 
SOD1 Misregulates Neurofilament Balance in Motor Neurons.” Cell Stem 
Cell 14(6): 796–809. 
38. Chen, Sheng, Pavani Sayana, Xiaojie Zhang, and Weidong Le. 2013. 
“Genetics of Amyotrophic Lateral Sclerosis: An Update.” Molecular 
neurodegeneration 8(1): 28. 
39. Chiang, Po-min et al. 2010. “Deletion of TDP-43 down-Regulates Tbc1d1, a 
Gene Linked to Obesity, and Alters Body Fat Metabolism.” Proceedings of 
the National Academy of Sciences of the United States of America 107(37): 
16320–24. 
40. Colombrita, Claudia et al. 2009. “TDP-43 Is Recruited to Stress Granules in 
Conditions of Oxidative Insult.” Journal of Neurochemistry 111(4): 1051–61. 
41. Cong, L et al. 2013. “Multiplex Genome Engineering Using CRISPR/Cas 
Systems.” science reports (February): 819–24. 
42. Corrado, Lucia et al. 2009. “High Frequency of TARDBP Gene Mutations in 
Italian Patients with Amyotrophic Lateral Sclerosis.” Human Mutation 30(4): 
688–94. 
43. Cozzolino, Mauro, and Maria Teresa Carri. 2012. “Mitochondrial Dysfunction 
in ALS.” Progress in Neurobiology 97(2): 54–66. 
44. D’Amico, Emanuele, Pam Factor-Litvak, Regina M Santella, and Hiroshi 
Mitsumoto. 2013. “Clinical Perspective on Oxidative Stress in Sporadic 
Amyotrophic Lateral Sclerosis.” Free radical biology & medicine 65: 509–27. 
45. Dalton, Ryan P., David B. Lyons, and Stavros Lomvardas. 2013. “Co-Opting 
the Unfolded Protein Response to Elicit Olfactory Receptor Feedback.” Cell 
155(2): 321–32. 
46. Darnell, Robert B. 2013. “RNA Protein Interaction in Neurons.” 
47. Defects, Reveal Age-related Nucleocytoplasmic et al. 2015. “Directly 
Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic 
Signatures and Article Directly Reprogrammed Human Neurons Retain 
Aging-Associated Transcriptomic Signatures and Reveal Age-Related 
Nucleocytoplasmic Defects.” : 1–14. 
48. Dejesus-hernandez, Mariely et al. 2011. “Expanded GGGGCC 
Hexanucleotide Repeat in Non-Coding Region of C9ORF72 Causes 
! 222!
Chromosome 9p-Linked Frontotemporal Dementia and Amyotrophic Lateral 
Sclerosis.” Neuron 72(2): 245–56. 
49. Deneen, Benjamin et al. 2006. “The Transcription Factor NFIA Controls the 
Onset of Gliogenesis in the Developing Spinal Cord.” Neuron 52(6): 953–68. 
50. Devlin, Anna-Claire et al. 2015. “Human iPSC-Derived Motoneurons 
Harbouring TARDBP or C9ORF72 ALS Mutations Are Dysfunctional despite 
Maintaining Viability.” Nature Communications 6: 1–12. 
51. Dewey, Colleen M. et al. 2010. “TDP-43 Is Directed to Stress Granules by 
Sorbitol, a Novel Physiological Osmotic and Oxidative Stressor.” Molecular 
and Cellular Biology 31(5): 1098–1108. 
52. Diehl, Adam G., and Alan P. Boyle. 2016. “Deciphering ENCODE.” Trends 
in Genetics 32(4): 238–49. 
53. Doyle, Michael, and Michael A Kiebler. 2011. “Mechanisms of Dendritic 
mRNA Transport and Its Role in Synaptic Tagging.” The EMBO journal 
30(17): 3540–52. 
54. van Eersel, Janet et al. 2011. “Cytoplasmic Accumulation and Aggregation 
of TDP-43 upon Proteasome Inhibition in Cultured Neurons.” PLoS ONE 
6(7). 
55. Elden, Andrew C et al. 2010. “Ataxin-2 Intermediate-Length Polyglutamine 
Expansions Are Associated with Increased Risk for ALS.” Nature 
466(August). 
56. Elkabetz, Yechiel et al. 2008. “Human ES Cell-Derived Neural Rosettes 
Reveal a Functionally Distinct Early Neural Stem Cell Stage.” Genes and 
Development 22: 152–65. 
57. Esmaeili, Mohammad A. et al. 2013. “Premature Death of TDP-43 (A315T) 
Transgenic Mice due to Gastrointestinal Complications prior to Development 
of Full Neurological Symptoms of Amyotrophic Lateral Sclerosis.” 
International Journal of Experimental Pathology 94(1): 56–64. 
58. Fan, Guoping et al. 2005. “DNA Methylation Controls the Timing of 
Astrogliogenesis through Regulation of JAK-STAT Signaling.” Development 
(Cambridge, England) 132: 3345–56. 
59. Ferraiuolo, Laura et al. 2011. “Molecular Pathways of Motor Neuron Injury in 
Amyotrophic Lateral Sclerosis.” Nature Reviews Neurology 7(11): 616–30. 
60. Fonslow, Bryan R et al. 2012. “The Importance of Preclinial Timing - a 
Potential Reason for the Disconnect between Mouse Studies and Human 
Clincal Trials in ALS.” 10(1): 54–56. 
61. Freeman, Marc R. 2010. “Specification and Morphogenesis of Astrocytes.” 
Science (New York, N.Y.) 330(6005): 774–78. 
62. Fu, Xinrong, Christine Ng, Daorong Feng, and Chun Liang. 2003. “Cdc48p 
Is Required for the Cell Cycle Commitment Point at Start via Degradation of 
the G1-CDK Inhibitor Far1p.” Journal of Cell Biology 163(1): 21–26. 
63. Gandhi, Sonia, and Andrey Y. Abramov. 2012. “Mechanism of Oxidative 
Stress in Neurodegeneration.” Oxidative Medicine and Cellular Longevity 
2012. 
64. Gendron, T.F., K.A. Josephs, and L Petrucelli. 2010. “Review: Transactive 
Response DNA-Binding Protein 43 (TDP-43): Mechanisms of 
Neurodegeneration.” Neuropathol Appl Neurobiol. 36(2): 97–112. 
65. Geser, Felix et al. 2009. “Amyotrophic Lateral Sclerosis, Frontotemporal 
! 223!
Dementia and beyond: The TDP-43 Diseases.” 256(8): 1205–14. 
66. ———. 2011. “NIH Public Access.” Pathology 67(10): 1238–50. 
67. Di Giorgio, Francesco Paolo et al. 2007. “Non-Cell Autonomous Effect of 
Glia on Motor Neurons in an Embryonic Stem Cell-Based ALS Model.” 
Nature neuroscience 10(5): 608–14. 
68. Di Giorgio, Francesco Paolo, Gabriella L. Boulting, Samuel Bobrowicz, and 
Kevin C. Eggan. 2008. “Human Embryonic Stem Cell-Derived Motor 
Neurons Are Sensitive to the Toxic Effect of Glial Cells Carrying an ALS-
Causing Mutation.” Cell Stem Cell 3(6): 637–48. 
69. Glisovic, Tina, Jennifer L Bachorik, Jeongsik Yong, and Gideon Dreyfuss. 
2008. “RNA-Binding Proteins and Post-Transcriptional Gene Regulation.” 
582(14): 1977–86. 
70. Grunz, Horst, and Lothar Tacke. 1989. “Neural Differentiation of Xenopus 
Zueuis Ectoderm Takes Place after Disaggregation and Delayed 
Reaggregation without Inducer.” 28: 211–17. 
71. Gupta, K et al. 2012. “Human Embryonic Stem Cell Derived Astrocytes 
Mediate Non-Cell-Autonomous Neuroprotection through Endogenous and 
Drug-Induced Mechanisms.” Cell Death and Differentiation 19(5): 779–87. 
72. Guthrie, P B et al. 1999. “ATP Released from Astrocytes Mediates Glial 
Calcium Waves.” The Journal of neuroscience!: the official journal of the 
Society for Neuroscience 19(2): 520–28. 
73. Hafner, Markus et al. 2010. “Transcriptome-Wide Identification of RNA-
Binding Protein and microRNA Target Sites by PAR-CLIP.” Cell 141(1): 
129–41. 
74. Haidet-Phillips, Amanda M et al. 2011. “Astrocytes from Familial and 
Sporadic ALS Patients Are Toxic to Motor Neurons.” Nature biotechnology 
29(9): 824–28. 
75. Hardiman, Orla, Leonard H. van den Berg, and Matthew C. Kiernan. 2011. 
“Clinical Diagnosis and Management of Amyotrophic Lateral Sclerosis.” 
Nature Reviews Neurology 7(11): 639–49. 
76. Hasegawa, M, T Arai, and T Nonaka. 2008. “Phosphorylated TDP-43 in 
Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis.” 
Annals of Neurology 64(1): 60–70. 
77. Hatada, Izuho et al. 2008. “Astrocyte-Specific Genes Are Generally 
Demethylated in Neural Precursor Cells prior to Astrocytic Differentiation.” 
PLoS ONE 3(9): 1–9. 
78. Hemmati-brivanlou, Ali, and Douglas A Melton. 1994. “Inhibition of Activin 
Receptor Signaling Promotes Neuralization in Xenopus.” 77: 273–81. 
79. Hirabayashi, M et al. 2001. “VCP/p97 in Abnormal Protein Aggregates, 
Cytoplasmic Vacuoles, and Cell Death, Phenotypes Relevant to 
Neurodegeneration.” Cell death and differentiation 8(10): 977–84. 
80. Hirabayashi, Y, and Y Gotoh. 2010. “Epigenetic Control of Neural Precursor 
Cell Fate during Development.” Nature Reviews Neuroscience 11(6): 377–
88. 
81. Hotta, Kentaro et al. 2013. “Vesnarinone Suppresses TNFα mRNA 
Expression by Inhibiting Valosin-Containing Protein.” Molecular 
pharmacology 83(May): 930–38. 
82. Howland, David S et al. 2002. “Focal Loss of the Glutamate Transporter 
! 224!
EAAT2 in a Transgenic Rat Model of SOD1 Mutant-Mediated Amyotrophic 
Lateral Sclerosis (ALS).” Proceedings of the National Academy of Sciences 
of the United States of America 99(3): 1604–9. 
83. Hsueh, Yi-Ping. 2012. “From Neurodevelopment to Neurodegeneration: The 
Interaction of Neurofibromin and Valosin-Containing protein/p97 in 
Regulation of Dendritic Spine Formation.” Journal of biomedical science 
19(1): 33. 
84. Huppertz, Ina et al. 2014. “iCLIP: Protein-RNA Interactions at Nucleotide 
Resolution.” Methods 65(3): 274–87. 
85. I.J.Huppertz. 2015. “Understanding the Dynamics of Ribonucleoprotein 
Assembly through iCLIP.” 
86. Ilieva, Ekaterina V. et al. 2007. “Oxidative and Endoplasmic Reticulum 
Stress Interplay in Sporadic Amyotrophic Lateral Sclerosis.” Brain 130(12): 
3111–23. 
87. Ingre, Caroline et al. 2015. “Risk Factors for Amyotrophic Lateral Sclerosis.” 
Clinical Epidemiology 7: 181–93. 
88. Jiang, Wenyan et al. 2013. “Articles RNA-Guided Editing of Bacterial 
Genomes Using CRISPR-Cas Systems.” Nature Biotechnology 31(3): 233–
39. 
89. Johnson, Brian S, J Michael McCaffery, Susan Lindquist, and Aaron D 
Gitler. 2008. “A Yeast TDP-43 Proteinopathy Model: Exploring the Molecular 
Determinants of TDP-43 Aggregation and Cellular Toxicity.” Proceedings of 
the National Academy of Sciences of the United States of America 105(17): 
6439–44. 
90. Johnson, Brian S. et al. 2009. “TDP-43 Is Intrinsically Aggregation-Prone, 
and Amyotrophic Lateral Sclerosis-Linked Mutations Accelerate Aggregation 
and Increase Toxicity.” Journal of Biological Chemistry 284(30): 20329–39. 
91. Johnson, Janel O. et al. 2010. “Exome Sequencing Reveals VCP Mutations 
as a Cause of Familial ALS.” Neuron 68: 857–64. 
92. Johnson, Rory, Wendy Noble, Gian Gaetano Tartaglia, and Noel J. Buckley. 
2012. “Neurodegeneration as an RNA Disorder.” Progress in Neurobiology 
99: 293–315. 
93. Ju, Jeong-Sun et al. 2009. “Valosin-Containing Protein (VCP) Is Required 
for Autophagy and Is Disrupted in VCP Disease.” The Journal of Cell 
Biology  187 (6 ): 875–88. 
94. Kabashi, Edor et al. 2008. “TARDBP Mutations in Individuals with Sporadic 
and Familial Amyotrophic Lateral Sclerosis.” Nature Genetics 40(5): 572–74. 
95. Kapeli, Katannya, and Gene W. Yeo. 2012. “Genome-Wide Approaches to 
Dissect the Roles of RNA Binding Proteins in Translational Control: 
Implications for Neurological Diseases.” Frontiers in Neuroscience 6(OCT): 
1–15. 
96. Kasai, Mana, Kiyotoshi Satoh, and Tetsu Akiyama. 2005. “Wnt Signaling 
Regulates the Sequential Onset of Neurogenesis and Gliogenesis via 
Induction of BMPs.” Genes to Cells 10(8): 777–83. 
97. Kiebler, Michael A., Peter Scheiffele, and Jernej Ule. 2013. “What, Where, 
and When: The Importance of Post-Transcriptional Regulation in the Brain.” 
Frontiers in Neuroscience 7(192). 
98. Kim, Hong Joo et al. 2013. “Mutations in Prion-like Domains in hnRNPA2B1 
! 225!
and hnRNPA1 Cause Multisystem Proteinopathy and ALS.” Nature 
495(7442): 467–73. 
99. Kim, Nam Chul et al. 2014. “VCP Is Essential for Mitochondrial Quality 
Control by PINK1/ Parkin and This Function Is Impaired by VCP Mutations.” 
78(1): 65–80. 
100. Kim, Sang Woo et al. 2010. “A Sensitive Non-Radioactive Northern Blot 
Method to Detect Small RNAs.” Nucleic Acids Research 38(7): 1–7. 
101. Kiskinis, Evangelos et al. 2014. “Pathways Disrupted in Human ALS Motor 
Neurons Identified through Genetic Correction of Mutant SOD1.” Cell Stem 
Cell 14(6): 781–95. 
102. König, Julian et al. 2011. “iCLIP Reveals the Function of hnRNP Particles in 
Splicing at Individual Nucleotide Resolution.” 17(7): 909–15. 
103. König, Julian, Kathi Zarnack, Nicholas M. Luscombe, and Jernej Ule. 2012. 
“Protein–RNA Interactions: New Genomic Technologies and Perspectives.” 
Nature reviews. Genetics 13(February): 3501–11. 
104. Koppers, Max et al. 2012. “VCP Mutations in Familial and Sporadic 
Amyotrophic Lateral Sclerosis.” Neurobiology of Aging 33(4): 837.e7–
837.e13. 
105. Kraemer, Brian C. et al. 2010. “Loss of Murine TDP-43 Disrupts Motor 
Function and Plays an Essential Role in Embryogenesis.” Acta 
Neuropathologica 119(4): 409–19. 
106. Krencik, Robert et al. 2011. “Specification of Transplantable Astroglial 
Subtypes from Human Pluripotent Stem Cells.” Nature biotechnology 29(6): 
528–34. 
107. ———. 2015. “Dysregulation of Astrocyte Extracellular Signaling in Costello 
Syndrome.” 7(286): 1–24. 
108. Kühnlein, Peter et al. 2009. “Two German Kindreds with Familial 
Amyotrophic Lateral Sclerosis due to TARDBP Mutations.” 65(9): 1185–89. 
109. Kuo, J J, T Siddique, R Fu, and C J Heckman. 2005. “Increased Persistent 
Na(+) Current and Its Effect on Excitability in Motoneurones Cultured from 
Mutant SOD1 Mice.” The Journal of physiology 563(Pt 3): 843–54. 
110. Kwiatkowski, T J et al. 2009. “Mutations in the FUS/TLS Gene on 
Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis.” Science  
323 (5918 ): 1205–8. 
111. Lagier-Tourenne, Clotilde et al. 2012. “Divergent Roles of ALS-Linked 
Proteins FUS/TLS and TDP-43 Intersect in Processing Long Pre-mRNAs.” 
Nature neuroscience 15(11): 1488–97. 
112. Lagier-tourenne, Clotilde, Magdalini Polymenidou, and Don W Cleveland. 
2010. “TDP-43 and FUS / TLS*: Emerging Roles in RNA Processing and 
Neurodegeneration.” 19(1): 46–64. 
113. Lee, Edward B., Virginia M.-Y. Lee, and John Q. Trojanowski. 2012. “Gains 
or Losses: Molecular Mechanisms of TDP43-Mediated Neurodegeneration.” 
Nature Reviews Neuroscience 13(1): 38–50. 
114. Lee, Hyojin et al. 2007. “Directed Differentiation and Transplantation of 
Human Embryonic Stem Cell-Derived Motoneurons.” Stem cells 25: 1931–
39. 
115. Li, Huei Ying et al. 2011. “Hyperphosphorylation as a Defense Mechanism 
to Reduce TDP-43 Aggregation.” PLoS ONE 6(8). 
! 226!
116. Li, X.J. et al. 2008. “Directed Differentiation of Ventral Spinal Progenitors 
and Motor Neurons from Human Embryonic Stem Cells by Small 
Molecules.” Stem Cells 26(4): 886–93. 
117. Li, Xue-Jun et al. 2005. “Specification of Motoneurons from Human 
Embryonic Stem Cells.” Nature biotechnology 23(2): 215–21. 
118. Liachko, Nicole F., Chris R. Guthrie, and Brian C. Kraemer. 2011. 
“Phosphorylation Promotes Neurotoxicity in a C. Elegans Model of TDP-43 
Proteinopathy Nicole.” 4(164): 16208–19. 
119. Licatalosi, Donny D et al. 2008. “HITS-CLIP Yields Genome-Wide Insights 
into Brain Alternative RNA Processing.” Nature 456(7221): 464–69. 
120. Lindholm, D, H Wootz, and L Korhonen. 2006. “ER Stress and 
Neurodegenerative Diseases.” Cell death and differentiation 13(3): 385–92. 
121. Ling, Shuo Chien, Magdalini Polymenidou, and Don W. Cleveland. 2013. 
“Converging Mechanisms in Als and FTD: Disrupted RNA and Protein 
Homeostasis.” Neuron 79(3): 416–38. 
122. Liscica, R. M. et al. 2008. “ALS and FTLD: Two Faces of TDP-43 
Proteinopathy.” European Journal of Neuroscience 15(8): 772–80. 
123. Liu, Lihua et al. 2012. “ER Stress Response during the Differentiation of H9 
Cells Induced by Retinoic Acid.” Biochemical and Biophysical Research 
Communications 417(2): 738–43. 
124. Lule, D., A. C. Ludolph, and A. G. Ludolph. 2008. “Neurodevelopmental and 
Neurodegenerative Diseases - Is There a Pathophysiological Link? 
Attention-Deficit/hyperactivity Disorder and Amyotrophic Lateral Sclerosis as 
Examples.” Medical Hypotheses 70(6): 1133–38. 
125. Lykke-Andersen, Jens, and Eric J. Bennett. 2014. “Protecting the Proteome: 
Eukaryotic Cotranslational Quality Control Pathways.” Journal of Cell 
Biology 204(4): 467–76. 
126. Majumder, Anirban et al. 2013. “Inhibition of DNA Methyltransferases and 
Histone Deacetylases Induces Astrocytic Differentiation of Neural 
Progenitors.” Stem Cell Research 11(1): 574–86. 
127. Malhotra, J D, and R J Kaufman. 2011. “ER Stress and Its Functional Link to 
Mitochondria: Role in Cell Survival and Death.” Cold Spring Harb Perspect 
Biol 3(9): a004424. 
128. Malik, Nasir et al. 2014. “Comparison of the Gene Expression Profiles of 
Human Fetal Cortical Astrocytes with Pluripotent Stem Cell Derived Neural 
Stem Cells Identifies Human Astrocyte Markers and Signaling Pathways and 
Transcription Factors Active in Human Astrocytes.” PLoS ONE 9(5). 
129. Maragakis, Nicholas J, and Jeffrey D Rothstein. 2006. “Mechanisms of 
Disease: Astrocytes in Neurodegenerative Disease.” Nature clinical practice. 
Neurology 2(12): 679–89. 
130. Maury, Yves, Julien Côme, Rebecca A Piskorowski, Nouzha Salah-
mohellibi, et al. 2014. “Combinatorial Analysis of Developmental Cues 
Efficiently Converts Human Pluripotent Stem Cells into Multiple Neuronal 
Subtypes.” (November): 1–10. 
131. Maury, Yves, Julien Côme, Rebecca a Piskorowski, Nouzha Salah-
Mohellibi, et al. 2014. “Combinatorial Analysis of Developmental Cues 
Efficiently Converts Human Pluripotent Stem Cells into Multiple Neuronal 
Subtypes.” Nat Biotechnol 33(November): 89–96. 
! 227!
132. Metzker, Michael L. 2010. “Sequencing Technologies - the next Generation.” 
Nature reviews. Genetics 11(1): 31–46. 
133. Meyer, Hemmo, and Conrad C Weihl. 2014. “The VCP/p97 System at a 
Glance: Connecting Cellular Function to Disease Pathogenesis.” Journal of 
cell science 127: 3877–83. 
134. Meyer, Kathrin et al. 2014. “Direct Conversion of Patient Fibroblasts 
Demonstrates Non-Cell Autonomous Toxicity of Astrocytes to Motor 
Neurons in Familial and Sporadic ALS.” Proceedings of the National 
Academy of Sciences of the United States of America 111(2): 829–32. 
135. Miller, Justine D. et al. 2013. “Human iPSC-Based Modeling of Late-Onset 
Disease via Progerin-Induced Aging.” Cell Stem Cell 13(6): 691–705. 
136. Mizuno, Yuji, Seiji Hori, Akira Kakizuka, and Koichi Okamoto. 2003. 
“Vacuole-Creating Protein in Neurodegenerative Diseases in Humans.” 
Neuroscience Letters 343(2): 77–80. 
137. Modic, Miha, Jernej Ule, and Christopher R. Sibley. 2013. “CLIPing the 
Brain: Studies of Protein-RNA Interactions Important for Neurodegenerative 
Disorders.” Molecular and Cellular Neuroscience 56: 429–35. 
138. Molliex, Amandine et al. 2015. “Phase Separation by Low Complexity 
Domains Promotes Stress Granule Assembly and Drives Pathological 
Fibrillization.” Cell 163(1): 123–33. 
139. Moore, Michael J et al. 2014. “Mapping Argonaute and Conventional RNA-
Binding Protein Interactions with RNA at Single-Nucleotide Resolution Using 
HITS-CLIP and CIMS Analysis.” Nat. Protocols 9(2): 263–93. 
140. Moreno, Julie a et al. 2013. “Oral Treatment Targeting the Unfolded Protein 
Response Prevents Neurodegeneration and Clinical Disease in Prion-
Infected Mice.” Science translational medicine 5(206): 206ra138. 
141. Morrison, S J et al. 2000. “Transient Notch Activation Initiates an Irreversible 
Switch from Neurogenesis to Gliogenesis by Neural Crest Stem Cells.” Cell 
101: 499–510. 
142. Nagai, Makiko et al. 2007. “Astrocytes Expressing ALS-Linked Mutated 
SOD1 Release Factors Selectively Toxic to Motor Neurons.” Nature 
neuroscience 10: 615–22. 
143. Nakamura, Haruko et al. 2015. “Quantitative Analysis of Intraneuronal 
Transport in Human iPS Neurons.” Journal of Pharmacological Science 
128(4): 170–78. 
144. Neumann, M et al. 2007. “TDP-43 in the Ubiquitin Pathology of 
Frontotemporal Dementia with VCP Gene Mutations.” J Neuropathol Exp 
Neurol. 66(2): 152–57. 
145. Neumann, Manuela et al. 2006. “Ubiquitinated TDP-43 in Frontotemporal 
Lobar Degeneration and Amyotrophic Lateral Sclerosis.” Science  314 (5796 
): 130–33. 
146. Nonaka, Takashi et al. 2009. “Truncation and Pathogenic Mutations 
Facilitate the Formation of Intracellular Aggregates of TDP-43.” Human 
Molecular Genetics 18(18): 3353–64. 
147. Nonhoff, Ute et al. 2007. “Ataxin-2 Interacts with the DEAD/H-Box RNA 
Helicase DDX6 and Interferes with P-Bodies and Stress Granules.” 
Molecular biology of the cell 18(December): 1385–96. 
148. Van Nostrand, Eric L et al. 2016. “Robust Transcriptome-Wide Discovery of 
! 228!
RNA-Binding Protein Binding Sites with Enhanced CLIP (eCLIP).” Nature 
methods 13(November 2015): 1–9. 
149. Okada, Yohei et al. 2008. “Spatiotemporal Recapitulation of Central Nervous 
System Development by Murine Embryonic Stem Cell-Derived Neural 
Stem/Progenitor Cells.” Stem Cells 26(12): 3086–98. 
150. Okita, Keisuke et al. 2011. “A More Efficient Method to Generate Integration-
Free Human iPS Cells.” Nature methods 8(5): 409–12. 
151. Pasinelli, Piera, and Robert H Brown. 2006. “Molecular Biology of 
Amyotrophic Lateral Sclerosis: Insights from Genetics.” Nature reviews. 
Neuroscience 7(September): 710–23. 
152. Patani, R et al. 2011. “Retinoid-Independent Motor Neurogenesis from 
Human Embryonic Stem Cells Reveals a Medial Columnar Ground State.” 
Nature communications 2: 214. 
153. Patani, Rickie, Patrick A. Lewis, et al. 2012. “Investigating the Utility of 
Human Embryonic Stem Cell-Derived Neurons to Model Ageing and 
Neurodegenerative Disease Using Whole-Genome Gene Expression and 
Splicing Analysis.” Journal of Neurochemistry (122): 738–51. 
154. Patani, Rickie, Christopher R. Sibley, Siddharthan Chandran, and Jernej 
Ule. 2012. “Using Human Pluripotent Stem Cells to Study Post-
Transcriptional Mechanisms of Neurodegenerative Diseases.” Brain 
Research 1462: 129–38. 
155. Pekny, Milos, and Marcela Pekna. 2014. “Astrocyte Reactivity and Reactive 
Astrogliosis: Costs and Benefits.” Physiological reviews 94(4): 1077–98. 
156. Philippidou, Polyxeni, and Jeremy S. Dasen. 2013. “Hox Genes: 
Choreographers in Neural Development, Architects of Circuit Organization.” 
Neuron 80(1): 12–34. 
157. Pringle, Nigel P et al. 2003. “Fgfr3 Expression by Astrocytes and Their 
Precursors: Evidence That Astrocytes and Oligodendrocytes Originate in 
Distinct Neuroepithelial Domains.” Development (Cambridge, England) 
130(1): 93–102. 
158. Pun, San et al. 2006. “Selective Vulnerability and Pruning of Phasic 
Motoneuron Axons in Motoneuron Disease Alleviated by CNTF.” Nature 
neuroscience 9(3): 408–19. 
159. Raponi, Eric et al. 2007. “S100B Expression Defines a State in Which 
GFAP- Expressing Cells Lose Their Neural Stem Cell Potential and Acquire 
a More Mature Developmental Stage.” Glia 55(14): 1416–25. 
160. Renton, Alan E et al. 2011. “A Hexanucleotide Repeat Expansion in 
C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD Alan.” 
Neuron 72(2): 257–68. 
161. Reubinoff, Benjamin E et al. 2001. “Neural Progenitors from Human 
Embryonic Stem Cells.” Nature Biotechnology 19(12): 1134–40. 
162. Ritson, Gillian P et al. 2010. “TDP-43 Mediates Degeneration in a Novel 
Drosophila Model of Disease Caused by Mutations in VCP/p97.” The 
Journal of neuroscience!: the official journal of the Society for Neuroscience 
30(22): 7729–39. 
163. Rodriguez-Ortiz, Carlos J. et al. 2013. “Neuronal-Specific Overexpression of 
a Mutant Valosin-Containing Protein Associated with Ibmpfd Promotes 
Aberrant Ubiquitin and TDP-43 Accumulation and Cognitive Dysfunction in 
! 229!
Transgenic Mice.” American Journal of Pathology 183(2): 504–15. 
164. Rogelj, Boris et al. 2012. “Widespread Binding of FUS along Nascent RNA 
Regulates Alternative Splicing in the Brain.” Scientific Reports 2: 1–10. 
165. Rossi, D et al. 2008. “Focal Degeneration of Astrocytes in Amyotrophic 
Lateral Sclerosis.” Cell death and differentiation 15(11): 1691–1700. 
166. Rothstein, J D et al. 1995. “Selective Loss of Glial Glutamate Transporter 
GLT-1 in Amyotrophic Lateral Sclerosis.” Annals of neurology 38(1): 73–84. 
167. Rothstein, Jeffrey D et al. 2005. “Beta-Lactam Antibiotics Offer 
Neuroprotection by Increasing Glutamate Transporter Expression.” Nature 
433(7021): 73–77. 
168. Rothstein, Jeffrey D. et al. 1996. “Knockout of Glutamate Transporters 
Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance 
of Glutamate.” Neuron 16(3): 675–86. 
169. Roybon, Laurent et al. 2013. “Human Stem Cell-Derived Spinal Cord 
Astrocytes with Defined Mature or Reactive Phenotypes.” Cell Reports 4(5): 
1035–48. 
170. Rumpf, Sebastian et al. 2014. “Drosophila Valosin-Containing Protein Is 
Required for Dendrite Pruning through a Regulatory Role in mRNA 
Metabolism.” Proceedings of the National Academy of Sciences of the 
United States of America 111(20): 7331–36. 
171. Sasaki, S. 2010. “Endoplasmic Reticulum Stress in Motor Neurons of the 
Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis.” J Neuropathol Exp 
Neurol 69(4): 346–55. 
172. Sasaki, Shoichi, and Makoto Iwata. 1995. “Synaptic Loss in the Proximal 
Axon of Anterior Horn Neurons in Motor Neuron Disease.” Acta 
Neuropathologica 90(2): 170–75. 
173. Sasaki, Shoichi, and Shoichi Maruyama. 1994. “Synapse Loss in Anterior 
Horn Neurons in Amyotrophic Lateral Sclerosis.” Acta Neuropathologica 
88(3): 222–27. 
174. Saxena, Smita, Erik Cabuy, and Pico Caroni. 2009. “A Role for Motoneuron 
Subtype-Selective ER Stress in Disease Manifestations of FALS Mice.” 
Nature neuroscience 12(5): 627–36. 
175. Schmitt, Angelika et al. 2003. “The Brain-Specific Protein MLC1 Implicated 
in Megalencephalic Leukoencephalopathy with Subcortical Cysts Is 
Expressed in Glial Cells in the Murine Brain.” Glia 44(3): 283–95. 
176. Scotter, Emma L., Han Jou Chen, and Christopher E. Shaw. 2015. “TDP-43 
Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic 
Targets.” Neurotherapeutics 12(2): 352–63. 
177. Serio, Andrea et al. 2013. “Astrocyte Pathology and the Absence of Non-
Cell Autonomy in an Induced Pluripotent Stem Cell Model of TDP-43 
Proteinopathy.” Proceedings of the National Academy of Sciences of the 
United States of America 110(12): 4697–4702. 
178. Shaltouki, Atossa et al. 2013. “Efficient Generation of Astrocytes from 
Human Pluripotent Stem Cells in Defined Conditions.” Stem Cells 31(5): 
941–52. 
179. Shaw, Pamela J. et al. 1995. “CSF and Plasma Amino Acid Levels in Motor 
Neuron Disease: Elevation of CSF Glutamate in a Subset of Patients.” 
Neurodegeneration 4(2): 209–16. 
! 230!
180. Shi, Yichen, Peter Kirwan, and Frederick J Livesey. 2012. “Directed 
Differentiation of Human Pluripotent Stem Cells to Cerebral Cortex Neurons 
and Neural Networks.” Nat. Protocols 7(10): 1836–46. 
181. Shih, Yu-Tzu, and Yi-Ping Hsueh. 2016. “VCP and ATL1 Regulate 
Endoplasmic Reticulum and Protein Synthesis for Dendritic Spine 
Formation.” Nature Communications 7(May 2015): 11020. 
182. Sitte, Nicolle, Michael Huber, Tilman Grune, and Axel Ladhoff. 1999. 
“Proteasome Inhibition by Lipofuscin / Ceroid during Postmitotic Aging of 
Fibroblasts.” The FASEB Journal. 
183. Sleigh, James, and Giampietro Schiavo. 2016. “Older but Not Slower: Aging 
Does Not Alter Axonal Transport Dynamics of Signalling 
Endosomes&amp;nbsp;in Vivo&amp;nbsp; &amp;nbsp; 
&amp;nbsp;&amp;nbsp;” Matters (July). 
184. Sofroniew, Michael V., and Harry V. Vinters. 2010. “Astrocytes: Biology and 
Pathology.” Acta Neuropathologica 119(1): 7–35. 
185. Soto, Claudio. 2013. “Protein Misfolding in Neurodegenerative Diseases*: 
The Key Pending Questions.” : 19–22. 
186. Spriggs, Keith a., Martin Bushell, and Anne E. Willis. 2010. “Translational 
Regulation of Gene Expression during Conditions of Cell Stress.” Molecular 
Cell 40(2): 228–37. 
187. Sreedharan, Jemeen et al. 2008. “TDP-43 Mutations in Familial and 
Sporadic Amyotrophic Lateral Sclerosis.” Science  319 (5870 ): 1668–72. 
188. Stern, Claudio D. 2005. “Neural Induction: Old Problem, New Findings, yet 
More Questions.” Development (Cambridge, England) 132: 2007–21. 
189. Takahashi, Kazutoshi, and Shinya Yamanaka. 2006. “Induction of 
Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures 
by Defined Factors.” Cell 126: 663–76. 
190. Tang, Yong et al. 2013. “Fast Vesicle Transport Is Required for the Slow 
Axonal Transport of Synapsin.” Journal of Neuroscience 33(39): 15362–75. 
191. Tollervey, James R et al. 2011. “UKPMC Funders Group Characterising the 
RNA Targets and Position-Dependent Splicing Regulation by TDP-43*; 
Implications for Neurodegenerative Diseases.” October 14(4): 452–58. 
192. Tong, Jianbin et al. 2013. “Expression of ALS-Linked TDP-43 Mutant in 
Astrocytes Causes Non-Cell-Autonomous Motor Neuron Death in Rats.” The 
EMBO journal 32(13): 1917–26. 
193. Tsai, Kuen-Jer et al. 2010. “Elevated Expression of TDP-43 in the Forebrain 
of Mice Is Sufficient to Cause Neurological and Pathological Phenotypes 
Mimicking FTLD-U.” The Journal of experimental medicine 207(8): 1661–73. 
194. Turner, Martin R et al. 2013. “Controversies and Priorities in Amyotrophic 
Lateral Sclerosis.” The Lancet Neurology 12(3): 310–22. 
195. Tyzack, Giulia E et al. 2014. “Astrocyte Response to Motor Neuron Injury 
Promotes Structural Synaptic Plasticity via STAT3-Regulated TSP-1 
Expression.” Nature communications 5: 4294. 
196. Ule, Jernej et al. 2003. “CLIP Identi Es Nova-Regulated RNA Networks in 
the Brain.” Science 302(November): 1212–15. 
197. ———. 2010. “iCLIP Predicts the Dual Splicing Effects of TIA-RNA 
Interactions.” PLoS Biology 8(10). 
198. Ule, Jernej, Kirk Jensen, Aldo Mele, and Robert B. Darnell. 2005. “CLIP: A 
! 231!
Method for Identifying Protein-RNA Interaction Sites in Living Cells.” 
Methods 37(4): 376–86. 
199. Vance, Caroline et al. 2009. “Mutations in FUS , an RNA Processing Protein 
, Cause Familial Amyotrophic Lateral Sclerosis Type 6.” Science 323(5918): 
1208–11. 
200. Vanderweyde, Tara, Katie Youmans, Liqun Liu-Yesucevitz, and Benjamin 
Wolozin. 2013. “Role of Stress Granules and RNA-Binding Proteins in 
Neurodegeneration: A Mini-Review.” Gerontology 59: 524–33. 
201. Vaz, Bruno, Swagata Halder, and Kristijan Ramadan. 2013. “Role of 
p97/VCP (Cdc48) in Genome Stability.” Frontiers in genetics 4(April): 60. 
202. Voigt, Aaron et al. 2010. “TDP-43-Mediated Neuron Loss In Vivo Requires 
RNA-Binding Activity.” PLoS ONE 5(8). 
203. Wainger, Brian J, Evangelos Kiskinis, Cassidy Mellin, Ole Wiskow, S W 
Steve, et al. 2014. “Intrinsic Membrane Hyperexcitability of ALS Patient-
Derived Motor Neurons.” Cell Reports 7(1): 1–11. 
204. Wainger, Brian J., Evangelos Kiskinis, Cassidy Mellin, Ole Wiskow, Steve S 
W Han, et al. 2014. “Intrinsic Membrane Hyperexcitability of Amyotrophic 
Lateral Sclerosis Patient-Derived Motor Neurons.” Cell Reports 7(1): 1–11. 
205. Walker, Adam K. et al. 2013. “ALS-Associated TDP-43 Induces 
Endoplasmic Reticulum Stress, Which Drives Cytoplasmic TDP-43 
Accumulation and Stress Granule Formation.” PLoS ONE 8(11): 1–12. 
206. Wang, Hsiao Fang et al. 2011. “Valosin-Containing Protein and 
Neurofibromin Interact to Regulate Dendritic Spine Density.” Journal of 
Clinical Investigation 121(12): 4820–37. 
207. Wang, Wenzhang et al. 2016. “The Inhibition of TDP-43 Mitochondrial 
Localization Blocks Its Neuronal Toxicity.” Nature Medicine (May). 
208. Wegorzewska, Iga et al. 2009. “TDP-43 Mutant Transgenic Mice Develop 
Features of ALS and Frontotemporal Lobar Degeneration.” Proceedings of 
the National Academy of Sciences of the United States of America 106(44): 
18809–14. 
209. Wegorzewska, Iga, and Robert H. Baloh. 2011. “TDP-43-Based Animal 
Models of Neurodegeneration: New Insights into ALS Pathology and 
Pathophysiology.” Neurodegenerative Diseases 8(4): 262–74. 
210. Weiduschat, N. et al. 2014. “Motor Cortex Glutathione Deficit in ALS 
Measured in Vivo with the J-Editing Technique.” Neuroscience Letters 570: 
102–7. 
211. Weihl, Conrad C. 2011. “Another VCP Interactor: NF Is Enough.” Journal of 
Clinical Investigation 121(12): 4627–30. 
212. Wen, Shu, Hong Li, and Jia Liu. 2009. “Dynamic Signaling for Neural Stem 
Cell Fate Determination.” Cell adhesion & migration 3(1): 107–17. 
213. Wichterle, H, I Lieberam, J a Porter, and T M Jessell. 2002. “Directed 
Differentiation of Embryonic Stem Cells into Motor Neurons.” Cell 110: 385–
97. 
214. Winton, Matthew J. et al. 2008. “A90V TDP-43 Variant Results in the 
Aberrant Localization of TDP-43 in Vitro.” FEBS Letters 582(15): 2252–56. 
215. ———. 2009. “Disturbance of Nuclear and Cytoplasmic TAR DNA-Binding 
Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and 
Aggregate Formation.” Journal of Biological Chemistry 283(19): 13302–9. 
! 232!
216. Xu, Chunhui et al. 2001. “Feeder-Free Growth of Undifferentiated Human 
Embryonic Stem Cells.” 19(October): 971–74. 
217. Xu, Ren-He et al. 2005. “Basic FGF and Suppression of BMP Signaling 
Sustain Undifferentiated Proliferation of Human ES Cells.” Nature methods 
2(3): 185–90. 
218. Yamanaka, Kunitoshi, Yohei Sasagawa, and Teru Ogura. 2012. “Recent 
Advances in p97/VCP/Cdc48 Cellular Functions.” Biochimica et Biophysica 
Acta - Molecular Cell Research 1823(1): 130–37. 
219. Yerbury, Justin J. et al. 2016. “Walking the Tightrope: Proteostasis and 
Neurodegenerative Disease.” Journal of Neurochemistry: 1–17. 
220. Yi, Ling et al. 2012. “Altered Intracellular Localization and Valosin-
Containing Protein (p97 VCP) Interaction Underlie ATP7A-Related Distal 
Motor Neuropathy.” Human Molecular Genetics 21(8): 1794–1807. 
221. Yin, H Z et al. 2012. “Slow Development of ALS-like Spinal Cord Pathology 
in Mutant Valosin-Containing Protein Gene Knock-in Mice.” Cell death & 
disease 3: e374. 
222. Zarnack, Kathi et al. 2013. “Direct Competition between hnRNP C and 
U2AF65 Protects the Transcriptome from the Exonization of Alu Elements.” 
Cell 152(3): 453–66. 
223. Zarnegar, Brian J et al. 2016. “irCLIP Platform for Efficient Characterization 
of protein–RNA Interactions.” Nature methods (April 2016). 
224. Zhang, Su-Chun et al. 2001. “In Vitro Differentiation of Transplantable 
Neural Precursors from Human Embryonic Stem Cells.” Nature 
Biotechnology 19(12): 1129–33. 
225. Zhang, Xiaochu, Eva Szabo, Marek Michalak, and Michal Opas. 2007. 
“Endoplasmic Reticulum Stress during the Embryonic Development of the 
Central Nervous System in the Mouse.” 25: 455–63. 
226. Zhang, Ye et al. 2016. “Purification and Characterization of Progenitor and 
Mature Human Astrocytes Reveals Transcriptional and Functional 
Differences with Mouse.” Neuron 89: 37–53. 
227. Zhang, Yong-jie et al. 2009. “Aberrant Cleavage of TDP-43 Enhances 
Aggregation and Cellular Toxicity.” 106(18). 
228. Zhang, Yong-Jie et al. 2010. “Phosphorylation Regulates Proteasomal-
Mediated Degradation and Solubility of TAR DNA Binding Protein-43 C-
Terminal Fragments.” Molecular Neurodegeneration 5(33): 1–13. 
229. Zhang, Zhen-Ning et al. 2016. “Layered Hydrogels Accelerate iPSC-Derived 
Neuronal Maturation and Reveal Migration Defects Caused by MeCP2 
Dysfunction.” Proceedings of the National Academy of Sciences 113(12): 
201521255. 
230. Zhou, Zhi Dong, Udhaya Kumari, Zhi Cheng Xiao, and Eng King Tan. 2010. 
“Notch as a Molecular Switch in Neural Stem Cells.” IUBMB Life 62(8): 618–
23. 
231. Zirra, Alexandra, Sarah Wiethoff, and Rickie Patani. 2016. “Neural 
Conversion and Patterning of Human Pluripotent Stem Cells*: A 
Developmental Perspective System*: An Overview.” 2. 
 
